DNA condensation by lipopolyamines by Neal, Adrian Paul
        
University of Bath
PHD








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 14. May. 2019
DNA CONDENSATION BY LIPOPOLYAMINES
Submitted by Adrian Paul Neal
for the degree of PhD
of the University of Bath
2002
COPYRIGHT
Attention is drawn to the fact that copyright of this thesis rests with its author. This copy of the 
thesis has been supplied on condition that anyone who consults it is understood to recognise 
that its copyright rests with the author and that no quotation from the thesis and no information 
derived from it may be published without prior written consent of the author.
This thesis may be made available for consultation within the University Library and may be 




INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U602188
Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
UNIVERC OF t
Lib, ■ aRY 
ItO 1 1 JUL 2G02
Abstract
Small molecule lipopolyamines for DNA condensation, and potentially as vectors for 
non-viral gene delivery, have been designed, prepared, purified and their complexes with DNA 
characterised. These lipopolyamines are mimics of the naturally occurring polyamines 
spermine and spermidine, conjugated to hydrophobic steroid moieties. Unsymmetrical 
polyamine-steroid conjugates have been synthesised using regiochemically-controlled 
protections of symmetrical spermine or homologation of the polyamine chain by reductive 
alkylation. Acylation with cholesterol, ergosterol and lithocholic acid then afforded cholesteryl 
and ergosteryl carbamates and lithocholic acid amides of polyammonium spermidine and 
spermine mimics.
Polyamines and lipopolyamines have been assayed for their ability to condense 
natural and synthetic DNA, and compared to poly-L-lysine by means of normal absorption- and 
fluorescence-based spectroscopic techniques. DNA condensation was assessed using an 
ethidium bromide fluorescence displacement assay, and has been correlated to particle 
formation by light scattering techniques in the context of lipoplex formation for gene delivery.
Fluorescent derivatives of these lipopolyamines have been designed. The synthesis 
of fluorescent cholesteryl-polyamine carbamates required a regio- and steroselective 
hydroboration of these alkenes. The major product was a 6a-hydroxy, trans-AB steroid. By 
preparing Fmoc protected 5-aminopentanoic acid esters of these hydroborated cholesteryl 
carbamates and also polyamine-lithocholic acid amides, the incorporation of fluorescent labels 
was achieved via Fmoc-deprotection with fluoride salts. This strategy is potentially useful for 
the introduction of fluorescent labels of choice and the synthesis of Oregon Green and dansyl 
labelled alkylspermine-cholesteryl carbamates has been achieved by this method.
Synthetic cis- and trans-AB steroidal putrescine and spermidine mimics of the natural 
antimicrobial product squalamine have been shown to bind to DNA by ethidium bromide 
displacement. Lipid shape is one of many factors affecting the DNA binding of these ligands. 
The trans-AB steroids impart greater relative binding affinity to such models for lipopolyamine- 
mediated DNA condensation. These SARs are important for new lipopolyamine vector design.
Naphthalimides are highly fluorescent lipophilic moieties and two examples of 
naphthalimide labelled alkylspermine-lithocholic acid amides have been prepared and purified. 
One of these, an n-butyl derivative has been shown, using normal absorption spectroscopy, to 
condense DNA with more efficiency than a long chain octadecyl analogue. These compounds 
and their DNA-complexes are novel fluorescent steroidal-based vectors designed as analytical 
tools for lipofection.
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Gene Delivery: An Introduction
A revised version of this chapter has been submitted to 
European Journal of Organic Chemistry
1
DNA drugs for gene therapy
The term “gene therapy” describes the use of corrective genes or some other 
polynucleic acid agent in the treatment of disease. Central to this approach is the delivery of 
polynucleic acids into the nucleus of target eukaryotic cells where they will hold some 
therapeutic value. The process of delivering a gene suitable for expression is called 
transfection. In gene therapy, the delivered polynucleic acid may be a correct copy of a 
defective gene or could be antisense oligonucleotides designed to disrupt the disease process. 
This method of treatment does not seek permanent manipulation of the genome and delivered 
polynucleic acids can be considered ultimately to be replacing the small molecule drugs used 
in conventional medicine. Gene therapy is considered by many to be the future of medicine 
yet there exists a gulf between today’s technology and the realisation of its routine use in the 
clinic (for recent reviews, see: Miller 1992, Anderson 1998, Li and Huang 2000). As an 
introduction to the work described in this thesis, we begin with a concise review and 
consideration of the issues currently associated with attempts to deliver genes into cells for 
gene therapy.
This introduction starts by describing in outline the biological role of deoxyribonucleic 
acid (DNA), relating organisation and function to structure and the control of this structure by 
large and small molecules. By describing DNA in this context, we may begin to develop DNA 
as a drug, which can ultimately be applied in the clinic. The delivery of such DNA for gene 
therapy generally requires a vector for efficient cellular transfection. However, this is not 
always the case and “naked DNA" has been the subject of certain, recent clinical trials in gene 
therapy (Anderson 1998). The majority of gene therapy trials employ a viral vector (Rosenberg 
et al 1990, Blease et al 1995, Bellon et al 1997). Due to the many, major problems (for 
example toxicity, immunogenicity) uncovered in these trials (Rosenberg eta l 1990), the future 
for gene therapy lies in non-viral gene delivery.
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Cell function by DNA structure control
Generally, eukaryotic cells are 10 to 100 fxm in diameter and human cells carry DNA 
with a total length of 2 m in the nucleus (Davis 1999). Proteins called histones mediate the 
packaging of this DNA and the protein-DNA complex is known as chromatin. Chromatin 
assembles into bundles, nucleosomes, which coil into fibres. These fibres form loops which 
pack close together to form a chromosome (for a review of chromatin structure, see: Demeret 
et al 2001). This arrangement renders the DNA tightly packed, yet genes remain accessible to 
proteins and especially enzymes which take roles in DNA repair and replication (Davis 1999).
DNA is a copolymer of nucleotide units, each monomer linked as deoxyribose 
phosphodiesters. Each deoxyribose sugar is linked to a nitrogenous base, one of (usually) two 
purines (adenine, A and guanine, G) or two pyrimidines (thymine, T and cytosine, C). Two 
polynucleotide chains associate as a duplex (double helix) through the H-bonding between 
complementary purine-pyrimidine base pairs (adenine-thymine and guanine-cytosine), which 
run through the centre of the helix, surrounded by the phosphate-sugar backbone. In its most 
stable form under physiological conditions, the duplex is right handed, with base pairs 
approximately perpendicular (86°) to the helix axis. This arrangement and the conformations 
of the sugar units render this duplex with two grooves, a major and a minor groove. This 
description (Dickerson etal 1982) characterises B-form DNA, the common solution polymorph 
(Fig. 3). Other forms of DNA exist and two are discussed below.
Phosphate diesters typically have pKaS of around 1.5 (Blackburn and Gait 1990); 
therefore the DNA sugar-phosphate backbone is polyanionic at physiological pH (7.4). DNA 
therefore binds small cations such as Na+ and Mg2+ which stabilise the duplex. These 
complexes are soluble in the aqueous media of cytoplasm and in vitro (Hnilica 1972). Histones 
are highly conserved proteins and contain a high proportion of the basic amino acids lysine 
and arginine, the side chains of which (containing primary amine and guanidine functional
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groups respectively) are cationic at physiological pH (pKas 10.8 and 12.5 respectively, Cowen
1997). Of the five major classes, H1 histones contain 29 % lysine (Hnilica 1972, Kasinsky et al 
2001). These facts have prompted studies of polymers of lysine and of arginine and their 
binding to DNA. Poly-L-lysine (PLL, Fig. 1) mimics lysine-rich H1b histone in its binding affinity 
for DNA (Tsuboi and Matsuo 1966). PLL has been shown to bind preferentially to DNA rich in 
A-T base pairing and poly-L-arginine (Fig. 1) shows preference towards poly [d(G-C)]2 over 
poly [d(A-T)]2 (Leng and Felsenfeld 1966). Electrostatic interactions between polyanionic DNA 
and cationic amino acid residues of histones favour tight binding in chromatin at physiological 
pH and ionic strength (Matsuyama and Nagata 1970).
NH2 n r \ ^ " n
poly-L-lysine J  poly-L-arginine
HN HN
H N ^ N H ,  H N ^ N H ,
Figure 1. Poly-L-lysine and poly-L-arginine: polycationic histone mimics
Polyamines are naturally occurring small molecules (Fig. 2) and are found in high 
concentrations particularly in eukaryotic cells. The pKa values of spermidine are typically 11.6, 
10.8, 9.5 and 11.5,11.0, 9.8,8.9 for spermine (Takeda et al 1983). Polyamines are often 
essentially fully protonated under physiological conditions and these polycations also bind to 
DNA. Polyamines are present in chromatin and are believed to be involved in many cellular 
events and also to protect DNA from damage by free radicals (Ha et al 1998). Charge 
neutralisation by histones and polyamines is effective in removing electrostatic repulsions on
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the DNA sugar-phosphate backbone causing local contractions of the helix and bending where 
this charge neutralisation occurs (Bloomfield 1996, Cohen 1998). This collapse of DNA into a 
compact form is called DNA condensation, and this accounts for the folded structure of DNA in 
cell nuclei. DNA condensation by this mechanism is said to be achieved when approximately 
90 % of the negative charge is neutralised (for a review, see: Bloomfield 1997). Polyamines 
are also found to condense DNA in viruses (Cohen 1998).
cadaverineputrescine
spermidine spermine
Figure 2. Some naturally occurring di- and polyamines: putrescine, cadaverine, spermidine and spermine
In contrast, bacteria (prokaryotes) lack the required amount of histone-like proteins to 
effect complete DNA condensation and also the polyamine spermidine (but not the diamine 
putrescine) makes a limited contribution (Cohen 1998). However, complete DNA condensation 
is observed in bacterial cells. It is thought, in this instance, that molecular crowding effects 
DNA condensation (Zimmerman 1993). Crowding simply implies that macromolecules (such 
as DNA) are compacted together by non-specific steric interactions with other macromolecules 
at high local concentrations in the cytoplasm. Such interactions are not sensitive to 
physiological salt and pH conditions as is charge neutralisation. Molecular crowding 
contributes mainly to the condensation of bacterial DNA into nucleoids, and is also involved in 
the condensation of foreign DNA introduced into bacteria by viruses (Zimmerman and Murphy 
1996).
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The B-form of DNA (Fig. 3) is the most commonly observed form of DNA in cells. The 
diamine putrescine (1,4-diaminobutane, Fig. 2), weakly stabilises the B-form, but the 
polyamines spermidine and spermine mediate the transition of B-DNA to the A-form (Minyat 
1978, Cohen 1998). A-DNA (Fig. 3) is also a right-handed duplex, but the base pairs are tilted 
significantly from the helix axis and the minor groove is shallower than in B-DNA (Dickerson et 
a! 1982). Short duplex oligonucleotides and RNA prefer to adopt A-form structures and, during 
transcription, the section of DNA being transcribed undergoes transition to the A-form to 
provide a closer template for the forming RNA strand (Voet and Voet 1995, Minyat 1978). It is 
believed that spermine and spermidine mediate this process during periods of transcription. 
Also, during replication, RNA primers (short pieces of RNA) must bind to sections of DNA to 
form RNA-DNA hybrids that have A-form structures and polyamines may be involved here. 
Polyamines have also been shown to mediate the transition of B-DNA to the Z-form (Dickerson 
etal 1982), a left-handed helix (Fig. 3), but the precise biological roles of Z-DNA have yet to be 
elucidated (Thomas et al 1988, Sines et al 2000).
A-DNA B-DNA Z-DNA
Figure 3. Molecular models of A-, B- and Z-form DNA
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These structural changes to DNA are induced at low concentrations of polyamines. At 
higher ligand concentrations, DNA condensation begins as anionic charge neutralisation 
becomes more widespread on the macromolecule. When DNA is condensed with polyamines, 
in the absence of histones in vitro, toroidal-shaped particles form. Recent atomic force 
microscopy (AFM) studies have probed the particles formed by spermidine-mediated DNA 
condensation (Lin et al 1998). At very low concentrations of DNA (a large excess of 
spermidine), toroids were shown to have the same volume as a single DNA molecule (termed 
monomolecular, or type I toroids). At higher concentrations of DNA (but still an excess of 
spermidine), toroids were significantly larger and made up of smaller particles which were 
similar in dimension to type I. These have been termed type II, or multimolecular toroids. This 
evidence points to a multi-stage condensation mechanism, sensitive to changes in polyamine- 
DNA mixing ratios.
The binding of histones and polyamines to polynucleic acids has been described here 
in terms of electrostatic interactions, but polyamines are also examples of DNA groove binders. 
There is much evidence that polyamines reside in the grooves of DNA whilst bound, but 
spectroscopic and molecular modelling studies have failed to yield an exact preferred 
orientation (Rodger et al 1994 and 2000), though it is thought these molecules favour the minor 
groove. Many small molecule DNA-binding ligands also adopt this binding mode, for example 
pyrrolobenzodiazepines (Wilson etai 1999). Such drugs tend to have a structure that allows 
the molecule to follow the helix contour in the groove. DNA-binding proteins involved in gene 
expression processes also use the grooves in their binding regime, in particular the wider 
major groove of B-DNA (Creighton 1993). These proteins have a number of structural motifs 
that allow intimate groove binding with DNA (Adams et al 1992). Examples of such constructs 
are zinc fingers (Berg 1990), leucine zippers (Struhl 1989) and helix-tum-helix (HTH) motifs 
(Brennan and Matthews 1989).
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Intercalation is another type of binding mode that small molecule drugs may adopt in 
their interactions with DNA. Planar, aromatic drugs (for example anthracyclines) may 
intercalate, i.e. insert between the base pairs of DNA. This type of binding will be discussed 
later in considering the fluorescent DNA probe ethidium bromide for the study of polyamine 
binding efficiency.
This section of the introduction has characterised DNA as an attractive target to a 
variety of molecular designs. Manipulation of this structure for determining biological function is 
an important consideration in the context of introducing foreign DNA for gene therapy. 
Knowledge of how a cell packages, organises and processes DNA is required to allow proper 
development of gene delivery as a technology, as this approach seeks to mimic natural cell 
processes (ultimately gene expression).
Gene delivery for gene therapy
Gene therapy requires the delivery of a gene or genes to the nucleus of target cells 
implicated in the disease, so that they may be expressed. The selection of gene or genes to 
be delivered is therefore decisive in determining if a condition may be treated using such a 
technology. The completion of the human genome project aids this selection process 
significantly, and genes responsible for certain diseases are now being discovered (Anderson 
1998). The treatment of cystic fibrosis has become the focus of many initial gene therapy 
studies, such studies aiming to successfully deliver the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene. Such genetic material is processed as a DNA plasmid, a 
circular piece of DNA. The pSV-p-galactosidase plasmid (6.8 x 103 basepairs in length, Tseng 
et al 1996) is typical of a reporter gene sequence (see later in this chapter) routinely 
transfected by non-viral vectors.
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The process of transfecting a eukaryotic cell begins with the requirement for foreign 
DNA to cross the plasma membrane, the first physical barrier to polynucleic acid delivery.
DNA is polar and polyanionic at physiological pH and therefore free (“naked”) DNA cannot 
easily traverse phospholipid bilayers (anionic lipids). For pieces of naked DNA (and large 
biopolymers generally) this represents large unfavourable molecular interactions and is one of 
several similar significant barriers to cross. Electroporation and microinjection of plasmids into 
the cytosol are techniques for this, but cannot find ready application in the genetic therapy of a 
disease state in vivo, so this introduction will focus on vectored approaches to gene delivery. 
Such vectors may be biological (viruses) or chemical (non-viral) and are discussed herein.
Viral vectors for gene therapy
Viruses are the natural gene delivery agents, as they rely on such processes to 
multiply their own numbers usually at the expense of the host cell. Recombinant viruses are 
commonly used to transfect cell lines and are highly efficient vehicles for gene delivery 
(Rosenfield et ai 1991, Douglas and Curiel 1997). The majority of gene therapy trials to date 
have used viral vectors (Rosenberg et al 1990, Blease et al 1995, Bellon et al 1997, Zhou et al
1998). However, there are significant problems associated with the use of viruses in gene 
therapy. Expression levels of the delivered gene deteriorate within weeks of administration 
and patients may develop an immune response to repeat or large doses of these viruses 
(Walther and Stein 2000). Administration of adenoviruses has been linked to cardiotoxicity and 
brain damage (Pouton and Seymour 2001). Cell specific targeting is difficult to achieve with 
adenoviruses, a limiting factor to their systemic administration. Also, the capacity of the 
current viral genomes is small (around 103 basepairs) so the size of the DNA that can be 
delivered is restricted (Behr 1993).
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Non-viral vectors for gene therapy
In this section we consider the cellular events that must occur for successful 
transfection by non-viral vectors alongside the natural cell processes that serve as barriers to 
this. There then follows an outline of the current approaches to transfection by the design and 
use of non-viral synthetic vectors. For reviews in non-viral approaches to gene therapy, see: 
Behr 1994, Mahato et al 1997, Pouton and Seymour 1998, Remy ef a /1998.
As previously described, the first requirement of a synthetic vector is to mediate the 
passage of a piece of DNA across the cell membrane. Small molecules (especially 
lipopolyamines) and cationic polymers mimic spermine and histones (Fig. 1) in the 
condensation of DNA plasmids into particles. These particles are of a suitable size (typically 
50-150 nm, Tang and Szoka 1997, Zelphati etal 1998) and charge to be taken up by 






Figure 4. Schematic of default cellular processes involved in 
particulate uptake (green arrows) and DNA nuclear delivery pathways (red arrows)
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Fig. 4 is a schematic representation of the default cellular pathways that can occur 
upon a particle interacting at such a site, namely endocytosis, lysosomal degradation and 
recycling and clearance. Also represented are the intracellular events that need to occur post- 
endocytosis for successful transfection, namely escape from the endosomal compartment and 
nuclear localisation.
DNA condensation is the first step required for efficient gene delivery, however, the 
natural polyamines are not suitably efficient DNA condensing agents for the delivery of DNA 
into cells. Therefore, polyamine conjugates with lipid moieties (lipopolyamines) and other 
synthetic cationic systems have been designed to achieve more efficient transfection. The 
following is an overview of the key compounds and concepts recently reported in the literature 
in this area of non-viral gene delivery.
Cationic polymers
Poly-L-lysine (PLL, Fig. 1) is a synthetic polymer, commercially available at various 
molecular weights and polydispersities. As introduced here, L-lysine is found extensively 
distributed in histones and carries a basic amine on its side-chain. PLL is therefore a 
polycation at physiological pH. Early work on histone-DNA interactions incorporated PLL-DNA 
binding studies (Leng and Felsenfeld 1966). PLL was shown to be efficient in the 
condensation of DNA. Since this earlier work, PLL has been used to condense DNA for gene 
delivery in vitro and in vivo and PLL-DNA condensates have been imaged as toroidal particles 
by AFM (Hansma et al 1998).
Starburst polyamidoamine (PAMAM) dendrimers are highly branched polymers (Kim 
and Zimmerman 1998). Spherical in shape, they present a surface of primary amino groups 
that may be protonated. Soluble in aqueous media, the cationic surface can efficiently bind to 
DNA and PAMAM dendrimers have been used as transfecting agents (Bielinska etal 1996,
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Kukowska-Latallo et al 1996, DeLong et al 1997). However, efficient transfection activity has 
been linked with high cytotoxicity in PAMAMs and PLL (Hill et al 1999).
Polyethylenimine (PEI, Fig. 5) is a commercially available branched or linear polymer 
of aziridine. Behr and co-workers have investigated the potential of PEI as a transfecting 
agent (Boussif et al 1995). They have shown PEI to be a highly efficient vector for the delivery 
of polynucleotides (Pollard et al 1998, Godbey et al 1999a and 1999b and 1999c).
Figure 5. Linear polyethylenimine: a cationic polymer
Cationic lipids I. Long chain aliphatic lipids
The cationic lipids are a class of compounds possessing a cationic headgroup 
covalently bound to a lipid moiety. The cationic nature of these compounds facilitates DNA 
condensation by charge neutralisation and the resulting particles are cationic lipoplexes.
These lipoplexes can bind to cell membranes and are taken up by endocytosis (for a review 
see: Miller 1998).
The first such compound for gene delivery was the unnatural diether-linked 
monocationic unsaturated lipid A/-[1-(2,3-dioleyloxy)propyl]-A/,/\/,A/-trimethylammonium chloride 
(DOTMA, Fig. 6) in 1987 (Feigner et al). Two years later the first commercially available 
formulation for transfection, Lipofectin, was marketed. Lipofectin is a 1:1 mixture of DOTMA 
and the naturally occurring zwitterionic lipid dioleoylphosphatidylethanolamine (DOPE, Fig 6. 
Feigner and Ringold 1989). DOTAP is the diester analogue of DOTMA and a number of 
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Figure 6. DOTMA and DOPE (the components of the Lipofectin reagent), a DOTMA analogue 
and an arsonium based cationic phosphonolipid
One of these DOTMA analogues is a cationic phosphonolipid with a quaternary 
arsonium moiety replacing the quaternary ammonium functional group (Guenin et a /2000). 
Arsenic occupies a greater covalent volume than fellow Group 15 element nitrogen, affording 
arsonium cations different ionic interactions than their ammonium counterparts, and also, 
potentially modified DNA binding characteristics (Guenin et al 2000).
Other workers have designed cationic lipids with two saturated C-18 chains. 
Dioctadecylamidoglycylspermine (DOGS, Transfectam, Fig. 7) is a polyamine conjugate which 
retains the methylene spacing of the natural DNA condensing polyamine, spermine (Behr et al 
1989). This was the first such lipopolyamine and is an efficient gene delivery vector in vitro 
(Remy et al 1998). Transfectam is a commercially available reagent for transfection of cell 
lines. The efficiency of this system relies on an excess of Transfectam with respect to 
lipopolyamine-DNA charge ratio, giving cationic lipoplexes. However, this has been shown to 
be less effective in Transfectam mediated transfection in vivo (Remy et al 1994).
HN
h2n
Figure 7. Transfectam (DOGS), a commercially available lipopolyamine
Byk and co-workers at Rhone-Poulenc Rorer have synthesised lipopolyamines with 
two C-18 lipid chains (Fig. 8), based on the established DOGS molecule (Byk etal 1998).
Using high dilution and solid phase methodologies (Byk etal 1997), this research group 
reported a rapid preparation of a library of unsymmetrical monofunctionalised polyamines. Byk 
and co-workers have shown higher in vitro gene delivery with linear, branched and “T-shaped” 
polyamine headgroups compared to globular geometries and attributes this to decreased pKa 
values in the globular polyamines. They (Byk et al 1998) also identify SARs in the linkers 
between the polyamine and lipid functions in these molecules. RPR-120535 is a linear 
polyamine linked covalently to two C-18 chains by glycine and has been shown to be the best 
compound in this series in the transfection of HeLa human carcinoma and NIH3T3 mouse 
fibroblasts with luciferase plasmid. This compound also displays significant in vivo transfection 





Figure 8. The RPR series of lipopolyamines: linear, globular, T-shaped and branched structures
15
Cationic lipids II. Steroidal lipids
In 1991, a cationic lipid was synthesised which used the natural steroid cholesterol as 
the lipid moiety. DC-Chol (Fig. 9) has a single amine functional group, linked to cholesterol as 
a carbamate (Gao and Huang 1991). DC-Chol/DOPE formulations were shown to have higher 
activity and lower cytoxicity in the transfection of A431 human epidermoid carcinoma cells than 
Lipofectin in vitro. This prompted other research groups to design cationic lipids using 
cholesterol as the lipid moiety. In 1996, b/s-guanidinium-spermine-cholesterol (BGSC) and 
b/s-guanidinium-fren-cholesterol (BGTC, Fig. 9) were synthesised (Vigneron eta l 1996).
These demonstrate DNA binding due to the high pKa of the guanidinium functional groups 
(typically 12.5) and in vitro transfection activity comparable to Lipofectin and Transfectam in a 
variety of cell lines (Pitard et al 1999).
A study of synthetic lipopolyamines by the Genzyme Corporation sought to establish 
structure-activity relationships within a series of polyamines conjugated to cholesterol and 
other lipid moieties (Lee et al 1996). These lipopolyamines and their DNA-complexes have 
been studied for their potential use in the treatment of cystic fibrosis by transfection of CFT1 
(CF airway epithelial) cells in vitro and mouse lung in vivo.
Me
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Figure 10. Genzyme lipopolyamines: lipid 53, lipid 67, lipid 75 and lipid 106
In the intranasal delivery of pCF1-pGal (p-galactosidase), pCF1-CFTR (cystic fibrosis 
transmembrane conductance regulator) and pCF1-CAT (chloramphenicol acetyltransferase) 
plasmids to the lungs of BALB/c mice (in vivo), Genzyme lipid 67, a "T-shaped" cholesteryl 
carbamate of spermine (Fig. 10) was found to be the most efficacious. “T-shaped" describes 
polyamines conjugated to lipids along the methylene chain or at a secondary amine. Lipid 67 
compared favourably to the spermidine conjugate, lipid 53 (one less amine) and the 
thermopentamine (3.4.3.3J conjugate lipid 75 (one more amine), showing the optimum number 
of basic amines in this series to be 3. To explain these results, the authors propose that the 
spermine headgroup of lipid 67 may have a specific molecular interaction within the mouse 
lung. They also ascribe the observed decrease in transfection activity of lipid 75 to increased 
cytotoxic micelle formation as a result of increased water solubility. Also, the regiochemistry of 
polyamine acylation was shown to be important -  linear lipopolyamines (acylated at the
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primary amine of the polyamine headgroup) were found to have less activity than their T -  
shaped” analogues. The linker is also important -  when an amide, amine (lipid 106) or urea 
replaces the carbamate function, some transfection activity is lost (Lee et al 1996).
Formulation with a co-lipid (DOPE) and subsequent optimisation of this formulation 
was found to give the highest transfection yields and lipid 67 was shown to be the best 
compound in vivo, mediating a 1000-fold higher expression than intranasal delivery of plasmid 
DNA alone. cAMP-stimulated chloride ion and fluid transport was observed in transfected 
tissues, functions lost in CF diseased cells. Transgene expression in the mouse was 
maintained by repeated intranasal administration of lipid 67:DOPE:plasmid DNA complexes. 
These and results for other compounds in this study did not correlate well with in vitro 
transfection assays. The most active compound in vitro was lipid 102, a T-shaped spermine 
conjugate diether-linked to two C-12 chains (Fig. 11). Despite this, compounds with low 
activity in vitro generally gave low in vivo gene expression. Although of some limited use in the 
biological testing of lipopolyamines for gene delivery, this does not provide a clear rationale for 
the design of novel efficient non-viral vectors.
NH. lipid 67 NH. lipid 102
Figure 11. Genzyme lipopolyamines: the most active compounds
in vivo (lipid 67) and in vitro (lipid 102) in their series
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In a later independent study, lipid 53 and lipid 67 together with their linear isomeric 
counterparts (Fig. 12) were used in transfection of myoblasts from dog muscle, a model study 
for the gene therapy of Duchenne muscular dystrophy (DMD), a human genetic disorder. In 
optimised formulations with DOPE, these cholesteryl carbamates were compared in vitro with 
canine myoblasts and human lung epithelial cells (A549). Transfection data between these 
cell lines did not correlate well, lipid 53 and lipid 67 having greater activity than the linear 
spermidine and spermine derivatives in the myoblast, trends not followed in the A549 cell 
model. Differences in the cationic-lipid mediated-transfection between cell lines make a 
comparison of these compounds difficult from the scientific literature as it currently exists, and 














Figure 12. Linear lipopolyamine regioisomers of Genzyme’s lipid 53 and lipid 67
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Genzyme have pursued their studies of polyamine-cholesteryl carbamates by variation 
of the polyamine headgroup, acylated at a primary amine to afford linear conjugates with 
"unnatural” methylene spacings between basic amine functional groups (Cooper et at 1998). 
The most active compound in vivo was CTAP (Fig. 13), when formulated with DOPE, achieving 
a similar level of transfection as lipid 67, in the delivery of pCF1-CAT to the lungs of female 
BALB/c mice. As in studies described previously, the most active compound in vivo was not 
the most active compound in vitro (linear thermopentamine conjugate CTAH, Fig. 13). CTAH 
differs from CTAP in that it contains a terminal 3-aminopropyl moiety rather than a terminal 2- 
aminoethyl moiety, implying different pKaS and a different overall cationic charge on the 
polyamine headgroup at physiological pH. Indeed, the authors conclude that methylene 
spacing in these lipopolyamines is more important than number of amine functional groups in 
conferring DNA binding strength and ultimately biological activity.
In parallel, linear cholesterol-polyamine carbamates with up to five amino functional 
groups, including polyethylenimine mimics (Fig. 14) were synthesised (Geall et ai 1998b). In 
this series of compounds, pKa values of these amines were measured and condensation of calf 
thymus DNA was studied. It was shown that regiochemical distribution of the amines was 
important in DNA condensation by lipopolyamines and that this is crucial in the design of these 





Figure 13. The linear polyamine cholesteryl carbamates CTAP and CTAH
Figure 14. A linear polyamine-cholesteryl carbamate as a lipopolyethylenimine mimic
Since the first cholesteryl carbamates appeared in the literature, lipopolyamines 
incorporating steroids other than cholesterol have been designed and synthesised for non-viral 
gene delivery (Geall et al 1998a, Walker et al 1996, Walker et al 1998). The bile acids are a 
class of naturally occurring steroids, characterised by cis-AB ring junctions and mono- to poly- 
hydroxylation. Polyamines substituted with lithocholic and cholic acid have been designed 
(Walker et al 1996, Geall et al 1998a, Blagbrough et al 2000). These bile acids have one and 
three hydroxyl groups respectively, which are present on one side (the a-face) of the steroid 
skeleton. These polyamine conjugates are therefore facial amphiphiles, with polar and non­
polar faces. This is in contrast to the other cationic lipids, which have a polar head and non­
polar lipid tail. Polyamine-lithocholic acid amides condensed DNA more efficiently than 
polyamine-cholic acid conjugates and this effect has been attributed to the higher 
hydrophobicity of lithocholic acid, carrying only one hydroxyl group (Geall et al 1998a). 
Currently, the best facial amphiphile in this series for in vitro gene delivery is a 7,12-bis- 
glucosylated-cholic acid acylated hexamine, Fig. 15 (Walker et al 1996 and 1998). It is 
reported that weak DNA binding (hence dissociation of DNA from the vector) and an 
endosome escape mechanism driven by unfavorable interactions between the polar steroid p- 
face and the lipid bilayer contribute to these molecules transfection activity (Walker eta l 1998).
Rho  R = a-glucoside
Figure 15. A glucosylated polyamine-cholic acid amide: a cationic facial amphiphile
Natural product steroidal amines are known to exert structural control on DNA, 
including irehdiamine A (Fig. 16), isolated from the West African ireh rubber tree (Hsieh et al 
1995, Muller et al 1995), and polyamine analogues of these compounds have been 
synthesised incorporating bile acids, for example a tetraamino steroid dimer (Fig. 16) which 
displays higher affinity for calf thymus and synthetic poly [d(A-T)]2 and poly [d(G-C)]2 DNAs 
than the tetraamine spermine (Hsieh et al 1994). These recent studies did not report the 
potential for these molecules (as cationic lipids) in the delivery of polynucleic acids into cells, 
however they focused on the binding to and structural manipulation of DNA, pertinent issues in 
the design of new non-viral transfection agents.
Figure 16. Natural and synthetic steroidal polyamines: irehdiamine A and synthetic amino steroids
Me




Particles of DNA-lipopolyamine (or other non-viral gene delivery vector) complexes are 
internalised by endocytosis (Miller 1998). At no time during this process does the DNA particle 
cross a lipid bilayer, indeed endocytosed material is enveloped by a phospholipid bilayer. 
Therefore, any material contained within the resulting endosome cannot be considered to have 
entered the cell. Natural cell processes dictate that material contained within an endosome is 
destined for enzymatic degradation by fusion with a lysosome. In addition to this, in order for 
the foreign genetic information to be expressed, it must be present in the cell nucleus and 
therefore must leave (escape) the endosome. Mechanisms for endosome escape vary 
between non-viral gene delivery vectors. Spontaneous escape may occur in small 
percentages of DNA-vector containing endosomes (Zabner et al 1995), or escape may be 
induced by addition of chloroquine (Miller 1996, Zelphati and Szoka 1996, Pouton and 
Seymour 1998). Viruses commonly express peptides on their protein coat which fuse which 
phospholipid bilayers and cause poration (Moradpour et al 1996) and these fusogenic peptides 
have been investigated for their ability to facilitate endosome escape in non-viral gene delivery 
systems (Moradpour et al 1996, Wyman et al 1997, Themis et al 1998). Buffering of 
endosome pH (5.5, Remy et al 1994) as a prelude to enzymatic degradation in the lysosome is 
a natural biochemical process. Fusogenic peptides adopt amphiphilic a-helical conformations 
around pH 5.0. Such helical structures interact with and disrupt phospholipid bilayers (Morris 
et al 2000). Some non-viral vectors, especially PEI and lipopolyamines containing aminoethyl 
moieties (e.g. CTAP), possess corresponding pKa values and are protonated during this 
process. This protonation drives osmolytic swelling of the endosome, leading to rupture and 
escape of the endosomal contents into the cytoplasm (Remy et al 1998, Godbey et al 1999c).
23
Nuclear translocation
The focus of some current research in the area of non-viral gene delivery has moved 
away from optimisation of the lipopolyamine vector. Byk, Behr and others (Neves et al 1999a, 
Zanta et al 1999) are attempting to increase transfection activity of cationic liposomes by 
increasing the amount of nucleic acid material that enters the cell nucleus once delivery into 
the cytoplasm is achieved. Poor nuclear translocation is a hurdle to efficient transfection. 
Nuclear localisation signals (NLS) are short peptides that mediate movement of large 
molecules into the cell nucleus (Davis 1999). Typically of 7-12 amino acid residues, most NLS 
peptides conserve a sequence of five consecutive cationic residues, made up of lysine and 
arginine (Zanta et al 1999). The amino acid sequence PKKKRKVEDPYC is typical of NLS 
peptides (Zanta et al 1999). Some viruses use an NLS in their protein coats to invade the 
nucleus of a host cell (Davis 1999). PKKKRKV is a conserved sequence in the large tumour 
antigen of Simian virus 40 (Morris et al 2000). Attempts are being made to couple NLS 
dodecapeptides into a non-viral gene delivery protocol (Ciolina ef a /1999, Neves etal 1999b, 
Zanta et al 1999). Natural and synthetically modified NLS peptides are being covalently 
coupled to plasmid DNA and oligonucleotides, which are delivered by cationic lipids. Results 
have thus far been mixed, but this approach has seen success in the HeLa cell line (Zanta et al
1999).
Study of transfection by fluorescent microscopy
Thus, although there is now a range of available non-viral agents that promote 
transfection, still little is known about the mechanisms that underlie this phenomenon. Zabner 
et al (1995) showed that cationic liposomes were taken up by endocytosis yet not all cells 
expressed genes taken up by this process. Therefore, successful transfection is reliant on 
efficient intracellular mechanisms and it is important to study this phase of cationic lipid-
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mediated gene delivery. Transfection efficiency cannot be improved without a greater 
knowledge of the molecular detail of intracellular events. Confocal microscopy with 
appropriate fluorescent molecular probes is now routinely used in the study of intracellular 
phenomena and is potentially useful for the study of lipopolyamine-mediated transfection.
There are various strategies that may be employed in the confocal imaging of in vitro 
transfection processes. By labelling either the vector or the polynucleic acid (or potentially 
both with suitably different non-overlapping fluorophores), there is the potential to track the 
distribution and time course of this distribution of these components in a cell cluster. In the 
study mentioned above, Zabner et al (1995) were the first to attempt direct study of the uptake 
and subsequent fate of cationic liposomes by fluorescent microscopy. Using DNA covalently 
labelled with the fluorescent dye ethidium and labelled DMRIE (a monocationic lipid), they 
observed endocytosis and fusion of endosomes near the nucleus. No fluorescent DNA was 
detected inside the nucleus and both fluorophores were not detected in the same experiment.
Byk and co-workers have designed a fluorescent probe in the RPR-series of 
lipopolyamines (Byk etal 1998). RPR-121653 (Fig. 17) is a derivative RPR-120535 (Fig. 8), 
the most efficacious compound in this series. The fluorescent label tetramethylrhodamine 
isothiocyanate is coupled as a thiourea onto the side chain of lysine, which links the polyamine 
and lipid functionalities. In fluorescence imaging experiments RPR-120535 has been 
formulated with RPR-121653 in a 30:1 ratio and incubated with DNA to form fluorescent 
lipoplexes (Helbling-Leclerc et al 1999). Cells were then transfected and the intracellular fate 
of the lipopolyamine coat followed by confocal microscopy. In their study, the fluorescent 
lipopolyamine was used to probe differences in myogenic cell uptake of cationic lipids to 





Figure 17. RPR-121653, a tetramethylrhodamine labelled lipopolyamine
DOTAP/DOPE liposomes have also been used in the delivery of antisense 
oligonucleotides in vitro (Marcusson et al 1997) for the inhibition of gene expression. For the 
confocal study of this phenomenon in A549 cells, a fluorescent derivative of DOTAP has been 
synthesised with a BODIPY fluorophore (Fig. 18). This has been used to deliver rhodamine- 
labelled 20-mer phosphorothioate oligonucleotides for targeting of protein kinase C-a mRNA. 
The study demonstrated that the BODIPY label did not affect the ability of the liposome to 
deliver the antisense DNA to its target sequence in the nucleus. Although short 
oligonucleotides of this type are not condensed, as are DNA plasmids, there is association with 
the cationic lipid in the liposome. This association is observed by fluorescence microscopy to 
break down before the DNA enters the nucleus. By comparing the fluorescence staining of an 
endosome I lysosome selective probe (TMA-DPH) to the fluorescence pattern observed for the 
BODIPY-DOTAP conjugate, the authors concluded that these are the final destination for 
cationic lipids in these cells, although the two fluorophorescent probes were never directly 
observed to co-localise due to overlap of their emission wavelengths. This limitation highlights
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issues in multicolour confocal studies in terms of experiment design, conjugate design and the 
appropriate choice of fluorophores.
As introduced above, the cationic polymer polyethylenimine (PEI) is an efficient DNA 
condensing agent. This has recently been derivatised with the fluorescent dye Oregon Green 
488 (Godbey et al 1999b). Labelled PEI was used to condense plasmid DNA labelled with a 
red fluorophore (rhodamine). The cellular uptake and subsequent fate of this doubly-labelled 
PEI-DNA complex has been tracked by fluorescent microscopy. The timescale of such events, 
and the distribution of these fluorophores have been studied. PEI-DNA complexes were seen 
to enter the cell by endocytosis and the observation of an apparently yellow fluorescence 
(combination of red and green emission wavelengths) at cell nuclei suggests that PEI and DNA 
make their way to the nucleus as associated complexes (Godbey et al 1999b and 1999c). In 
their studies, it was also reported that PEI is endocytosed and undergoes nuclear localisation 
even when administered without nucleic acid material.
Expression of transfected genes may be imaged using a plasmid gene that encodes 
for a fluorescent protein product or an enzyme that catalyses the formation of fluorescent small 
molecule products. These genes are known as reporter genes. An example of a fluorescent 
gene product is the green fluorescent protein (GFP, Cody et al 1993). GFP is a natural 
product from the jellyfish Aequorea victoria that undergoes posttranslational modification of 
three sequential amino acid residues (serine-tyrosine-glycine, S65-Y66-G67). The folding of
o
Figure 18. A fluorescent cationic lipid: a BODIPY derivative of DOTAP
the protein promotes cyclisation to an imidazolone followed by an oxidation step to afford 
conjugation to the phenolic side chain of Y-66 (Fig. 19, Reid and Flynn 1997). The resulting 
fluorophore is protected from solvent quenching by the surrounding p-sheets and emits visible 
light at 508 nm upon excitation with UV light. For reviews on the structure, chemistry and use 
of GFP plasmids as reporter genes, see: McCapra et al 1988, Cody et al 1993 and Ormo et al 
1996.
Examples of enzymic gene products are p-galactosidase (p-Gal) and luciferase. 
These enzymes catalyse the conversion of a non-fluorescent substrate into a fluorescent 
product. This substrate has to be fed to the cell culture during the transfection experiment. 
The substrates for the p-galactosidase assay are conjugates of p-D-galactopyranoside sugars 
where the enzyme catalyses the hydrolysis of p-glycosidic bonds (acetal moieties). A number 
of substrates are commercially available for this assay, including a 4-methylumbelliferyl 
conjugate and a fluorescein conjugate (Fig. 20). In this conjugate, the fluorescein is locked 
into the non-fluorescent spirolactone form by bls-O-glycosylation with two p-D- 
galactopyranoside sugars. In the p-galactosidase assay, these are specifically hydrolysed by 
the newly expressed enzyme to liberate the highly fluorescent fluorescein (Fig. 20).
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Figure 20. Substrates for the p-galactosidase gene expression assay
Aims of this thesis
The aims of this thesis are to understand, design and prepare small molecule 
lipopolyamines for non-viral gene therapy. Initially, a concise review of the scientific literature, 
mainly published prior to the start of these synthetic and analytical studies sets the scene for 
our own medicinal chemistry research in this area of non-viral gene therapy. In order to study 
the synthesis, analysis and the molecular details of intracellular interactions of lipopolyamine 
vectors, we outline the design of polyamine-lipid conjugates based on naturally occurring 
polyammonium and steroid moieties.
The study of the molecular interactions between lipopolyamine gene delivery vectors 
and polynucleic acids requires an understanding of the synthesis of such designed molecules. 
Starting from the naturally occurring polyammonium DNA condensing agent spermine, we 
present the design of its conjugates with the steroidal lipids cholesterol and lithocholic acid. 
These polyamine-cholesteryl carbamates and polyamine-lithocholic acid amides incorporating 
alkyl spermidine and spermine polyammonium moieties represent the first synthetic targets, 
and their interactions with, and condensation of, natural and synthetic DNA will be evaluated.
Non-viral vector mediated cell transfection remains a poorly understood phenomenon 
both in vitro and in vivo. In order to study the intracellular distribution and fate of 
lipopolyamine-DNA complexes we aim to synthesise designed fluorescent models of our 
synthetic polyamine conjugates of cholesterol and lithocholic acid. Such target fluorescent
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lipopolyamines may be considered as analytical tools for the tracking, by confocal microscopy, 
of lipopolyamine-DNA complexes in cells. Such transfection studies are necessary to observe 
intracellular events such as endosome escape and nuclear trafficking, two barriers to efficient 
gene delivery in current non-viral vectored systems. The synthesis of these analytical tools will 
require chemical modification and manipulation of steroid moieties possessing variation in the 
configuration at the AB ring junction, and of commercially available fluorophores to produce 
highly fluorescent lipopolyamine conjugates.
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CHAPTER 2
Synthesis and analysis of steroidal lipopolyamines
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Synthesis and analysis of steroidal lipopolyamines
Polyamines are distributed extensively in natural biological systems, and along with 
their alkylated and acylated derivatives, they are involved in a variety of roles such as DNA 
replication, DNA damage protection, tumour proliferation, ion-channel modification and as 
components in invertebrate (spider and wasp) venoms. Therefore, syntheses of a wide variety 
of spermine 1 and spermidine 2 derivatives have been published in the scientific literature (for 
recent reviews on the roles of polyamine conjugates and their synthesis, see: Blagbrough et al 
1997, Kariagiannis and Papaioannou 2000, Kuksa et al 2000). Initially, our studies of 
steroidal-polyamine conjugates for non-viral gene delivery focused on the acylation of suitably 
protected spermine 1 as a route to lipopolyamine carbamates and amides.
The first targets for this work were monoacylated spermine conjugates of the steroids 
cholesterol 7 and lithocholic acid 17 (Fig. 21) thereby incorporating spermidine 2 as the 
polyammonium moiety. Fig. 21 illustrates the common structural motifs of our lipopolyamines 
-  a hydrophobic lipid region, which varies in shape about the AB-ring junction, covalently 
attached to a polyammonium (at physiological pH) DNA-binding region. These hydrophobic 
and hydrophilic moieties are connected through a linker region built from an amide or 
carbamate, and this represents a point of disconnection in the synthesis of these molecules.
Many literature syntheses of polyamines build a polyamine chain from smaller units 
(Pak and Hesse 1998), especially through Michael-additions to acrylonitrile (ethenyl cyanide) 
and subsequent reduction (of the nitrile functional group) (Bergeron and Garlich 1984). 
Polyamines and their conjugates may be constructed in this way, or may be derivatised from 
commercially available polyamines (Blagbrough and Moya 1995, Moya and Blagbrough 1995, 
Blagbrough et al 1996, Geall et al 1998b). This may be performed on the solid phase (Byk et 







Figure 21. Spermine 1, spermidine 2 and target steroidal lipopolyamines: 
cholesteryl carbamate 7 and lithocholic acid amide 17
For this work we chose a solution synthesis, starting from the readily available 
spermine 1. This approach required an efficient monoacylation of this symmetrical tetraamine 
at a primary amine to afford linear steroidal polyamines. Literature procedures (Ashton et al 
1995, Blagbrough and Moya 1995, Bischoff et al 1997) for the synthesis of such monoacylated 
polyamine conjugates often rely on the use of large excesses of free polyamine in the 
presence of the electrophile, and therefore a statistical selectivity for monoacylation of the 
polyamine, resulting in low yields and the requirement for rigorous chromatographic 
purification.
Spermine 1 is a symmetrical polyamine with four nucleophilic amines. Therefore, 
directly acylating this compound with the majority of acylating agents (such as acid chlorides,
cationic spermidine moiety
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anhydrides or chloroformates) yields mixtures of regioisomers (Bischoff et al 1997, Bergeron 
and McManis 1998) of mono-, di-, tri-acylated species along with the tetra-acylated polyamine. 
In order to address this problem in the synthesis of linear lipospermine derivatives, Blagbrough 
and Geall (1998) developed a route for the stepwise protection of spermine to afford A/1,A/4,A/9- 
tri-Boc spermine 5 (Fig. 22). Starting from spermine 1, a selective protection of one primary 
amine with ethyl trifluoroacetate affords the trifluoroacetamide 3. The trifluoroacetyl group is a 
known protecting group for amines and ethyl trifluoroacetate has been shown to be a useful 
reagent for the introduction of trifluoroacetyl groups to the primary amines of polyamines 
(O’Sullivan and Dalrymple 1995, Blagbrough and Geall 1998). Selectivity for acylation or 
alkylation of primary over secondary amines in polyamines is partly derived from the higher 
reactivity of primary amines due to steric over electronic effects. However, trifluoroacetamides 
of secondary amines are known (Pak etal 1998, Pak and Hesse 1998). This selectivity in 
polyamines has been further established by demonstration of 1,3-acyl migrations of 
trifluoroacetyl groups from secondary amines to newly deprotected primary amines (Pak and 
Hesse 1998).
In the synthesis published by Blagbrough and Geall (1998, Geall and Blagbrough
2000), the remaining three amines of 3 are Boc-protected, then trifluoroacetamide 4 is cleaved 
at pH 11 with conc. aq. NH3 affording primary amine 5. This route has the convenience of 
being one-pot in MeOH throughout these three steps and may be performed on a multi-gram 
scale. Therefore, it was the protection strategy of choice in our synthesis of polyamine- 
cholesteryl carbamate 7 and lithocholic acid amide 17.
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Figure 22. Synthesis of W.W.A/Mri-Boc protected spermine 5 
i. CF3C02Et, MeOH, -78 °C to 0 °C over 1 h; ii. (Boc)20, MeOH, 0 °C to 25 °C over 1 h, 18 h; 
iii. Cone. aq. Nhb, MeOH, 25 °C, 18 h
Following this route (Fig. 22), A/1,A/4,A^-tri-Boc spermine 5 was routinely synthesised 
on multi-gram scales (typically 3-6 grams of 1 affording typically 4-7 grams of 5 , 45-55 % yield) 
in 24 h and following only one chromatographic separation from A/4,A/9-di-Boc spermine 
(derived from an initial di-trifluoroacetylation). Compound 5, with the appropriate mass 
spectrum (Fig. 23, FAB-HRMS C34H57N2O2 requires 503.3809 (MH+), found 503.3829), 
displayed fragmentation consistent with the loss of up to three Boc groups, this pattern
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(multiple losses of 100 m/z) was reproducible and was regularly observed with the poly-Boc 
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Figure 23. FAB mass spectrum (positive ion mode), showing fragmentation of A/1,A/4,A/Mri-Boc spermine 5
Synthesis of polyamine-cholesteryl carbamates
The primary amine of 5 was acylated with cholesteryl chloroformate to afford, after 
workup and chromatography (EtOAc-hexane 7:3 v/v, Rf 0.65), the carbamate 6 in 86 % yield 
(Fig. 24). This compound was then treated with TFA in CH2CI2 (1:9 v/v) to effect the Boc- 
deprotection. The success of this step relies on the cholesteryl carbamate (derived from a 
secondary alcohol) remaining intact while the Boc carbamates (derived from tertiary alcohols) 
are deprotected through nitrogen protonation, loss of CO2 and /so-butylene.
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Figure 24. Synthesis of target polyamine cholesteryl carbamate 7 
i. Cholesteryl chloroformate, CH2CI2, TEA, 25 °C, 6 h; ii. TFA-CH2CI2 (1:9), 25 °C, 4 h
These deprotections render polyamines as their poly-TFA salts and hence they are 
very polar. Even with the use of MeOH and conc. aq. NH3 in high proportion of the mobile 
phase, column chromatography gives unsatisfactory results in the purification of these 
polyvalent (polycationic) compounds. As polyamines are known to be hygroscopic and vary in 
salt content, melting points and elemental analysis are not reproducible and therefore not 
particularly relevant techniques for the determination of purity in these instances. Therefore, 
compound 7 was recrystallised (EtOAc) to provide an analytical sample for NMR analysis, 
whose spectral data were in agreement with published literature values (Geall et al 2000). For 
DNA work, semi-preparative RP-HPLC (MeCN-0.1 % aq. TFA 6:4 v/v, /r 7.7 min) was used to 
purify 10 mg of this material as the poly-TFA salt (99.4 % purity measured by HPLC).
Fig. 25 outlines the numbering system used in the NMR assignment of cholesteryl 
carbamate 7. Lithocholic acid polyamine amides are similarly numbered. We have named 
these target lipids as the parent polyamine and occasionally refer to the abbreviated 
polymethylene spacing for convenience and comparison. Under this system, spermine 1 is 
named 1,12-diamino-4,9-diazadodecane (polymethylene spacing 3.4.3) and carbamate 7 is 
(/V1-cholesteryl-3’-oxycarbonyl)-1,12-diamino-4,9-diazadodecane (3.4.3-Chol).
Synthesis of Genzyme lipopolyamines
Polyamine-cholesteryl carbamates such as 7 are lead compounds in the area of non- 
viral gene delivery, in particular Genzyme’s “T-shaped” lipid 67 10, where spermine 1 is 
monoacylated at a secondary amine. This compound is currently in clinical trials for the 
delivery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene for the gene 
therapy of cystic fibrosis. In order to improve on literature methods for the preparation of lipid 
67 (uncontrolled acylation of spermine 1, Bischoff et al 1997) and to measure pKa values so 
that DNA condensation may be compared to our synthesised linear regioisomer 7, we devised 
a synthesis using the trifluoroacetyl group to mask selectively both primary amines of spermine
21 * 22 '  24 '  26 '
Figure 25. Numbering system for polyamine cholesteryl carbamate 7
(Fig. 26).
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R1 = H, R2 = H, R3 =H spermine 1 
R1 = COCF3, R2 = H, R3 = H 8 
R1 = COCF3, R2 = C02Cholesteryl, R3 = H 9
R1 = H, R2 = C02Cholesteryl, R3 = H lipid 67,10
Figure 26. Proposed synthesis of lipid 6710 
i. CF3C02Et, MeOH, -78 °C to 0 °C over 1 h; ii. Cholesteryl chloroformate, TEA, CH2CI2 , 25 °C;
iii. Cone. aq. NH3, MeOH, 25 °C
This route was initially attempted as a one-pot procedure, in an analogous manner to 
the synthesis of 5. However, the initial trifluoroacetylation proved to be too inefficient for 
adequate control of the subsequent acylation with cholesteryl chloroformate. The need for 
MeOH in the final deprotection step limited a one-pot approach in this case, as it is not an 
appropriate solvent for using cholesteryl chloroformate where there was poor solubility and low 
nucleophilic reactivity. However, when CH2CI2 was used as the solvent, trifluoroacetylation 
and acylation with cholesteryl chloroformate proceeded cleanly to afford 9 in good yield (76 %). 
However, this was only achieved after problematic purification by column chromatography 
(partial trifluoroacetyl deprotection on the column due to use of NH3 in the mobile phase 
(CH2Cl2-MeOH-conc. aq. NH3100:10:1 v/v/v, R< 0.38).
Attempts to deprotect ditrifluoroacetamide 9 using conc. aq. NH3 in MeOH largely 
failed due to the poor solubility of 9 in MeOH-H20 mixtures. Even in solution (requiring large 
volumes of MeOH, typically 900 ml to dissolve 500 mg of 9), the deprotection only partially
proceeded, leading to crude mixtures of starting material (FAB-MS m/z 807 (MH+),
C42H68N4O4F6 requires 806) and two monotrifluoracetamides (more polar, ninhydrin positive 
spots by TLC, FAB-MS m/z 711 (MH+), C40H69N4O3F3 requires 710). This method was 
pursued by bubbling NH3 gas through neat MeOH at -5  °C, sealing the solution in an airtight
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Schott-Duran bottle then heating at 40 °C for 3 days (similar deprotections taking 6 days have 
been reported in the literature -  Doll et al 1994). This led to full consumption of starting 
material 9 and the appearance of a new polar compound by TLC, though attempts to isolate 
this material failed. The crude material gave the correct mass spectral data for lipid 6710 
(FAB-MS m/z 615 (MH+), C42H68N4O4F6 requires 614; FAB-HRMS calculated 615.5577 (MH+), 
found 615.5579). The product gave different chromatography to that of the linear regioisomer 
7 (tn 7.7 min by RP-HPLC, Supelcosil ABZ+Plus, 5 jam, 15 cm x 4.6 mm, MeCN-0.1 % aq. 
TFA, 6:4 v/v), having less affinity for a reverse phase column (/r 7.5 min, MeCN-0.1 % aq.
TFA, 4:6 v/v), in good agreement with data published by Bischoff et al (1997). Disappointingly, 
this method was not efficient enough for the production of sufficient quantities for further 
analysis.
During this time, other attempts using literature procedures for the cleavage of 
trifuoroacetamides employing a variety of bases including K2CO3 in MeOH, and 
trimethylbenzylammonium hydroxide in CH2CI2 (Greene and Wuts 1991, O’Sullivan and 
Dalrymple 1995, Golding et al 1999) also failed. However, a detailed search of the literature 
revealed deprotections of /\/1,A/4,A/12-triacylated spermine trifluoroacetamides are known by 
these reagents (O’Sullivan et al 1997).
As part of these synthetic studies in ”T-shaped’’ polyamine-cholesteryl carbamates we 
acylated spermidine at the secondary amine in an analogous manner to 9 (Fig. 27) to afford 
ditrifluoroacetyl protected lipid 5312. In repeated small-scale reactions (of upto 40 mg), this 
product was readily deprotected under a variety of basic conditions (NH3-MeOH, K2CO3- 
Me0H-H20) to give lipid 5313 (with the appropriate mass spectral data: FAB-MS m/z 558 




 R1 = H, R2 = H spermidine 2
= r R 1 = COCF3, R2 = H 11
-  R1 = COCF3, R2 = C02Cholesteryl 12
 ► R1 = H, R2 = C02Choiesteryl, R3 = H lipid 53,13
Figure 27. Synthesis of lipid 5313 
i. CF3C02Et, CH2CI2, -78 °C to 0 °C over 1 h; ii. Cholesteryl chloroformate, TEA, ChhCh, 25 °C, 18 h;
iii. Cone. aq. NH3, MeOH, 25 °C, 1 h
This success encouraged us to pursue a modified route to the spermine analogue, 
lipid 6710 (Fig. 28). Starting with the A/1,A/12-ditrifluoroacetyl protected spermine 8, cleanly 
prepared in high yield (93 %) using the procedures of O’Sullivan and Dalrymple (1995), we 
acylated the A/4-secondary amine with cholesteryl chloroformate to afford conjugate 9 as 
previously described. The remaining free amine (A/9) was Boc protected (Boc anhydride in 
CH2CI2) and the predicted non-polar product 14 was purified by column chromatography (Ri
0.46, CH2Cl2-hexane 7:3 v/v). 1H and 13C NMR data for this compound showed the clear 
presence of a Boc carbamate (28.8 and 80.9 ppm for Boc methyls and sp3 quaternary carbons 
respectively), yet FAB and electrospray mass spectrometry failed to indicate this. Given the 
predicted chromatography and NMR data, it is likely that the Boc carbamate is particularly 
labile in compound 14 under the ionisation conditions applied. Due to time constraints we 
were not able to pursue this point rigorously, but preliminary results show that compound 14 is 
readily deprotected (MeOH-conc. aq. NH3) to afford a polar baseline spot by TLC. We argue 
that compound 15 is readily formed under standard conditions for the cleavage of a 
trifluoroacetamide (MeOH-conc. aq. NH3, Greene and Wuts 1991, O’Sullivan and Dalrymple 
1995), under which trifluoroacetamides of lipid 6710, such as conjugate 9, were stable. Also,
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after this step, without purification of 15, the Boc deprotection should be immediately effected 
(TFA-CH2CI2) in order to purify polyamine conjugate 10 by RP-HPLC.
R1 = COCF3, R2 = C02Cholesteryl, R3 = H 9 
R1 = COCF3, R2 = C02Cholesteryl, R3 = Boc 14 
R1 = H, R2 = C02Cholesteryl, R3 = Boc 15 
R1 = H, R2 = C02Cholesteryl, R3 = H lipid 67,10
Figure 28. Proposed modified route for the synthesis of lipid 6710
i. Boc20, CH2CI2, TEA, 25 °C; ii. Cone. aq. NH3, MeOH, 25 °C; iii. TFA-CH2CI2 (1:9), 25 °C
Synthesis of polyamine-lithocholic acid amides
The cis-AB ring configuration affords bile acids such as lithocholic acid with a 
different shape compared to the steroid cholesterol which can considered to be planar.
Structural differences such as AB ring configuration have been shown to bestow different DNA- 
binding activities upon amino-steroids (Hsieh e ta l 1995). As discussed in Chapter 1, 
polyamine amides of lithocholic acid and other bile acids have been shown to condense DNA 
(Geall et al 1998a) and to mediate DNA delivery (Walker et al 1996). Spermidine mimics 
incorporating bile acid moieties are therefore probes of steroid conformation and its influences 
on DNA binding affinity or transfection efficiency. As part of our synthetic studies of steroidal 



















Figure 29. Synthesis of target polyamine-lithocholic acid amide 17 
i. Lithocholic acid. EDC, HOBt, CH2CI2. 25 °C, 16 h; ii. TFA-CH2CI2 (1:9), 0 °C, 4 h
In order to prepare amide 16, the primary amine of 5 was acylated with lithocholic acid, 
using the carbodiimide EDC as the dehydrating agent, with a catalytic amount (typically 0.5 
molar equivalents) of HOBt. This reaction proceeded smoothly in 86 % yield. Whilst initial 
attempts to make this compound succeeded, later larger scale preparations suffered from an 
unclean reaction where the starting acid was not fully consumed. As the product has a similar 
(higher) Rf to lithocholic acid in a variety of mobile phases, purification proved more difficult.
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Washing with base (aq. NaOH) failed to remove this hydrophobic acid. Reaction yields 
improved when the EDC was added to the suspension of lithocholic acid in anhydrous CH2CI2, 
followed by HOBt only when the solution cleared (usually after 5 min), indicating the acid had 
been activated. The amine was added last and this order of addition was used for all future 
amide (or ester) forming reactions. Where DCC replaced EDC as the coupling reagent, a 
precipitate of DCU was visible shortly after the addition of the amine (or alcohol for ester 
formation).
The deprotection of amide 16 proceeded upon treatment with TFA-CH2CI2 (1:9 v/v), 
however 1H and 13C NMR data were consistent with the trifluoroacetyl ester 18 of the 3a- 
hydroxyl group (steroid 3’-CH resonances, values in ppm, for 16 in brackets): 1H NMR 4.87- 
4.98 in d6-DMSO (3.55-3.64 in CDCI3); 13C NMR 79.5 (72.1). The elemental composition 
provided by the accurate mass spectrum confirmed the ester 18 (C36H64N4O3F3 requires 
657.4931 (MH+), found 657.4961).
New hydrophobic moieties in non-virai gene delivery vectors
Transfection efficiency is still too low with published non-viral vectors (Li and Huang 
2000, Brown et al 2001, Pouton and Seymour 2001, Schatzlein 2001). Together with a need 
for further understanding the mechanisms underlying gene delivery, we and others are 
designing new non-viral vectors containing, novel structural motifs. One example of such 
design is a new class of cationic lipid incorporating a Buckminster fullerene C60 core. One 
hemisphere of the buckyball has been conjugated, via cycloaddition, to a tetraammonium 
moiety (19, Fig. 30, Nakamura et a /2000).
GS4 (20, Fig. 30) is a cationic gemini surfactant with two Ci2-lipid chains conjugated to 
four lysine residues, affording up to six positive charges at physiological pH. This compound has 
some in vitro transfection activity when used alone, below its critical micelle concentration.
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When used in formulation with the zwitterionic "helper” lipid dioleoylphosphatidylethanolamine 
(DOPE) and a basic polypeptide, transfection activity is enhanced. Novel spermine-based 
cationic gemini surfactants symmetrically acylated with two Cis-lipid and two tri-lysine chains, 
with up to 8 positive charges, have also recently been reported (Ronsin et al 2001).
19
Figure 30. Polyamine-Buckminster fullerene conjugate 19 and GS4, a cationic gemini surfactant 20
During our synthetic studies in lipopolyamine-mediated DNA condensation, new 
cationic lipids for gene delivery have been designed incorporating the D-vitamins as the lipid 
moieties (Ren et al 2000). Vitamin D2 (ergocalciferol, 21, Fig. 31) and vitamin D3 
(cholecalciferol, 22, Fig. 31) are steroids possessing an open B-ring, formed by UV irradiation 
of the biochemical precursors ergosterol (23, Fig. 31) and 7-dehydrocholesterol respectively 






Figure 31. Structures of vitamin D2 21, vitamin D3 22 and ergosterol 23, the biosynthetic precursor of vitamin D3
Ren et al (2000) designed and synthesised carbamates of vitamin D2 and vitamin D3 
incorporating primary, tertiary (24, Fig. 32), quaternary and poly- (25, Fig. 32) amine moieties 
as the cationic headgroups. Vitamin D3 conjugate 24 carries a dimethylaminoethyl carbamate 
moiety which, at physiological pH, mimics the one positive charge possessed by 3p-[A/,-(A/’,/\/"- 
dimethylaminoethane)-carbamoyl]-cholesterol (DC-Chol, 26, Fig. 32, Gao and Huang 1991), 
the first steroid (cholesterol)-based cationic lipid for gene delivery. The polyamine-vitamin D 
carbamates are monoacylated triethylenetetraamine (tren) conjugates (e.g. carbamate 25, Fig. 
32) and are therefore small molecule mimics of branched polyethylenimine (see Chapter 1). 
The authors of this study do not detail pKa values for carbamate 25, but it is likely these basic 
moieties are dications (not trications) at physiological pH due to the presence of two p- 
aminoethylamine groups. These fre/7-based steroidal polyamines are similar to second 
generation cholesterol-carbamates such as b/s-guanidium-fre/7-cholesterol BGTC (27, Fig. 32, 
Vigneron et al 1996, Pitard et al 1999). However, the charge of a protonated guanidine moiety 
is delocalised over four atoms, therefore the regiochemical distribution of positive charges at 
any given time is not neccesarily the same in molecules 25 and 27. Despite guanidines having 
high pKas and high binding affinity for DNA (explained by net charge neutralisation and also
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hydrogen bonding, Vigneron et al 1996), the precise interactions of these b/s-guanidine 
cationic lipids are unclear. A comparison of the structures of these cholesterol and vitamin D 
based cationic lipids follows (Fig. 32).
7
Figure 32. Structures of vitamin D-based cationic lipids (24 and 25) and related cholesteryl carbamates (DC-Chol 
26, BGTC 27 and 7) and target polyamine ergosteryl carbamate 31
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Polyamine-carbamates of vitamins D2 and D3 were shown to be the most active in the 
transfection of BL-6 murine melanoma cells with luciferase plasmid over a wide a range of 
lipid:DNA charge ratios (lipids were 1:1 formulation with the co-lipid DOPE). Therefore, we 
have designed the novel steroidal polyamine carbamate 31 (Fig. 32), incorporating ergosterol 
23 (Fig. 31) as the steroid moiety. Using our readily prepared A/1,A/4,A/Mri-Boc spermine 5 we 
aimed to couple a polyamine moiety to ergosterol using 1,1-carbonyldiimidazole (CDI) coupling 
(Totleben et al 1997, Ren et al 2000) in order to introduce an alkyl spermidine polyammonium 
moiety bearing 2.4 positive charges at pH 7.4 (using pKa values inferred from cholesteryl 
carbamate 7 , Geall et al 1998b and 1999).
Initially, our proposed synthesis of carbamate 31 (Fig. 33) followed the route of Ren et 
al (2000), using CDI to couple amine 5 to ergosterol 23 via an introduced carbonyl (carbamate) 
group. In their syntheses of vitamin D analogues of steroidal amines (including 26 and 27 
carboxylic ester. This chloroformate equivalent (cf. our synthesis of cholesteryl carbamate 7 
using the readily available chloroformate) was then stirred at 25 °C with two molar equivalents 
of the appropriate commercially available amine. In order to validate this procedure, a model 
carbamate, 6-benzyloxycarbonylaminohexanyloxy-A/-carbonylpropylamine 28 (Fig. 33), was 
prepared from primary alcohol 41 (described later in this chapter) and 1-propylamine (1.1 
equivalents) in 64 % yield with the appropriate 1H and 13C NMR spectra and FAB accurate 
mass data (FAB-HRMS C18H29N2O4 requires 337.2127 (MH+), found 337.2131).
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Figure 33. CDI chemistry: synthesis of 28 and proposed synthesis of target ergosteryl carbamate 31 
i. CDI, TEA, CH2CI2 reflux then 1-propylamine, 25 °C, 2 h;
ii. CDI, TEA, CH2CI2 reflux; iii. 5, CH2CI2, 25 °C; iv. TFA-CH2CI2 (1:9), 25 °C
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In our hands, this method proved unsatisfactory for the synthesis of tri-Boc protected 
ergosteryl carbamate 31. Subsequent to the addition of one equivalent of amine 5, a product 
less polar than ergosterol was observed which stained with ninhydrin when monitored by TLC. 
This product was isolated by column chromatography (EtOAc mobile phase) and was identified 
as the imidazole carboxylic ester intermediate 29 by the presence of aromatic signals in the 1H 
NMR (8.12 (1 H, d, J=  1.17, N-CH-N), 7.41 (1 H, dd, 1.56,1.17, CH-CH-NCO-O), 7.05 (1 
H, d, J = 1.56, CH-CH-NCO-O)) and the 3’a  proton in resonance at 4.87-4.95 ppm. In 
separate procedures this pure compound was reacted with amine 5, yet all attempts to prepare 
target carbamate 30 (including use of elevated temperatures) failed using this route.
In a model reaction, intermediate 29 was stirred with a large excess (more than 10 
equivalents) of A/,A/-dimethylamino-3-propylamine to afford carbamate 33 (Fig. 34). This 
ergosteryl carbamate is a dimethylaminopropyl mimic of the first steroidal cationic lipid in the 
area of non-viral gene therapy, DC-Chol 26 (Fig. 34, Gao and Huang 1991) which incorporates 
cholesterol as the steroid moiety.
In an attempt to provide an efficient route to ergosteryl carbamates, via a more 
reactive intermediate, we sought to make first ergosteryl chloroformate 32. Chloroformates are 
common reagents for the synthesis of carbamates and carbonates, in reaction with amines and 
alcohols respectively and are invariably made through the reaction of the relevant alcohol and 
the highly toxic phosgene (Cotarca et al 1996). In order to make ergosteryl chloroformate, we 
attempted to use the safer “phosgene reagent” triphosgene (for a comprehensive review of 
triphosgene chemistry, see: Cotarca et al 1996). Triphosgene (bis-(trichloromethyl) 
carbonate) is a crystalline solid at room temperature (therefore easy to handle) and reacts with 
nucleophiles in a manner consistent with three molecules of phosgene and has therefore been 
used in the preparation of isocyanates and chloroformates (Cotarca et al 1996). In our hands, 
triphosgene was unsuitable for the rapid and efficient conversion of ergosterol into its
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chloroformate (less polar, when monitored by TLC). When an excess of phosgene in toluene 
(20 % w/v solution) was used in accordance with literature procedures (Reed et al 1995) we 
observed quantitative conversion of the alcohol to the chloroformate 32. Reaction of 32 rapidly 
afforded carbamate 33 upon reaction with A/,A/-dimethylamino-3-propylamine (analytical data 
comparable to the previously synthesised sample). Ergosteryl chloroformate was successfully 
reacted with polyamine 5 to afford carbamate 30 in 60 % yield, displaying comparable 
chromatography and spectroscopy to the poly-Boc-protected cholesteryl carbamate 30 (steroid 
3’-CH resonances, values in ppm for 6 in brackets): 1H NMR 4.52-4.64 (4.43-4.53); 13C NMR 









Figure 34. Synthesis of ergosteryl carbamate 33 (cf. DC-Chol 26) 
i. COCI2 (20 % in PhMe), THF, 25 °C, 2 h; ii. /V,A/-dimethylamino-3-propylamine, CH2CI2 , 25 °C, 1 h
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Synthesis of steroidal spermine mimics -  retaining the net cationic charge of spermine
The acylated spermine derivatives synthesised here are spermidine mimics in that 
they retain the 3.4-methylene spacing between ammonium moieties. The pKas of cholesteryl 
carbamate 7 are 10.1,8.6 and 7.3 (potentiometrically measured, Geall e ta !  1998b), affording 
our steroidal-polyamine conjugates a net positive charge of 2.4 at physiological pH (according 
to the Henderson-Hasselbach equation, Geall et al 1998b, 1999 and 2000). DNA binding and 
condensation are sensitive to the number and distribution of positive charges (Geall et al 
1998b, Geall et al 2000 and Chapter 4). Spermine, the natural DNA condensing polyamine 
has a net positive charge of 3.8 at pH 7.4 (Geall et al 1998b). Therefore, we aimed to increase 
the number of positive charges (from 2.4) on our steroidal polyamines to mimic the charge and 
cation distribution of spermine.
Reduction of polyamine-lithocholic acid amides
Of the many procedures for amine synthesis, reduction of an amide is established in 
polyamine chemistry (Lane 1976, Kuksa et a/2000, Wang et a /2000). The reintroduction of a 
fourth pKa from acylated spermine moieties may be achieved by this procedure. We 
investigated the reduction of lithocholic acid amides of spermine with borane reagents. Muller 
et al (1996) synthesised steroidal-tetraamines such as 37 (Fig. 35) through the reduction of 
diacylated putrescine (1,4-diaminobutane) with borane-THF. The steroid dimer 37 is a 
tetraamine with two hydrophobic c/'s-AB steroid moieties. In DNA binding studies, compound 
37 displayed higher binding affinities for calf thymus, poly[d(G-C)]2 and poly[d(A-T)]2 
sequences than analogous single steroid triamines and simple polyamines such as spermine 
(Hsieh et al 1995, Muller et al 1996). The polymethylene spacing in compound 37 is greater 
than in natural polyammonium ions such as spermine. In order to probe the DNA binding of 
symmetrical steroidal spermine derivatives and to provide a model for the reduction of
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Figure 35. Synthesis of dialkylated lipospermine 36 and the structure of tetraamino-steroid 37 
i. Lithocholic acid, EDC, HOBt, CH2CI2, 25 °C, 16 h; ii. TFA-CH2CI2 (1:9), 25 °C, 2 h; iii. BH3.DMS, THF, reflux,
12 h then dil. aq. HCI, THF, reflux, 2 h
54
The di-A/-terminally acylated spermine derivative 35 was synthesised by analogous 
chemistry to the mono-acylated poly-Boc proteced polyamine 16. Di-Boc spermine 34 was 
synthesised from A/1,A/12-ditrifluoroacetyIated spermine 8. Preliminary studies showed the Boc 
carbamates were sensitive to borane reduction. Instead of attempting a selective reduction of 
amide 35, we followed the procedures of Hsieh et al (1995) and effected a Boc-deprotection 
prior to treatment of the amide with a reducing agent. Reduction of both amides was achieved 
with borane-DMS after Boc-deprotection to afford the symmetrically dialkylated spermine 
conjugate 36. This spermine derivative is the first compound in the area of non-viral gene 
delivery designed with two steroid moieties. However, this compound was insoluble in a range 
of solvents, and only weakly soluble in d6-DMSO for analysis by 1H NMR. Also, this 
compound, despite possessing two hydroxyl functional groups and existing as the poly­
hydrochloride salt was not water soluble and therefore was unsuitable for assessment of its 
interactions with calf thymus or synthetic DNA. Assuming further manipulation of the salt form 
will increase water solubility of the polyamine (for example, making the poly-nitrate salt instead 
of the poly-hydrochloride), knowledge of the pKa values of this spermine derivative is essential 
to assess DNA binding as a function of polyamine/DNA charge ratio.
This reduction of polyamine amides is an efficient route for the incorporation of 
polyammonium moieties into steroidal lipopolyamine gene delivery vectors, mimicking the 
charge and charge distribution of spermine for efficient DNA condensation. This amide 
reduction approach is readily applied to the bile acid amide-based lipopolyamines, but an 
alternative route to cholesteryl carbamate-based spermine mimics is required.
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Unsymmetrical polyamine extension by reductive amination
We sought to synthesise lipophilic spermine polyammonium DNA condensing agents 
by alkylation of the polyamine prior to derivatisation with steroids. In order to effect a regio- 
controlled unsymmetrical extension of spermine, we chose a reductive alkylation strategy (Fig. 
36). This methodology has been established in this group (Blagbrough and Geall 1998, Geall 
and Blagbrough 2000). The synthesis conveniently starts with the previously described 
A/1, A/^A/Mri-Boc spermine 5 and proceeds by alkylation of the primary amine with the 
appropriate Z-protected aldehyde. Z is orthogonal to Boc (each protecting group may be 
added/removed in the presence of the other), and Z may be deprotected by a palladium 
catalysed hydrogenation, which is our chemistry of choice over other hydrogenation methods 
involving acetic acid which might deprotect Boc groups.
The synthesis of tetra-Boc protected A/-alkyl spermine derivatives began with the 
desymmetrisation of spermine to yield A/1,A^4,A^-tri-Boc spermine 5 as previously described. In 
parallel, 3-aminopropan-1-ol 38 and 6-aminohexan-1-ol 39 were treated with an excess of 
benzyl chloroformate in DCM with triethylamine (to scavenge any HCI byproduct), to yield the 
respective Z-protected co-amino alcohols 40 and 41, which were isolated from any traces of 
benzyl chloroformate, by column chromatography to give both products, typically in 80-90 % 
yield.
These Z-protected amino alcohols were oxidised to their respective aldehydes with 
activated DMSO (Swern conditions: DMSO/oxalyl chloride, triethylamine work-up; Mancuso et 
al 1978, for a review, see: Marx and Tidwell 1984). The desired aldehydes 42 and 43 were 
obtained under these conditions, with full consumption of the starting alcohols observed after 
30 min in almost all attempts. These reactions were typically performed on a 1.0-2.5 gram 
scale, in around 60 ml solvent. Although formation of acetals is known under these conditions 
(Tidwell 1990), in our hands these side-reactions were not observed.
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Figure 36. Synthesis of N-alkyl spermine derivatives 46 and 47 by reductive amination of aldehydes 42 and 43 
i. Benzyl chloroformate, TEA, CH2CI2, 25 °C, 4-18 h; ii. Oxalyl chloride, DMSO, CH2CI2, -78 °C, 30 min, then 
TEA 0 °C; iii. 5, NaBHaCN, cat. glacial AcOH, MeOH, 25 °C, 24 h; iv. (Boc)20, CH2CI2, 25 °C, 3 h; v. 
Pearlman’s catalyst (Pd(OH)2, 20 % on carbon), H2, MeOH, 25 °C, 18 h
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The target aldehydes were separable from their starting alcohols (by TLC, 
EtOAc/hexane) and initially confirmed as new aldehydes by the formation of 2,4- 
dinitrophenylhydrazones on treatment with acidic 2,4-dinitrophenylhydrazine (2,4-DNP) 
solution. After purification (silica gel chromatography), these aldehydes 42 and 43 were 
confirmed by (data for 42) 1H NMR (9.78 ppm) 13C NMR (201.3 ppm) and IR (1713 cm-1). 
DMSO and DMS were common contaminants, rendering these products oils.
These Swern oxidations generally proceeded smoothly and cleanly (60-70 % yield) 
provided solvent and all reagents were rigorously dried. In our hands, the use of wet DMSO in 
the reaction of primary alcohol 40 gave a clean product less polar than the starting material by 
TLC, with the same Rf value (0.52, EtOAc-hexane 8:2 v/v) as the desired aldehyde. In this 
instance, the product spot did not stain with 2,4-DNP. Although formation of the corresponding 
acetals was suspected, purification (silica gel) and subsequent characterisation (1H/13C NMR 
and FAB+ MS) identified the product as the Z-protected alkyl diester of oxalic acid 51. This 
reproducible result was observed for both the propanol 40 and hexanol 41 derivatives.
The reaction between amines and aldehydes is in equilibrium with the corresponding 
imine and water, therefore drying of the solvent and reagents and inclusion of molecular sieves 
to remove water in situ were employed in order to drive the reaction of polyamine 5 with 
aldehydes 42 and 43 in the desired direction. However, this equilibrium is believed to result in 
the modest yields obtained and the need for rigorous purification after these and subsequent 
steps. These reductive alkylations of tri-Boc spermine were performed at pH 5, with catalytic 
addition of glacial acetic acid. At this pH, sodium cyanoborohydride reduces iminium species 
faster than aldehydes, again a driving force for imine formation as iminium is irreversibly 
removed from the system. Some reduction of aldehydes 42 and 43 was observed and this 
also may have contributed to lower yields. These reactions were stopped typically after 24-48 
hours, and following difficult purification over silica gel, the secondary amine intermediates
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were obtained with significant, but not unmanageable quantities of primary amine and Z- 
protected amino alcohol. The new secondary amine was then Boc-protected with an excess of 
Boc anhydride in CH2CI2. Without purification (though an analytical sample of 45 was purified 
by silica gel column chromatography, FAB-HRMS C44H78N5O10 requires 836.5749 (MH+), found 
836.5747), the Z-protected terminal amines 44 and 45 were deprotected by hydrogenation 
(Pearlman’s catalyst/H2). Prior to this step the reaction mixture was treated with conc. aq. 
ammonia in MeOH to quench any excess of Boc anhydride as substitution of Z for Boc 
carbamates during hydrogenation in the presence of Boc anhydride is known (Greene and 
Wuts 1991). The resulting unsymmetrically homologated poly Boc-protected polyamines
3.4.3.3 (thermopentamine) 46 and 3.4.3.6 47 were purified (silica gel) from tetra-Boc spermine 
and the respective amino alcohols.
Synthesis of steroidal spermine mimics
Tetra-Boc protected polyamines 46 and 47 were coupled to steroids of our choice. 
Acylation with cholesteryl chloroformate in CH2CI2 and tertiary base (Fig. 37) gave the 
respective polyamine-cholesteryl carbamates 48 and 49 in high yields (typically 61-95 %).
n = 4, 49
Figure 37. Synthesis of poly-Boc protected cholesteryl carbamates 48 and 49 
i. Cholesteryl chloroformate, TEA, CH2CI2, 25 °C, 18 h
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In order to synthesise lithocholic acid amide 50, the acid was reacted with an excess 
of EDC and catalytic HOBt, followed by the addition of amine 46 (Fig. 38). As discussed 
earlier in this chapter, pre-activation of the acid in anhydrous solvents was found to give the 










Figure 38. Synthesis of poly-Boc protected lithocholic acid amide 50 




In this chapter, the synthesis of polyamine-steroid conjugates in the context of non- 
viral gene delivery has been discussed. These conjugates of cholesterol and lithocholic acid 
incorporating Boc-protected spermidine and spermine moieties are precursors to 
lipopolyammonium DNA condensing agents and their fluorescent derivatives, the design and 
synthesis of which is discussed in Chapter 3.
60
CHAPTER 3
Synthesis of fluorescent steroidal lipopolyamines: 
Magic markers for the transfection process
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Synthesis of magic markers for the transfection process
Non-viral gene therapy vectors achieve the delivery of packaged foreign DNA into 
target cells, but barriers inside the cell limit the degree of expression of these newly introduced 
genes. Transfection efficiency cannot be improved without a greater knowledge of the 
molecular detail of intracellular events. Using such detail as a rational starting point for the 
design of new gene delivery vectors may aid the realisation of a clinically useful non-viral 
approach to gene therapy. As discussed in Chapter 1, fluorescence-based confocal 
techniques are useful for the microscopic study of transfection at the cellular level. This 
requires the design and synthesis of new analytical tools for the accurate determination of the 
interactions and processes mediated by such vectors. Herein we continue our studies in 
steroidal lipopolyamines through the design and synthesis of steroid-based fluorescent gene 
delivery vectors.
Initial targets were based on polyamine amides of lithocholic acid and cholesteryl 
carbamates, the synthesis of which was discussed in Chapter 2. Lithocholic acid is 
characteristic of bile acids which have c/s-AB ring junctions, but also possess a 3a-hydroxyl 
group, which we rationalised might be suitable for functionalisation with fluorescent moieties 
(Fig. 39). The alcohol functional group might not be ideal, being a secondary alcohol (rather 
than a primary), but it is sterically accessible, on the lower (a) face of the steroid. 3p- 
Cholesteryl carbamates however, lack even such suitable functionality for the preparation of 
analogous fluorescent compounds (Fig. 39).
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Figure 39. Points of modification of protected lithocholic acid amide 16 and 
cholesteryl carbamate 6 for the design of fluorescent conjugates
In order to solve this problem and to enable the synthesis of fluorescent steroidal 
polyamines, we chose a modification of the A5-alkene of cholesterol in order to furnish the 
steroid with a hydroxyl group so that analogous treatment of planar and c/'s-AB hydroxylated 
steroids (sterols) may be carried out. Such a hydration of cholesterol should be regio- and 
stereochemically controlled. There are many ways of introducing oxygen functionality to 
alkenes and a detailed search of the literature revealed cholesteryl alkene oxidations by 
epoxidation (Holland and Kahn 1985) and hydroboration (Nussim eta l 1964a, Tavares eta l 
1993, Izzo et al 1998). These hydroborations of cholesteryl and of other steroidal alkenes 
(Boynton and Hanson 1995, Hanson et al 1995, Kuhl eta l 1999) exemplify an attractive route 
which we will use to access hydrated cholesterols in one step (cf. an epoxidation strategy) with 
a degree of regio- and stereoselectivity.
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In order to hydroborate cholesteryl carbamate 6, we selected and then modified the 
procedures of Tavares et al (1993) who reported difficulties during their hydroboration of 0- 
acetyl protected cholesterol derivatives. In their model hydroboration of the A5-alkene of 
cholesteryl-3p-acetate using 20-24 equivalents of borane-THF complex (Bhb-THF), cleavage 
of the ester was observed even with a range of mildly basic (NaOAc) or neutral pH (phosphate 
buffer, pH 7.0) oxidiative workups. Despite this, the alkene hydroboration was successful, 
affording the desired 6a-hydroxyl group. The authors attributed this result to reduction of the 
ester functionality in competition with the hydroboration of the tri-substituted alkene (hindered 
and therefore less reactive).
With this in mind, we sought to hydroborate our cholesteryl carbamate 6 which bears 
four carbamate functional groups which may be sensitive to reduction by BH3 reagents. First, 
we repeated the hydroboration of cholesteryl-3p-acetate, with the intention of optimising the 
reaction conditions, we especially wanted to lower the number of equivalents of BH3 required, 
in order that the four less electrophilic carbamates (cf. cyclohexyl esters) would survive and not 
be reduced to their methylamines (March 1985).
Using BH3-dimethyl sulfide complex (BH3-DMS, 10 M solution in DMS) we were able 
to effect the hydroboration of cholesteryl acetate (Fig. 40,2.5 eq. BH3, 25 °C, 4 h, then 
NaHC03-H202 workup, 0 °C, 1 h) to afford initially, mixtures of the desired hydroborated 
product 6a-hydroxy-5a-cholesteryl-3-acetate 52 and the 3p,6a-diol 53. After a rigorous 
literature search, improved yields of acetate 52 following the addition of EtOAc (10 % v/v in 
CH2CI2) were achieved. The addition of 10 % EtOAc is said to inhibit ester reduction by BH3, 
allowing selective reactions of carboxylic acids, alkenes and ketones in the presence of esters 
(Lane 1976). We used BH3-DMS due to its favourable stability in air and to heat compared to 
BH3-THF (Lane 1975). Also, it is a milder BH3 reagent, suitable for selective reactions of BH3
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sensitive functional groups as reported by Brown (1982). As well as its convenience of use, it 













Figure 40. Hydroboration of cholesteryl acetate 
i. BHa-DMS (10 M in DMS), CH2Cl2-EtOAc (9:1), 25 °C, 4 h then NaHC03/H202, 0 °C
Under these conditions (without the addition of EtOAc), cholesteryl carbamate 6 was 
hydroborated (Fig. 41) to yield two products, both more polar than the starting material and 
separable by column chromatography. The major product 54 (65 % yield) was confirmed as 
the 6-hydroxy regioisomer by the appropriate accurate mass spectrum, and appropriate new 
signals for 6-CH resonances in the 1H NMR (upfield from 5.37 to 3.34 ppm) and 13C NMR 




















Figure 41. Hydroboration of 6, to afford the major product 54 and a minor product 55 
i. BHs-DMS (10 M in DMS), CH2CI2 , 25 °C then NaHC03/H202, 0 °C
Fig. 42 shows values from the 13C NMR DEPT spectrum (methine carbons only) for 
product 54 which are in good agreement with our observed values for hydroborated cholesteryl 
acetate 52 and literature values for 3p,6a-dihydroxy-5a-cholestane 53 (Grover and Stothers 
1974).
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Assignment 54 52 3p,6a-dihydroxy- 5a-cholestane 53
3’ 73.8 73.6 71.1
5’ 51.7 51.7 51.6
6’ 69.4 69.5 69.3
8’ 34.4 34.4 34.3
9’ 53.7 53.7 53.7
14’ and 17’ 56.1 56.1,56.2 N/A
20’ 35.8 35.8 N/A
Figure 42. 13C NMR assignment for cholesteryl carbamate 54 and ester 52 compared to literature values for 
3p,6a-dihydroxy-5a-cholestane 53 (Grover and Stothers 1974). Values expressed in ppm, measured in CDCb
The minor product 55 was isolated in 3 % yield and found to have the same mass as 
the major product 54, with the same fragmentation pattern. Alkene hydroborations are known 
to be syn-additions of H2O, through the concerted addition of B H 3 (Lane 1974). Based on this 
and coupling constants measured for 6-H in the 1H NMR spectrum of 54 (Fig. 43), we assign 
the major product 54 as the trans-AB ring (5a-H,6ot-hydroxy) product and the minor product 
55 as the diastereoisomer (c/'s-AB ring, 5p-H,6p-hydroxy). The Karplus relationship predicts 
3Jhh values according to the dihedral angle. In a 6-membered ring (such as the B-ring of 54), 
dihedral angles are fixed, and the Karplus equation predicts the largest coupling constants 
(typically 9-13 Hz) for antiperiplanar protons (axial-axial coupling) where the dihedral angle is 
close to 180° (Williams and Fleming 1989). The 6-H of the major product displays two large 
axial-axial couplings (3Jhh = 10 Hz) and one smaller axial-equatorial coupling (3Jhh = 4 Hz), 
giving rise to the observed dt at 3.34 ppm (interactions shown bold, Fig. 43). This is consistent 
with the 6a-hydroxy product (frans-AB) and with the findings of Tavares and co-workers who
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described the major product of a cholesterol hydroboration as a 6a-hydroxy trans-AB product 
(Tavares et al 1993) and also of Izzo et al (1998) who also isolated the minor diastereoisomer 








Figure 43. Portion of the 1H NMR spectrum of alcohol 54, showing the dt for 6'p-proton and the 
AB ring geometry of this, the major hydroboration product (only AB-rings shown for clarity)
The high stereoselectivity of this hydroboration for the steroid a-face is consistent with 
literature reports that cholesterol and other steroid frameworks are hindered by angular methyl 
groups at positions 10 and 13 (Breslow et al 1984, Tavares e ta l 1993, Hanson 1995, Izzo e ta l 
1998, Kuhl et al 1999).
During this work, Jung and Johnson published (2000) a hydroboration of cholesterol 
derivatives, again substantiating our own results and those of others (Tavares e ta l 1993) 
regarding the reactivity and facial selectivity in the hydroboration of steroid alkenes. There is 
continued and growing interest in compounds with steroid moieties hydroxylated at position 6, 
particularly in the area of marine natural products. Jung and Johnson (2000) use 




inositol phospholipase C inhibitor and mild cytotoxic (against L1210 murine leukaemia cells) 
obtained from the marine sponge Xestospongia bergquistia. Xestobergsterol A 56 and its 
related compounds possess a trans-AB ring junction with a 6a-hydroxyl group (cf. cholesteryl 
carbamate 54). In the same year, the structures of three new compounds isolated from the 
starfish Goniopecten demonstrans were published (De Marino e ta l2000), each a 6a- 
hydroxylated frans-AB ring steroid with anti-biofouling activity against the brown macroalga 
Hincksia irregularis. This is a further example of starfish natural products with this 
hydroxylation pattern and complements the work of Izzo and co-workers who used a 
hydroboration reaction to access a trans-AB steroid followed by inversion of the major product 







Figure 44. Structures of 6a-hydroxylated polyamine cholesteryl carbamate 54 and two marine natural products,
xestobergsterol A 56 and starfish cytostatic 57
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In Chapter 2 we described the synthesis of mono- and polyamine carbamates 
incorporating the steroid ergosterol as the lipid moiety in novel agents for DNA condensation 
and non-viral gene delivery. Following the success of our hydroboration of cholesterol as a 
means of utilising functionality on unsaturated steroids, we searched the literature for 
ergosterol hydroborations. Ergorsterol 23 acetate (shown in Fig. 45) has a conjugated diene in 
the B-ring, as well as a remote alkene in the side chain. Hydroboration of ergosterol and its 
derivatives and other steroidal 5,7-dienes are known in the literature (Nussim et al 1964b, 
Evans et al 1975, Goldstein 1996). Here we consider two hydroboration reactions of steroidal 
dienes (Fig. 45). Nussim et al (1964) report boron addition to carbon 6 or 7, followed by 
hydrolysis of the alkylborane intermediate and rearrangement to afford the A6-alkene 58. 
Goldstein (1996) claimed a similar hydroboration of the B-ring of ergosteryl acetate, with the 
usual oxidation of the alkylborane intermediate to furnish the 6a-hydroxy-7-ene 59. Goldstein 
(1996) reported selectivity for hydroboration of the B-ring over the side-chain alkene, with two 
molar equivalents of borane-DMS.
Selective side-chain hydroxylation of ergosteryl-based cationic lipids, allows 
fluorescent moieties to be introduced to a steroid side-chain, a probe of SARs in the binding of 
fluorescent steroidal lipopolyamines to DNA. In order to hydroborate selectively the side-chain 
of ergosterol, Evans ef a/ (1975) protected the B-ring diene with a tricarbonyliron moiety 60. 
Using diborane, these workers report the hydroboration of ergosterol, but the regio- and 
stereoselectivity of this reaction were not investigated. Given these potential problems in 
hydroboration of the triene ergosterol, we attempted to hydroborate ergosteryl carbamate 33 
(Chapter 2) with the dialkylborane 9-borabicyclo[3.3.1]nonane (9-BBN). This reagent has been 
reported as useful for high regio- and stereoselectivity in hydroborations (Chen 1978, March 















HO (Evans et al 1975)HO
Figure 45. Hydroborations of steroidal B-ring dienes: Nussim et al 1964b, Evans et al 1975, Goldstein 1996
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Treatment of ergosteryl carbamate 33 with 9-BBN (solution in THF) afforded a single 
more polar spot when monitored by TLC (CFhCb-MeOH-conc. aq. NH3 100:10:1 v/v/v), with 
consumption of starting material 33. Following treatment of this compound with alkaline H2O2, 
purification of this material over silica gel afforded a product with an identical 1H NMR 
spectrum to the starting material. We discount the conclusion that a borane-trialkylamine 33 
complex accounted for the more polar component by TLC and identical spectroscopy to 
starting material 33. Borane-trialkylamine complexes are known to be useful, commercially 
available reagents for the hydroboration of alkenes (Lane 1976) and therefore are known to be 
oxidised by alkaline H2O2. We conclude that the initial organoborane intermediate eliminated 
the alkene starting material 33 upon further manipulation.
Fluorescent lipopolyamine targets based on cholesterol and lithocholic acid
Our hydroboration of polyamine cholesteryl carbamate 6 together with our rapidly 
accessed lithocholic acid polyamine amide allowed us to design highly fluorescent 
lipopolyamines based on these trans-AB and c/s-AB steroids. Initially, we conceived targets 61 
and 62 (Fig. 46) with spermidine as the polyammonium moiety and incorporating fluorescein, a 
commonly used fluorophore for confocal microscopy (Boturyn et al 1997). Fluorescein is 
commercially available as the isothiocyanate, making it suitable for covalent labelling of a 
range of biomolecules to produce highly fluorescent conjugates which may be imaged under a 
fluorescent microscope. In our designed lipopolyamines, we aimed to conjugate fluorescein 
isothiocyanate (FITC) as a thiourea to an amino acid chain, to link the fluorophore to the 
steroid scaffold. The 5-carbon linker is readily available as 5-aminopentanoic acid (5- 
aminovaleric acid) and we set out to prepare esters of 5-aminopentanoic acid from our 
hydroxylated steroidal polyamines.
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Figure 46. Initial fluorescent lipopolyamine targets 61 and 62
Initially we aimed to synthesise these targets through a disconnection of the ester thus 
preparing first the fluorophore-5-aminopentanoate portion then coupling (to make the ester 
bond) to the poly-Boc protected steroidal polyamine in a convergent route. We prepared three 
A/-substituted 5-aminopentanoic acids (Fig. 47) in order that we could couple these, as esters, 
to the 3a-hydroxy group of our previously described lithocholic acid polyamine amide (Boc- 
protected to avoid /V-acylation of the polyamine). Starting from 5-aminopentanoic acid, the 
amino group was reacted with FITC to afford thiourea 63 (thiocarbonyl, C=S, observed at
182.3 ppm in the 13C NMR spectrum). During these studies, Neves et al (2000) reported 
lissamine rhodamine B (LRB) conjugated plasmid DNA for use in in vitro transfection studies 
tracked by fluorescent confocal microscopy. Lissamine rhodamine B and other examples of 
rhodamine dyes (Vinayak 1999) are structurally related to fluorescein, but their excitation and 
emission wavelengths are longer {X& = 568 nm, tam = 583 nm for LRB) relative to fluorescein 
(Xex = 494 nm, Xem = 519 nm), making LRB a useful tool for multicolour imaging of two
fluorophores simultaneously. LRB is commercially available as the sulfonyl chloride for 
conjugation to amines or alcohols. Therefore, as a complement (or alternative) to fluorescein, 
we synthesised the LRB conjugate, sulfonamide 64. We also prepared the A/-carbobenzyloxy 












Figure 47. Preparation of chromophore-conjugated 5-aminopentanoic acids 63, 64 and 65
i. 5-aminopentanoic acid, 1 M aq. NaOH, EtOH, 25 °C then pH 3 (2 M aq. HCI);
ii. 5-aminopentanoic acid, 1 M aq. NaOH, acetone, 25 °C then pH 3 (2 M aq. HCI);
iii. 5-aminopentanoic acid, 2 M aq. NaOH, 25 °C then pH 3 (2 M aq. HCI)
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We then attempted to esterify these fluorescent pentanoic acids with the previously 
described lithocholic acid amide 16. There are several approaches available for the 
preparation of esters from carboxylic acids and alcohols. Most of these involve activating the 
acid so that it is electrophilic enough to be effectively attacked by the nucleophilic oxygen of 
the alcohol. Routes to esters are variations on this transesterification theme, e.g. NHS, HOBt, 
including the use of acyl halides. Alternatively, Mitsunobu conditions convert the alcohol into a 
leaving group (cf. conversion into an alkyl halide), for O-alkylation, this strategy results in 
retaining both oxygen atoms of the carboxylic acid in the ester product.
For the preparation of esters of lithocholic acid amides, we first tried to prepare the 
monopentafluorophenyl (PFP) ester 66 (an “active ester”) of FITC conjugate 63 using 
dicyclohexylcarbodiimide (DCC) coupling (Fig. 48). However, this proved difficult and resulted 
in inseparable mixtures of starting material and more and less polar components. The FITC 
and LRB conjugates were poorly soluble in appropriate organic solvents for these reactions, 
and the FITC conjugate contains a benzoic acid which may have prevented the desired 
reaction. Also, we used the significantly less expensive mixture of FITC regioisomers (the 
isothiocyanate at position 5 -  “isomer I” and position 6 -  “isomer II” 9:1) which were separable 
on silica.
HO o HO' O'
F
63 66
Figure 48. Attempted selective pentafluorophenyl esterification of FITC conjugate 63.
i. Pentafluorophenol, EtOAc, DCC, 25 °C
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In order to conserve the fluorescent conjugates, we pursued this route by next making 
the acid chloride of Z-protected 5-aminopentanoic acid 65 using oxalyl chloride in toluene.
After quantitative consumption of the starting material (monitored by TLC) the resulting solution 
was evaporated to dryness and the resulting crude mixture was found to be 86 % acid chloride 
65a by 13C NMR (acid chloride carbonyl at 170.7 ppm). However, attempts to esterify this 
mixture by heating (50 °C) and later refluxing with alcohol 16 in anhydrous pyridine failed to 
yield the desired product. Instead, we obtained mixtures of starting alcohol 16 and acid 65, 
possibly due to the low nucleophilicity of the secondary alcohol and also because of hydrolysis 
of the acid chloride as the solvent became wet on extended reaction times.
Synthesis of Fmoc-protected aminopentanoate esters and their rapid deprotection for the 
generation of fluorescent lipopolyamine libraries
The synthesis of fluorescent lipopolyamines via esterification of the 3a- and 6a- 
hydroxyl functional groups of synthetic poly-Boc protected lipopolyamines was achieved by a 
linear route. Initial attempts, which focused on introducing convergence to the total synthesis 
by coupling activated fluorophores to 5-aminopropanoic acid, prior to esterification with the 
steroid core, were abandoned due to solubility problems of these fluorescent conjugates and 
the current high cost associated with obtaining practical quantities of FITC, LRB-sulfonyl 
chloride, and other activated fluorophores, some available only in single milligram quantities.
To aid these synthetic studies of fluorescent lipopolyamines, a model lithocholic acid 
amide 67 was synthesised from the acid and n-propylamine. Unfortunately, this product, 
prepared from the DCC/HOBt coupling reaction, was insoluble in the range of deuterated 
solvents available, therefore we were unable to characterise the product by NMR, which we 
hoped would be of use in subsequent NMR assignments.
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At the same time, we investigated the possibility of using a 9-fluorenylmethoxycarbonyl 
(Fmoc, Carpino and Han 1970, Atherton et al 1978) protecting group to mask the primary 
amine of our designed lipopolyamine steroid esters of 5-aminopentanoic acid. Fmoc is a 
common nitrogen protecting group (for a recent review of nitrogen protecting groups, see: 
Theodoridis 2000), especially known in the area of automated solid phase synthesis (Li and 
Chou 2000) and peptide synthesis (Ueki and Ameniya 1987), where its deprotection may be 
rapidly monitored by fluorescence. Fmoc carbamates may be deprotected by bases, 
particularly secondary amines (e.g. piperidine), and Fmoc groups are resistant to strong acid. 
These properties are in contrast to the widely used Boc protecting group and the two protecting 
groups may be orthogonally manipulated (Greene and Wuts 1991). In addition, Fmoc 
carbamates are inert to hydrogenation conditions, making Fmoc a useful alternative to the Z 
carbamate, should a synthetic sequence require hydrogenation (Li et al 1993a and 1993b).
Therefore, we conceived a new linear route to our designed fluorescent 
lipopolyamines based on selective deprotection of Fmoc carbamates in order to introduce 
fluorescent labels. In Fig. 49 we outline this route, which we investigated starting with the 
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Figure 49. Proposed synthesis of fluorescent lithocholic acid amides via Fmoc-protected amino esters. 
Synthesis of Fmoc-protected 5-aminopentanoic acid 68 
i. 1-propylamine, CH2CI2, DCC, HOBt, 25 °C, 3 h; ii. 5-aminopentanoic acid, NaHCC>3, 
dioxane-water (3:2), 25 °C then pH 3 (2 M aq. HCI); iii. 4-nitrophenol, DCC, EtOAc, 25 °C, 16 h
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The Fmoc-protecting group may be introduced with a variety of activated reagents.
We used the /V-hydroxysuccinimide ester (NHS) according to the procedures of Beyermann et 
al (1990). The reaction with 5-aminopentanoic acid proceeded cleanly in dioxane-water (ratio 
3:2) to afford the desired product 68 (82 % yield). Although the esterification of this Fmoc- 
protected amino acid is analogous to the efforts previously described, the reaction in rigorously 
dried CH2CI2 with pre-activation with DCC/DMAP succeeded after attempts using the acid 
chloride in pyridine and the para-nitrophenyl (PNP) ester 71 both failed. This less polar 
product 69 was confirmed as the ester by 1H and 13C NMR (from which we inferred the identity 
of amide 67), in which we observed three quaternary carbon resonances at 156.2,172.7,
173.2 which we identify as the carbonyls of carbamate, ester and amide. We can assign with 
confidence the carbamate to 156.2 ppm. Typically, secondary amides of lithocholic acid (e.g. 
amide 16) appear at around 174.0 ppm. However, without the data for the starting material, 
propylamide 67, we do not over interpret the data here.
We required a one-pot reaction for the Fmoc deprotection step, followed by fluorescent 
labelling in situ. This approach avoids the need for purification of the deprotected amine 
intermediate. Piperidine is a commonly used base in the deprotection of Fmoc groups, but as 
a secondary amine it is nucleophilic and reactive to electrophiles such as isothiocyanates. We 
predicted an excess of piperidine would compete with the deprotected primary amine for 
reaction with FITC. Therefore, this reagent was unsuitable for our requirements, without 
rigorous extraction. In solid phase organic synthesis, piperidine is removed by extensive 
washing of the resin in the rinse cycle. An alternative to piperidine is tetra-n-butylammonium 
fluoride (TBAF, Greene and Wuts 1991), which despite being a well-known reagent for 
deprotecting silicon based protecting groups, has so far found only limited application in the 
literature for cleaving Fmoc carbamates (Ueki and Ameniya 1987, Wilson et al 1999).
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Using an excess of TBAF (1 M solution in THF), the deprotection of 50 mg of 69 was 
complete within two minutes, as monitored by TLC, yielding a polar spot which stained with 
ninhydrin. Methylidenefluorene, the elimination product of an Fmoc deprotection, was also 
detected as a UV absorbing non-polar component. This was followed by the addition of an 
equimolar quantity of fluorescein isothiocyanate, isomer I (Molecular Probes, Oregon), giving a 
visible (green), less polar compound by TLC which stained with PMA and was fluorescent 
(green) when visualised at 366 nm. Despite the apparent success of the reaction, attempts to 
purify the mixture were largely unsuccessful. However, FAB accurate mass data were 
acquired, displaying the appropriate elemental composition for the desired product 70 (FAB- 
MS m/z 906 (MH+), C53H67N3O8S requires 905; FAB-HRMS C53H68N3O8S requires 906.4727 
(MH+), found 906.4762).
Interpreting this result as a proof-of-principle, we began the synthesis of a range of 
fluorescent lipopolyamines based on spermidine and spermine polyammonium moieties. In 
using the Fmoc deprotection chemistry, we have devised a synthetic route that enabled the 
introduction of a variety of fluorophores. Our new immediate targets were therefore 
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Figure 50. Precursors to fluorescent polyamine lithocholic acid amides: Fmoc protected esters 72 and 73.
i. 68, DCC, HOBt, CH2CI2 , 25 °C
Starting from poly-Boc protected 3.4.3-Litho 16 and 3.4.3.3-Litho 50 (previously 
described in Chapter 2), we prepared esters of Fmoc-protected 5-aminopentanoic acid 68 
using DCC/HOBt coupling as with the model 69. These reactions (Fig. 50) proceeded 
smoothly in anhydrous CH2CI2 and, after column chromatography, afforded protected 
spermidine mimic 72 and spermine mimic 73, typical yields were 40-80 %, the highest yields 
were obtained when the reaction was stirred for two days.
Satisfactory 1FI and 13C NMR data were obtained for these esters (3’p-H shifted 
downfield from 3.6 to 4.7 ppm in compound 73, typical of a CH-OH to CH-OCO transformation, 
Williams and Fleming 1989). Appropriate FAB mass spectral data were obtained, although we 
were unable to collect an accurate mass spectrum for compound 73 (the low resolution mass 
was correct). Requiring a M+1 m/z of 1339, this coincided with m/z 1339 of the polyethylene 
glycol monomethyl ether (PEG-MME) reference used for accurate mass measurements 
(University of Bath Mass Spectrometry service). Upon advice from the EPSRC National Mass
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Spectrometry Service (University of Swansea) we sought the use of Csl clusters as references 
for accurate mass measurement of compound 73. We were further advised by the EPSRC MS 
Service that, in this case, accurate mass data are only as reliable as low resolution data for 
elemental formula determination at M+1 over 1000.
In order to demonstrate the poly-Boc deprotection of such compounds and the stability 
of the ester linkage towards the strongly acidic conditions (TFA) used in such deprotections, 
we treated compound 72 with TFA (1:9 v/v solution in CH2CI2) for 3 h, then purification of 10 
mg of this crude material by semi-preparative HPLC (isocratic mobile phase: 0.1 % aq. TFA- 
MeCN 20:80 % v/v) afforded the spermidine mimic 74 (Fig. 51).
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Figure 51. Synthesis of Fmoc-labelled lithocholic acid amide 74. 
i. TFA-CH2CI2 (1:9), 25 °C, Semi-Prep RP-HPLC
Accurate FAB+ MS data for this compound indicated the desired fully deprotected 
compound with the ester and Fmoc carbamate intact (C54H84N5O5 requires 882.6472 (MH+), 
found 882.6444). Polyamine conjugate 74 is a fluorescent lipopolyamine, although the 
excitation wavelength of the Fmoc fluorophore is low in the UV region (A,ex: 265 nm), out of the 
range of most modern confocal microscopes, making it unsuitable for sensitive cell imaging 
(Johnson 1998). The fluorescence of our Fmoc conjugate 74 was determined to be Amax (Ex): 
265 nm, A, max (Em): 320 nm.
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Next we prepared the analogous cholesterol derivatives 76 and 77, starting with Boc- 
protected polyamine cholesteryl carbamates 6 and 48 respectively (Fig. 52).
Boc>.
Bocv
n = 1, 6
n = 2, 48
n = 1, 54







Figure 52. Synthesis of precursors to fluorescent polyamine cholesteryl carbamates:
Fmoc protected esters 76 and 77. 
i. BHs-DMS (10 M in DMS), CH2CI2 , 25 °C then NaHCOa/FbCk, 0 °C; ii. 68, DCC, HOBt, CH2CI2 , 25 °C
Spermidine mimic tri-Boc-3.4.3-Chol 6 was hydroborated as previously described to 
afford alcohol 54 and spermine mimic tetra-Boc-3.4.3.3-Chol 48 was reacted according to the 
same procedure, affording alcohol 75. These 6a-hydroxyl groups were then acylated in an 
analogous manner to the lithocholates affording esters 76 and 77 respectively. Upon 0- 
acylation, the dt (1H NMR) associated with the methine proton at 6-C shifts downfield from 3.38
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ppm in alcohol 75 to 4.68 for the desired ester 77. In the 13C spectra the methine carbon at 
position 6 is deshielded by the ester, downfield from 69.6 to 72.7 ppm in ester 77. This was 
accompanied by the shielding of 5-C, upfield from 52.0 to 49.2 ppm. Analogous shifts were 
observed for the esterification of 54 (1H NMR: dt 3.34, «C: 69.4) to 76 (1H NMR: dt 4 .69,13C: 
72.3). These spectral effects upon O-acylation are in agreement with NMR shift additivity rules 
(Williams and Fleming 1989).
Choice of fluorophore
Having designed precursors to fluorescent-labelled steroidal polyamine derivatives we 
had established a route by which we can introduce a range of fluorophores that will find ready 
application in the imaging of intracellular transfection events. One of many, or a combination 
of considerations may influence the choice of fluorophore label for confocal microscopy work. 
These include the spectral properties of the fluorophore (for example excitation/emission 
wavelength, pH dependent fluorescence, photobleaching, quantum yield). Also, the availability 
of fluorophores that are easily incorporated into a labelling synthesis might be an issue 
(activated, reactive fluorophores, for example isothiocyanates are available; some are 
marketed in the form of labelling “kits").
Fig. 53 shows of some the various structures that contribute to the wealth of 
fluorophores available for intracellular imaging by fluorescence microscopy. These examples 
are all appropriate to our requirements in that, in their activated forms, they may be used to 
label our steroidal lipopolyamines 72,73,76 or 77, following an Fmoc deprotection with a 
fluoride reagent such as TBAF.
84
Figure 53. Structures of some commercially available fluorophores: Oregon Green 488 NSE 78, 
BODIPY-FL NSE 79 and dansyl chloride 80
Synthesis of fluorescent alkylspermine cholesteryl carbamates
As discussed in Chapter 1, rhodamine fluorophores (such as lissamine rhodamine B, 
LRB, see our earlier synthetic work in this chapter) have been incorporated into RPR-121653 
81 (Fig. 54). This fluorescent thiourea was synthesised from the commercially available 
tetramethylrhodamine B isothiocyanate (Byk et al 1998).
Figure 54. The fluorescent lipopolyamine RPR-121653 81
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Complementary to the red rhodamine-type fluorophores is Oregon Green 488 (2’,7’- 
difluorofluorescein). This and other green fluorophores with a fluorescein-like fluorescence 
profile have spectra that do not overlap with rhodamines and therefore are suitable for use 
together in dual-colour imaging experiments. The "488” refers to the wavelength, in nm, of the 
spectral line of the argon ion laser, used in a fluorescence microscope. The absorption 
maximum (498 nm) of Oregon Green 488 closely matches this emission line. A range of these 
dyes is available to match other laser emission lines, for example Oregon Green 514. Oregon 
Green 488 is available as an alternative to fluorescein, offering improved photostability 
(illumination of biological samples may cause irreversible destruction of the fluorophore -  
“photobleaching”). The phenolic pKa of Oregon Green 488 is 4.7, cf. 6.4 for fluorescein. When 
the phenol is protonated the fluorescence intensity is diminished (Sun et al 1997). Therefore, 
Oregon Green may be used to image acidic organelles (such as lysosomes, pH 5.5), useful in 
non-viral gene delivery systems where endosome escape and lysosomal degradation are 
barriers to efficient transfection (Sun et al 1997).
These properties of Oregon Green 488 were persuasive in our choice of fluorophore, 
together with our previous experience in handling fluoresceins (see model conjugate 70 
described previously). Also, its precedented use in multicolour imaging of gene delivery 
systems (Godbey e ta l 1999b) with rhodamine-labelled DNA (Vinayak 1999, Neves e ta l2000, 
Yoo and Juliano 2000) encouraged us to design Oregon Green 488 labelled polyamine 
cholesteryl carbamate 82 (Fig. 55).
Starting with Fmoc-protected 77, treatment with TBAF in THF and immediate addition 
of Oregon Green 488 NSE gave a complicated mixture of spots when monitored by TLC. 
Working on a small scale (this fluorophore was available in 5 mg units for £120), the separation 
of this mixture was not attempted. It appeared the presence of TBAF was causing 
components to run faster with streaking. A careful literature search for examples of solution
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phase Fmoc-deprotections followed by amine derivatisation in situ, yielded only three reports 
of KF used to cleave Fmoc carbamates in one-pot procedures in the presence of acylating 
agents (Li et al 1993a and 1993b, Li and Chou 2000). Using these procedures, Fmoc 
protected 77 was treated with KF in DMF and TEA, then Oregon Green 488 NSE added. On 
this occasion, clean TLC allowed us to monitor the deprotection through the appearance of the 
methylidenefluorene by-product and the absence of the deprotected amine (by comparison 
with a “blank” deprotection, that is the same reaction, without the fluorophore present). These 
TLC were performed in basic (NH3 containing) mobile phases, but attempts to resolve the 
fluorescent baseline spots with other mobile phases failed. However, we were able to infer the 
presence of a poly-Boc protected fluorescent conjugate by staining the fluorescent spots with 
PMA.
Figure 55. Synthesis of Oregon Green labelled alkyl-spermine cholesteryl carbamate 82 
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Without purification, this mixture was treated with TFA in order to effect the poly-Boc 
deprotection, then the reaction was stopped after 3 h and the mixture purified by semi­
preparative RP-HPLC (fo 4.5 min, X = 488 nm, MeCN-0.01 % aq. TFA 9:1 v/v). The collected 
peak corresponded to an intense green product (in solution) which was fluorescent green 
under UV light (366 nm) and stained red with ninhydrin, indicating the polyamine moiety. The 
normal absorption and fluorescence spectroscopy were also appropriate for product 82 
(absorption A,max (H2O): 489 nm, fluorescence Xmax (Ex): 490 nm, A,max (Em): 528 nm).
However, the mass spectrum of this compound showed that at some point between purification 
and FAB sample ionisation, the ester in 82 had degraded to give the alcohol 83 and the 
Oregon Green conjugate of 5-aminopentanoic acid 84. Alcohol 83 had further reacted with 
TFA to form the trifluoroacetyl ester 85 or an isomeric trifluoroacetamide (Fig. 56). Further 
evidence for the success of the reaction and subsequent purification, is that we predict acid 84 
will have a longer column retention time than the peak collected, based on the model FITC 
conjugate 63 (fo 12.9 min, X = 495 nm, MeCN-0.1 % aq. TFA 8:2 v/v). We conclude we have 
satisfactorily purified fluorescent lipopolyamine conjugate, the desired product 82 and not 
collected an unresolved mixture of alcohol 83 and acid 84, which would display similar 
fluorescence and ninhydrin staining as polyamine ester 82.
As discussed in Chapter 1, during our studies in non-viral gene delivery, Oregon 
Green 488 labelled polyethylenimine (PEI) has been used by Godbey et al (1999b and 1999c) 
in transfection experiments, though detailed imaging studies of endosome related events were 
not reported. However, Oregon Green labelled PEI was observed to translocate to the nucleus 
in the absence of DNA (Godbey et al 1999b). In a similar study, labelling with Oregon Green 
increased the transfection activity of PAMAM dendrimers (Yoo and Juliano 2000) although any 
specific translocating role played by Oregon Green remains unreported. However, Oregon 
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Figure 56. FAB+ mass spectral evidence for the degradation of 82
We also investigated the dansyl labelling of lipopolyamines, using the reagent dansyl 
chloride 80 (Fig. 53). Dansyl chloride (5-dimethylaminonaphthalene-1-sulfonyl chloride) is a 
commonly used reagent for the fluorescent labelling of amino acids and peptides. Dansyl
chloride is non-fluorescent, but it reacts with nucleophilic amines, affording fluorescent 
sulfonamides (dansyl amides). Here we report the coupling of this reagent with A/1IA/2,A/3-tri- 
Boc spermine 5 (Fig. 57), and later with a polyamine cholesteryl carbamate (Fig. 58). Fig. 57 
illustrates the single, regiochemically-controlled labelling of protected spermine 5 with the 
dansyl fluorophore, followed by the selective removal of the Boc protecting groups.
^oc
Figure 57. Synthesis of dansyl labelled spermine 87 
i. 80, CH2CI2, TEA, 25 °C, 5 h; ii. TFA-CH2CI2 (1:9), 25 °C. 3 h
90
A/1,A/4 ,AP-Tri-Boc spermine 5 was reacted with dansyl chloride affording a less polar 
product 86 by TLC (Rf 0.82 compared to 0.20 for 5, ChhCb-MeOH-conc. aq. NH3 100:10:1 
v/v/v). The product 86, which had similar chromatography to dansyl chloride 80 was 
distinguishable from the yellow non-fluorescent starting material by a blue-green fluorescence 
when visualised under UV light (366 nm). Compound 86 was deprotected with TFA-CH2CI2 
(1:9) to afford the monodansylated spermine conjugate 87 (FAB-HRMS C22H38N5O2S requires 
436.2746 (MH+), found 436.2734).
Dansylated spermine conjugates are of interest in the detection and analysis of 
polyamines which, in possessing poor spectroscopic properties, may be difficult to detect either 
sensitively or quantitatively (Page et al 1998, Carrington et al 1999). Cationic dansyl amide 
derivatives are known to interact with duplex DNA (Wang and Schneider 1998) and the dansyl 
fluorophore is sensitive to lipid environments (displaying enhanced fluorescence in non-polar 
solvents or certain cellular environments, Wang and Schneider 1998). These are potentially 
useful properties for the study of DNA-lipopolyamine particle formation and intracellular 
transfection processes. Therefore, we included dansyl in our designed fluorescent 
lipopolyamine probes. The synthesis of dansylated 87 provided us with a model route to our 
proposed lipopolyamine-dansyl conjugates. With this in hand, we followed our fluoride Fmoc 

























Figure 58. Synthesis of dansyl labelled poly-Boc protected cholesteryl carbamate 88 
i. KF, 80, TEA, DMF, 25 °C, 3 h
Once again, KF was found to be a convenient reagent for the Fmoc deprotection, and 
dansyl labelling followed in situ, the reactions were monitored by TLC (EtOAc). A new, non­
polar spot (Rf 0.93) displaying the distinctive blue-green fluorescence (excitation at 366 nm), 
stained with PMA, indicating fluorophore and Boc-protected polyamine present in this 
component, was assumed to be dansyl conjugate 88. Unreacted dansyl chloride, possessing 
similar (although resolved) chromatography, was distinguished as a visible bright yellow, non- 
fluorescent spot which did not react with PMA. Although the product 88 and dansyl chloride 
were separable by chromatography, it was not practical on this single milligram scale. Instead, 
the product 88 was washed into ether, affording a rapid separation from polar materials (e.g. 
the excess of KF, triethylammonium chloride). The product 88 displayed the desired accurate 
mass spectrum (FAB-HRMS C78H132N7O14S requires 1422.9553 (MH+), found 1422.9454).
This Boc-protected product 88 was treated with TFA-CH2CI2 (1:9 v/v). A more polar, baseline
92
spot, monitored by TLC (ChhCh-MeOH-conc. aq. NH3 100:10:1 v/v/v), was formed though no 
attempt was made to purify the lipopolyamine-dansyl conjugate due to time constraints.
The non-viral gene delivery vectors described so far are cationic lipids, and interact 
with DNA through electrostatic interactions between the cationic moiety and the anionic 
polyphosphate backbone of DNA. These compounds possess weak UV chromophores and 
require the introduction of a fluorescent label in order to be visualised by spectroscopic 
techniques. During our synthetic studies of fluorescent lipopolyamines, a novel gene delivery 
system based on non-electrostatic groove-binding has been designed and synthesised (Soto 
et al 2000). Carbamate 89 (Fig. 59) is a single C18 lipid chain conjugated to Hoechst 33258. 
Hoechst 33258 is known to bind in the minor groove of double-stranded DNA (Moon et al 
1995). Although conjugate 89 contains a basic piperazine moiety which may be protonated at 
pH 7.4, the authors report that binding of conjugate 89 to DNA does not lead to DNA 
compaction, as is observed with cationic lipids (Soto et al 2000). The fluorescent intensity of 
Hoechst 33258 increases upon binding to DNA, and therefore has found application as a 
fluorescent DNA probe (Gago et al 1988). Potentially, the intracellular study of complexes 
between conjugate 89 and plasmid DNA may be achieved using fluorescent microscopy, 
though currently its efficacy as a non-viral gene delivery tool has not been published.
Hoechst 33258
Figure 59. Structure of Hoechst 33258 conjugate 89 -  a fluorescent DNA-binding lipid designed for gene delivery
93
Synthesis o f fluorescent alkylspermine-based lipopolyamines incorporating lipophilic 
naphthalimide fluorophores
Lucifer yellow 90 (Fig. 60) is a fluorescent dye used in the study of neurones. 
Electrically coupled neurones allow exchange of Lucifer yellow where other cells do not, and 
are said to be “dye-coupled”. Under intense illumination, Lucifer yellow dyes mediate cell 
death and therefore have the potential of forming the basis of selective tumouricidal agents 
(Chang et al 1999). These dyes are substituted 4-amino-1,8 -naphthalimides that offer high 
photostability and fluorescence and, as well as fluorescent labels, have found application in 
liquid crystal displays and brightners in paints and plastics (Grabtchev et al 1996, Chang e ta l
1999). Professor David Lewis and co-workers (University of Wisconsin Eau-Claire) have 
prepared highly fluorescent lipophilic 1,8 -naphthalimides (including 91 and 92, Fig. 60, Chang 
et al 1999). Lipophilic fluorophores such as BODIPY (Fig. 53 and see also Chapter 1) have 
been incorporated into oligonucleotide delivery systems (Marcusson et al 1998). As part of our 
studies in fluorescent vectors for non-viral gene delivery, we were interested in incorporating a 
variety of fluorophores, including lipophilic moieties. To this end, Lewis generously supplied us 
with naphthalimides 91 and 92.





and Lewis naphthalimides 91 and 92
94
In order to synthesise fluorescent naphthalimide lipopolyamine probes we proposed a 
short-chain linkage from the steroid to the fluorophore in analogy with our first series of 
fluorescent lipopolyamines, i.e. using the 3a-hydroxyl functionality of bile acid amide 50. N- 
Alkyl-4-amino-1,8-naphthalimide dyes 91 and 92 contain a primary amine functional group. 
The design of fluorophores 93 and 94 allows us to tether these amines to the lipid scaffold via 
a succinate chain, giving a linker between lipid and fluorophore (Fig. 61) comparable with our 
designed 5-aminovalerate esters described earlier in this chapter.
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Figure 61. Structures of designed target naphthalimide-based lithocholic acid alkylspermine conjugates 93 and 
94 and model studies of hemisuccinate ester 95 formation 
i. Succinic anhydride, pyridine, 110 °C, 20 h
95
Preliminary model studies (Fig. 61) demonstrated that hemisuccinate esters such as 
95 could be prepared in CH2CI2 from the secondary alcohol, succinic anhydride and one 
equivalent of pyridine. However, heating (110 °C) in neat pyridine was established to be a 
superior method, affording homogeneous hemisuccinates in good yields (typically 80-90 %). 
We then employed this procedure for generating the hemisuccinate ester of polyamine- 
lithocholic conjugate 50 so that naphthalimides 91 and 92 could be coupled through an amide 
of succinic acid mono ester. As fluorescent naphthalimides 91 and 92 were precious 
materials, a linear synthesis also suited this small-scale work.
Alcohol 50 was heated under reflux in pyridine with an excess of succinic anhydride to 
afford the hemisuccinate ester 96 (Fig. 62). The steroidal 3p-proton in 96 was deshielded 
upon esterification from 3.57-3.66 ppm in 50 to 4.69-4.80 ppm, a typical observation in 1H 
NMR spectra following the formation of esters. Carboxylic acid 96 was aminated with 
naphthalimide 91 (used without further purification), to afford the A/-butyl naphthalimide 
derivative 97 which was purified over silica gel {R\ 0.62, CH2Cl2-MeOH 10:1 v/v). This 
naphthalimide 97 displayed the appropriate accurate mass data (C79H127N8O14 requires 
1411.9472 (MH+), found 1411.9495). In addition, up to four losses of 100 m/z were observed 
for conjugate 97, indicating poly-Boc fragmentation.
Analogous treatment of carboxylic acid 96 with amine 92 afforded highly lipophilic N- 
octadecyl naphthalimide derivative 98 which was purified over silica gel (Ri 0.80, CH2CI2- 
MeOH 10:1 v/v). Conjugate 98 displayed the appropriate accurate mass data (C93H155N8O14 
requires 1608.1663 (MH+), found 1608.1648). Again, up to four losses of 100 m/z were 
observed, inferring an intact poly-Boc protected polyamine moiety is present in conjugate 98. 





Figure 62. Synthesis of naphthalimide-labelled lipopolyamines 93 and 94 
i. Succinic anhydride, pyridine, 110 °C, 16 h; ii. 91 (n = 1) or 92 (n = 15), EDC, HOBt, CH2CI2, 25 °C, 16 h;
iii. TFA-CH2CI2 (1:9), 25 °C, 3 h
Compounds 97 and 98 were then treated with TFA-CH2CI2 (1:9 v/v) in order to 
deprotect these polyamine conjugates. Upon addition of TFA to these solutions in anhydrous 
CH2CI2, the colour turned from vibrant fluorescent yellow to orange, and we concluded that the 
4-aminonaphthalimide moiety has a degree of pH-dependent fluorescence. These poly-Boc 
deprotections were monitored by TLC (CFbCh-MeOH-conc. aq. NH3 100:10:1 v/v/v) until all
97
fluorescent (visualised at 366 nm excitation) and ninhydrin stained spots had moved to the 
baseline, typically after 3 h. Deprotected polyamine conjugates 93 and 94 were purified by 
semi-preparative RP-HPLC, detecting the naphthalimide chromophore at 430 nm (MeCN-0.01 
% aq. TFA 9:1 v/v).
Fig. 63 shows a typical chromatogram following the TFA deprotection of poly-Boc 
spermine conjugate 97. The retention time (fo 19.5 min) of the poly-Boc protected starting 
material 97 was confirmed by co-injection. The first large peak (fe 5.2 min) was collected and 
assumed to be the desired product 93 (the major product, a tetraammonium salt, the most 
polar component and therefore eluting first under reversed-phase chromatographic conditions). 
This product afforded green fluorescence when visualised at 366 nm, and strongly stained red 
with ninhydrin indicating that both fluorophore and polyamine were present. The FAB+ mass 
spectrum supported the conclusion that these moieties were present in the same molecule (93, 
C59H94N8O6 requires 1010, found 1011 (MH+)) and polyamine fragmentation was observed 





Figure 63. Semi-prep RP-HPLC chromatogram of poly-Boc deprotection of 97 
(Supelcosil ABZ+Plus, 5 ^m, 25 cm x 10 mm, X = 430 nm, MeCN-0.01 % aq. TFA 9:1 v/v)
Fluorescent lipopolyamine 93 was freely soluble in water and spectroscopic analysis 
yielded similar fluorescence data (excitation 460 nm, emission 531 nm) to those 
published for naphthalimide 91 (Chang et al 1999, excitation >,max: 450 nm, emission A,max: 540 
nm, measured in EtOH). The absorption spectrum (Fig. 64, Xm*. 453 nm, smax = 1.3 x 104) is 
similar to published values for 4-aminonaphthalimides in EtOH (Chang et al 1999, Xmax: 434 
nm, Smax = 1.2 x 104). These spectroscopic data confirm our lipopolyamine conjugate 93 as a 
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Figure 64. Normal absorption spectrum of 93 in H2O
Fig. 65 shows sequential chromatograms for the collection of homogeneous product 
94. Mass spectral data confirm the collected component as the desired product 94 
(C73H122N8O6 requires 1207, found 1208 (MH+) 1230 (M+Na+) and 1247 (M+K+)) and 
polyamine fragmentation was again observed (1150 [MH -  (CH2)3NH2]+; 1079 [MH -  
(CH2)4NH(CH2>3NH2]+). Conjugate 94, bearing a single C18 lipid chain substituted fluorophore 
gave slightly shifted fluorescence (excitation ; w  450 nm, emission Xmax: 530 nm) and 
absorption (similar spectrum to that of 93, A,max: 439 nm) data, from which we concluded that 
these naphthalimides may be spectroscopically sensitive to hydrophobic environments. These 
properties may be useful for monitoring the intracellular status of DNA-lipopolyamine 
complexes, as many fluorophores change their fluorescence profile upon dissociation from 
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Figure 65. Semi-prep RP-HPLC sequential chromatograms of poly-Boc deprotection of 98 
(Supelcosil ABZ+Plus, 5 pm, 25 cm x 10 mm, X = 430 nm, MeCN-0.01 % aq. TFA 9:1 v/v)
Nomenclature and NMR assignment of key Fmoc protected intermediates
In this chapter, we report the design and synthesis of fluorescent lipopolyamines 
based on cis- and trans-AB steroids. The 13C NMR spectra for the key spermine equivalents 
73 and 77 have been rigorously assigned. By way of conclusion to this synthetic chapter, we 
present the nomenclature and total, unambigous 13C NMR spectroscopic assignments of 
crucial precursors to our fluorescent lipopolyamines probes. The Boc-deprotected fluorescent 
lipopolyamines interact with DNA as discussed and characterised in Chapter 4.
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Numbering system for A/4,/V8,A/13,/V16-(tetra-fe/t-butyloxycarbonyl)-A/1-(3’a-hydroxy-5’p-cholan-24'-carbonyl)- 
1,16-diamino-4,8,13-triazahexadecane 5"-(9"'-fluorenylmethoxycarbonyl)-aminopentanoic acid ester 73
5" 3”









13C NMR assignment for ester 73 (integer values in ppm
156
°  29
interchangeable values in parentheses)
AN404 14578 9 - 8 - 0 1
Pulse Sequence: s2pul
S olvent:  CDC13 
Ambient temperature  
F i l e :  PROTON 
Mercury-400BB "nmr2"
PULSE SEQUENCE 
Relax, delay 1 .000 sec 
Pulse 45 .0  degrees 
Acq. t im e 2 .561 sec 
Width 6396.6  Hz 
32 r e p e t i t io n s  
OBSERVE H I ,  399.7890720 MHz 
DATA PROCESSING 
FT s ize  32768 
T o ta l  time 1 m1n, 59 sec
-0 ppm
AN404 14579 9 - 8 - 0 1
Pulse Sequence: s2pul 
S olvent :  CDC13 
Ambient temperature  
Mercury-400BB "nmr2"
PULSE SEQUENCE 
R elax, delay 2.000 sec 
Pulse 54 .2  degrees 
Acq. time 1.199 sec 
Width 25000.0 Hz 
816 r e p e t i t io n s  
OBSERVE C13, 100.5270516 MHz 
DECOUPLE HI', 399 .7911219 MHz 




Line broadening 1.0  Hz 
FT s ize  65536
T o ta l  t ime 641 h r ,  56 min, 11 sec
Numbering system for A/4IA/B,A/13,A/16-(Tetra-fe/f-butyloxycarbonyl)-A/1-(6,a-hydroxy-5,a-cholesteryl- 
3’-oxycarbonyl)-1,1 6-diamino-4,8,13-triazahexadecane 5”-(9’”-fluorenylmethoxycarbonyl)- 
aminopentanoic acid ester 77
13C NMR assignment for ester 77 (integer values in ppm, 
interchangeable values in parentheses)
AN 420 1 5 0 3 8  3 - 9 - 0 1
Pulse Sequence: s2pul
S o lv ent :  CDC13 
Ambient temperature  
Mercury-400BB "nmr2"
PULSE SEQUENCE 
Relax, de lay 1 .000 sec 
Pulse 45 .0  degrees 
Acq. t ime 1 .304 sec 
Width 25131.8  Hz 
512 r e p e t i t io n s  
OBSERVE C13, 100.5270194 MHz 
DECOUPLE H I ,  399 .7911219 MHZ 
Power 43 dB 
co nt inuo usly  on 
WALTZ-16 modulated  
DATA PROCESSING
Line broadenl 
FT s iz e  65536 
To ta l  t im e 20
O
CT>
o60 40 2080160 140 120180 ppm
CHAPTER 4
Analysis of DNA condensation by lipopolyamines: 
Normal absorption and fluorescence studies
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Analysis of DNA condensation by lipopolyamines
Polyamine-DNA interactions have been extensively studied in the literature in order to 
attempt to understand the biological roles of polyamines. Natural and synthetic polyamines 
(such as spermine 1 3.4.3, spermidine 2 3.4 and thermine 99 3.3.3 norspermine) are known to 
mediate a number of structural changes in DNA, such as the B—>Z transition (Minyat et al 
1978, Dickerson et al 1982, Thomas and Messner 1988) and may adopt a variety of binding 
orientations (Rodger et al 1995, Cohen 1998). Methods for the study of polyamine binding 
include NMR (Onash et al 1984) and molecular modelling (Liquori et al 1967, Adlam et al 1994, 
Rodger et al 1995). However, binding studies using these techniques are limited to relatively 
short sequences of duplex DNA (up to around 20 base pairs). Other techniques include X-ray 
crystallography (Drew and Dickerson 1981, Dickerson and Drew 1981), and recently, Raman 
spectroscopy (Deng et al 2000).
Although polyamines have weakly UV-visible absorbing chromophores, absorption 
spectroscopy may be used to study changes of “signature” DNA profiles upon polyamine 
binding. Variations of absorption spectroscopy include normal absorption, circular dichroism 
(CD, Parkinson et al 2000) and linear dichroism (LD, Rodger et al 1994). Although the aromatic 
hetereocyclic bases of DNA do not fluoresce, fluorescence spectroscopy is an available 
technique, provided a suitable fluorescent molecular probe is used. Examples of such probes 
are ethidium bromide (EtBr) 100 (a DNA intercalating agent, Dougherty and Pigram 1982) and 
Hoechst 33258 (a groove binder, see Chapter 3 Fig. 59, Moon etal 1995) and these may be 
displaced by polyamines, causing a change in the fluorescence (Patterkine and Ganesh 1999, 
Geall and Blagbrough 2000b). Normal absorption and fluorescence, using EtBr 100 as a DNA 
probe, are the basis of the spectroscopic studies reported here for the assessment of 
polyamine-DNA interactions in the context of non-viral gene delivery.
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Polyamine-DNA binding studies
We have studied the DNA-binding of three simple polyamines, spermine 1, spermidine 
2 and thermine 99 (Fig. 70) using an EtBr 100 displacement assay (Geall and Blagbrough 
2000b). This fluorescence technique, relies on polyamines displacing EtBr (Fig. 70), a cationic 
tricyclic intercalating agent. EtBr-DNA complexes are highly fluorescent (Geall and Blagbrough 
2000b), but the fluorescence of unbound EtBr is quenched in aqueous media. By measuring 
the depreciation of fluorescence intensity as a function of increasing polyamine concentration, it 






Figure 70. Structures of polyamines spermine 1, spermidine 2, thermine 99 and ethidium bromide 100
EtBr emits at 600 nm, upon excitation at 546 nm, with a higher quantum yield when 
bound to DNA (Geall and Blagbrough 2000b). However, when the bases of EtBr bound-DNA 
are excited at 260 nm, fluorescence emission is observed at 600 nm. This energy transfer from 
the DNA bases to the intercalated EtBr allows us to measure only the intercalated EtBr with an 
approximately 10-fold increase in sensitivity over direct EtBr excitation at 546 nm and is 
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Figure 71. EtBr displacement profiles of spermine 1, spermidine 2 and thermine 99: calf thymus DNA (20 mM
NaCI buffer, 2mM HEPES, 0.05 mM EDTA)
The displacement of EtBr was measured and plotted as a function of ligand 
ammonium:DNA phosphate ratio (charge ratio, Feigner eta! 1997, Fig. 71). Spermine 1 with a 
net positive charge of 3.8 at pH 7.4 displaces EtBr with greater efficiency than spermidine 2 
with 2.5 positive charges (Geall et al 1999). Thermine 99 binds with a similar affinity to 
spermine 1, though the data are not identical, a reflection of the difference in the central 
methylene spacing reducing from four in spermine to three in thermine (sometimes called 
norspermine, see Fig. 70). Polyamine-DNA binding has been shown to be a function of charge 
and the regiochemical distribution of polyammonium ions (Geall et al 1998b and 1999) and 
these results are in agreement with this.
Polyamines are known to condense DNA into toroidal shaped particles (Hud 1995, Hud 
etal 1995) and these particles have recently been imaged using AFM and electron microscopy 
(Lin et al 1998). EtBr displacement is also a measure of DNA condensation by polyamines, as 
charge neutralisation effects changes in the intercalation binding-sites making them
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unfavourable for EtBr intercalation. DNA bending has recently been observed by LD, during 
the condensation process (Rodger et al 2000). DNA condensation is predicted to occur when 
around 90 % of the DNA polyanionic charge has been neutralised (Manning 1978, Wilson and 
Bloomfield 1979). In the assays reported here, DNA condensation is not complete around a 
12-fold cationic charge excess of polyamine. We conclude that DNA condensation by simple 
polyamines is an inefficient process. These results are in agreement with literature findings 
(Geall et al 1998b).
DNA condensation for gene delivery: cationic polymers and cationic lipids
DNA condensation is a key first step in the transfection process, during which cells 
internalise DNA particles. Therefore, we have used the EtBr displacement to assess poly-L- 





Figure 72. Structures of cholesteryl carbamate 7 and poly-L-lysine
In Fig. 73, we show the EtBr displacement assay of spermidine mimic cholesteryl 
carbamate 7 (Fig. 72) measured at 20 mM NaCI (“low salt”) and at 150 mM NaCI (“high salt”, 
the physiological salt concentration). DNA-binding experiments are frequently reported at low 
salt concentrations in the literature (commonly 20 mM NaCI) and are therefore important for the 
purpose of comparison. Polyamines and their conjugates afford salt dependent DNA-binding 
profiles, a reflection of the electrostatic nature of the interactions involved. At 20mM NaCI, DNA 
is condensed efficiently by carbamate 7, with efficient displacement of EtBr at a charge ratio of 
around 1. That the EtBr fluorescence is not fully quenched indicates some EtBr is retained in 
the condensed particle, possibly due to aggregation of DNA condensates. The condensation 
process is less efficient at 150 mM NaCI possibly due to the significantly increased electrostatic 
competition.
100
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Figure 73. EtBr displacement profiles of cholesteryl carbamate 7: 
calf thymus DNA at low salt (20 mM NaCI buffer, 2mM HEPES, 0.05 mM EDTA) (blue) 
and high salt (150 mM NaCI buffer, 2mM HEPES, 0.05 mM EDTA) (red)
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In order to correlate EtBr displacement with particle formation (in order to show that 
EtBr displacement is related to a condensation mechanism and change in DNA structure), we 
have also conducted light-scattering studies. The normal absorption spectra of polyamine-DNA 
increases above 300 nm as the concentration of polycation is increased (Wilson and Bloomfield 
1979, Patterkine and Ganesh 1999), a background light-scattering effect caused by the 
formation of particles of DNA.
0.9
0.8
0.7- charge ratio 0.69
0.76 DNA condensedI 06«o
C  0.5




340 360 380200 220 240 260 280 300 320 400
Wavelength (nm)
Figure 74. Normal absorption spectra of 60 ng calf thymus DNA (red) and 60 ng calf thymus DNA + increasing 
concentrations of cholesteryl carbamate 7 (blue) until DNA condensation and precipitation (green): 
low salt 20 mM NaCI buffer, 2mM HEPES, 0.05 mM EDTA
In Fig. 74, we show a changing normal absorption profile for calf thymus DNA upon 
increasing concentrations of cholesteryl carbamate 7, measured at low salt. As drug load on 
the DNA increases, the profile intensifies and broadens across the spectrum. The band 
centred around 260 nm is composed of a complex number of transitions associated with the 
DNA bases. In B-form double stranded DNA the absorption is significantly less than the sum of 
the bases. This hypochromic effect (an effect leading to decreased absorption intensity) is
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caused by n-n interactions between stacked base pairs. In Fig. 74, hyperchromicity (increase 
in absorbance) is observed for the band at 260 nm and is accompanied by a red shift, 
indications that polyamine conjugate 7 is binding to DNA. These observations are consistent 
with stages in a condensation mechanism. The extent of the DNA-base stacking is diminished 
by polyamine-induced DNA bending. The n-n interactions that are effective in lowering the 
absorption of DNA in the absence of polyamines are disrupted by conformational changes of 
the DNA upon polyamine binding. Therefore, a hyperchromic effect is observed in the normal 
absorption spectroscopy of DNA-polyamine complexes (Rodger et al 2000). The 
conformational changes and ultimately, DNA condensation upon polyamine binding, also 
account for the displacement of ethidium cations from intercalation sites in the fluorescence 
assay. Increasing the drug load eventually leads to DNA condensation (charge ratio 0.76) and 
further titration with cholesteryl carbamate 7 causes a decrease in absorption as condensed 
DNA aggregates precipitate, which is visible to the naked eye (charge ratio 0.82). Although 
these values for DNA condensation do not correlate well with the fluorescence assay values (at 
charge ratio 0.82, around 25 % EtBr is complexed to DNA), time between addition of aliquots of 
cholesteryl carbamate 7 was not rigorously controlled during the collection of absorption data. 
The size of condensed DNA particles is known to vary with time (Lee and Huang 1996). In the 
fluorescence assay, polyamine addition is separated by one minute intervals, a consistent 
equilibration time. As absorption studies are not as sensitive as fluorescence measurements, 
solutions are 10-fold more concentrated than for the fluorescence experiments and do not 
include EtBr. Having established the spectroscopy, we repeated this experiment, measuring 
absorbance at a fixed wavelength (320 nm), with the addition of cholesteryl carbamate 7 at 
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Figure 75. Light scattering profiles of cholesteryl carbamate 7: calf thymus DNA at low salt (20 mM NaCI buffer, 
2mM HEPES, 0.05 mM EDTA) (blue) and high salt (150 mM NaCI buffer, 2mM HEPES, 0.05 mM EDTA) (red)
Fig. 75 is the fixed wavelength (320 nm) light scattering assay for cholesteryl 
carbamate 7 binding to calf thymus DNA showing an increase in light scattered as a function of 
charge ratio. Particle formation occurs at both low and high salt concentrations, as predicted 
from the EtBr displacement assay. By superimposing the light scattering and fluorescence 
curves for cholesteryl carbamate 7 at low salt concentration (Fig. 76), it is possible to compare 
the binding of polyammonium ligand (displacement of EtBr) and DNA particle formation (light 
scattering). At charge ratios of around 1.1, the absorbance and EtBr displacement approach 
maxima indicating particle formation by DNA condensation is complete (though only within the 
time parameters of these experiments). However, the two systems described here are at 
different concentrations, and in the light scattering experiments, EtBr is absent. EtBr may 
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Figure 76. DNA Condensation and particle formation: superimposed EtBr displacement (red) and light scattering 
(blue) profiles of cholesteryl carbamate 7 with calf thymus DNA at low salt (20 mM NaCI buffer, 2mM HEPES, 0.05
mM EDTA)
Base-sequence preference o f lipopolyamines and cationic polymers
We have investigated the binding of cholesteryl carbamate 7 and poly-L-lysine (PLL) to 
natural and synthetic sequences of DNA. Binding of these gene delivery agents to duplex 
alternating copolymers of complementary DNA bases is a measure of sequence preference. 
The EtBr displacement profiles for cholesteryl carbamate 7 binding to calf thymus DNA, 
poly[d(A-T)]2 and poly[d(G-C)]2 at low salt concentration are shown in Fig. 77. Calf thymus 
DNA (a mixed polymer of A-T (58 %) and G-C (42 %), Voet and Voet 1995) and poly [d(G-C)]2 
are condensed with similar efficiency. Condensation of poly[d(A-T)]2 is a more efficient process 
than the other sequences studied. This is in agreement with other published studies (Hsieh et 
al 1995) where a preference of steroidal polyamines for A-T rich sequences was reported.
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Figure 77. EtBr displacement profiles of cholesteryl carbamate 7 with natural and synthetic DNA:
Calf thymus DNA (blue), poly [d(G-C)]2  (red) and poly [d(A-T)]2 (green) 
at low salt (20 mM NaCI buffer, 2mM HEPES, 0.05 mM EDTA)
Similar conclusions may be drawn from data acquired for the binding of a 255-mer PLL 
(Fig. 78) and are in agreement with the findings of Leng and Felsenfeld (1966). Salt 
concentration has less effect on efficient DNA condensation (cf. data for cholesteryl carbamate 
7, Fig. 73).
PLL is an efficient transfection vector and a mimic of histones conserving lysine-rich 
sequences in the condensation of DNA. PLL is commercially available in various average 
molecular weights and polydispersities. The influence of molecular weight on transfection 
activity of another cationic polymer polyethylenimine (PEI) has recently been reported (Godbey 
et al 1999a) indicating that higher average molecular weight PEI affords the highest transfection 
efficiency. Using the EtBr and light scattering assays, we investigated the condensation of calf 



















1 1.2 1.4 1.60 0.2 0.4 0.6 0.8
Charge ratio (*■/■)
Figure 78. EtBr displacement profiles of 255-mer poly-L-lysine with natural and synthetic DNA:
Calf thymus DNA, poly [d(G-C)]2 and poly [d(A-T)]2 at low salt (blue) (20 mM NaCI buffer, 2mM HEPES, 0.05 mM 
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Figure 79. EtBr displacement profiles of 38-, 120- and 255-mer poly-L-lysine: 
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Figure 80. Light scattering profiles of 38-, 120- and 255-mer poly-L-lysine: 
calf thymus DNA at low salt (20 mM NaCI buffer, 2mM HEPES, 0.05 mM EDTA)
Under low salt conditions, PLL 120 is the most efficient average length polymer for 
DNA condensation, as followed by EtBr displacement (Fig. 79) and light scattering (Fig. 80). 
Particle formation followed by precipitation was observed for PLL 120 at a charge ratio less 
than 0.9. PLL of all degrees of polymerisation tested are more efficient than cholesteryl 
spermidine mimic 7. Similar results were recorded at the high salt concentration (Fig. 81 and 
82).
In the context of gene delivery, cationic vectors have been shown to transfect cells at 
charge ratios above 1.0 (Miller 1998, Schwartz etal 1999). At these charge ratios, all lengths 
of PLL mediate DNA particle formation at physiological pH (7.4) and salt concentration.
It is reasonable to propose that larger particles will increase the angle of light scattering 
thereby elevating the apparent absorbance as less light is collected by the instrument. Under 
this assumption, particles formed at 150 mM NaCI are larger than those formed at only 20 mM 
NaCI. Aggregation of DNA condensates may account for this and the observed precipitation at
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higher charge ratios. Aggregation of PLL-DNA and polyamine-DNA complexes is consistent 
with electron microscopy studies revealing large (2000 nm diameter) PLL-DNA structures (Tang 
and Szoka 1997). Furthermore, the amount of light scattered by lipopolyamine carbamate 7- 
DNA complexes is greater than cationic polymer PLL-DNA complexes at both salt 
concentrations used here (see Fig. 75), however, a higher charge ratio is required for 
cholesteryl carbamate 7. In scanning force microscopy studies, Transfectam (DOGS, a di-C18 
chain lipopolyamine spermine mimic, Fig. 83) was shown to condense DNA into larger particles 
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Figure 81. EtBr displacement profiles of 38-, 120- and 255-mer poly-L-lysine: 
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Figure 82. Light scattering profiles of 38-, 120- and 255-mer poly-L-lysine: 




Figure 83. Structures of the lipopolyamine Transfectam and the linear cationic polymer PEI
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Monocationic steroidal carbamates such as DC-Chol 26 (Chapter 2) are known to be 
useful tools for the transfection of cells in vitro (Gao and Huang 1991). This biological activity in 
some part relies on interactions between the cationic lipid and DNA. Using fluorescence and 
absorption spectroscopic techniques, we have made an initial assessment of these interactions 
between monocationic ergosteryl carbamate 33 (Fig. 84) and a natural sequence - calf thymus 
DNA. Fig. 84 shows a normal absorption curve of calf thymus DNA that changes upon the 
addition of ergosteryl carbamate 33. The spectrum is observed to broaden and intensify 
especially at the 265 nm band and background above 300 nm. This is the same effect 
observed for the polyamine cholesteryl carbamate 7 described earlier and is also consistent 
with DNA condensation and light scattering through particle formation. Although ergosteryl 
carbamate 33 is a conjugated diene, it has a weakly absorbing chromophore which at the dilute 
concentrations reported here, does not interfere significantly with the normal absorption 
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Figure 84. Structure of ergosteryl carbamate 33 and normal absorption spectra of 60 pg calf thymus DNA (red) 
and 60 pg calf thymus DNA + 3 pg carbamate 33 (blue) at 20 mM NaCI buffer, 2mM HEPES, 0.05 mM EDTA
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Armed with these data, ergosteryl carbamate 33 was assayed for EtBr displacement 
which showed that carbamate 33 does mediate DNA condensation at low salt (Fig. 85) with 
more efficiency than the natural polyamine spermine 1. DNA condensation is complete at a 
charge ratio of around 6 (90 % of EtBr displaced). This is less efficient than the lipopolyamines 
or cationic polyamines assayed in this work - this is in agreement with the literature that 
describes DNA condensation as a function of, in one measure, cationic charge at physiological 
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Figure 85. EtBr displacement profiles of ergosteryl carbamate 33 compared to spermine 1. 
(Calf thymus DNA, 20 mM NaCI buffer, 2mM HEPES, 0.05 mM EDTA)
DNA binding studies of cis-AB and trans-AB steroidal lipopolyamines
In addition to DNA binding affinity, polyamine-steroid conjugates have recently been 
shown to exhibit antimicrobial activity (Kikuchi et al 1997, Kim et al 2001). These steroidal 
lipopolyamines have been designed as mimics of squalamine 101 (Fig. 86), a powerful 
antimicrobial agent obtained naturally from the dogfish shark (Squalus acanthias, Kim et al 
2001). Squalamine 101 is a steroidal spermidine derivative, hydroxylated at position 7 on the
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a-face of the trans-AB steroid nucleus, and therefore structurally related to our hydroborated 
cholesteryl polyamine conjugates, especially protected spermidine mimic 54 (Fig 86). 
Analogues of squalamine 101 have been designed, based on hydroxylated natural products, 
the bile acids, especially polyamine conjugates of lithocholic acid 17 (see also Chapter 2) or 















Figure 86. Structures of squalamine 101, hydroborated cholesteryl carbamate 54, 
lithocholic acid amide 17 and hyodeoxycholic acid amide 102
Squalamine 101 and its analogues are currently in development as new antibiotics with 
an as yet undetermined mode of action and are therefore of clinical interest for use against 
resistant strains of bacteria such as methicillin-resistant Staphylococcus aureus (MRSA,
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Kikuchi et al 1997). Lipopolyamine carbamates NP-1, NP-2, NP-3, NP-4 and urea NP-5 (Fig. 
87) have been shown to be more potent against S. aureus than squalamine 101 in vitro (Kim et 
al 2001). The polyamine carbamates were synthesised by activation of the relevant alcohol 
with phosgene (20 % solution in toluene) to afford the chloroformate intermediate, in an 













Figure 87. Structures of the Kim lipopolyamines NP-1, NP-2, NP-3, NP-4 and NP-5 
Lipopolyamines NP-1, NP-2, NP-3, NP-4 and NP-5 (Fig. 87) are relevant to our DNA
condensation studies in that they vary in polyammonium moiety, steroid geometry and
incorporate a carbamate or urea linker moiety. As part of our synthetic studies of c/s- and
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trans-AB ring steroids for the condensation of DNA, and in a collaboration with Professor Hong- 
Seok Kim (Kyungpook National University, South Korea), we were generously supplied with 
these steroidal polyamines.
Fig. 88 shows the EtBr displacement profiles of the five NP-lipopolyamines, with calf 
thymus DNA, at low salt concentration. As may be predicted from the literature (Geall et a! 
1998a, Blagbrough et al 2000) regarding hydroxylated steroids binding to DNA, spermidine 
mimics NP-4 and NP-5 condense calf thymus DNA with the greatest efficiency compared to 
putrescine mimics NP-1 and NP-2. Also, the trends in binding between comparable cis- and 
trans-AB ring steroids show that the relative binding affinity of cis-AB lipopolyamines may be 
predicted from the observation that lithocholic acid polyamine amides (cis-AB) are less efficient 
in the condensation of DNA than their cholesterol-based counterparts. The frans-AB steroids 
NP-4 and NP-2 are more efficient than their cis-AB counterparts, NP-1 and NP-3 respectively. 
These observations may be explained by differences in the hydrophobic packing of bound 
steroid on the DNA (Muller et al 1995). In that case, perhaps surprisingly, NP-5, a cis-AB 
spermidine mimic with a urea linker has a similar EtBr displacement profile to that of NP-4. The 
alkyl urea linker in NP-5 is two atoms longer than the corresponding carbamates of the other 
conjugates, and the linker is also a candidate for SAR studies in the design of new 
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Figure 88. EtBr displacement profiles of lipopolyamines NP-1, NP-2, NP-3, NP-4 and NP-5.
(Calf thymus DNA, 20 mM NaCI buffer, 2mM HEPES, 0.05 mM EDTA)
Naphthalimide-labelled lipopolyamines: DNA interactions studied by normal absorption
Fluorescent naphthalimide-conjugated lipopolyamines 93 and 94 (Fig. 89) were shown 
to be unsuitable for the EtBr displacement assay due to emission interference. Naphthalimide 
93 absorbs at 260 nm and 450 nm and the emission band (531 nm) significantly overlaps with 
EtBr (600 nm) at increasing concentrations of naphthalimide (data not shown). Therefore, 
normal absorption spectra of calf thymus DNA-naphthalimide complexes at increasing charge 
ratio were measured (Fig. 90 and 91).
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Figure 90. Normal absorption spectra of 60 pg calf thymus DNA (red) and 60 pg calf thymus DNA + increasing 
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Figure 91. Normal absorption spectra of 60 pg calf thymus DNA (red) and 60 pg calf thymus DNA + increasing 
concentrations of naphthalimide conjugate 94 (blue): low salt 20 mM NaCI buffer, 2mM HEPES, 0.05 mM EDTA
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The UV spectra (Fig. 90 and 91) show changes characteristic of polyamine binding and 
DNA condensation. Both conjugates cause the background light-scattering that accompanies 
DNA particle formation. Naphthalimide 93 causes the red shift and increased intensity of the 
band at 260 nm associated with the disruption of DNA-base stacking. Initially (charge ratio 
0.28), naphthalimide 94 causes a lowering of the band at 260 nm, then further addition has the 
characteristic hyperchromic effect and light scattering is observed. Both naphthalimides 93 and 
94 condense DNA upon addition of sufficient charge equivalents (6.34 for 93,9.51 for 94). In 
both experiments, the appearance of the cuvette solution turned from yellow to colourless, as 
condensed DNA aggregated and was visible to the naked eye as a yellow precipitate. In 
addition to the observed turbidity, the DNA absorbance diminished across the spectrum. That 
the designed fluorescent lipopolyamines are visibly incorporated into DNA particles is an 
encouraging result for future work, where a fluorescent DNA particle may be useful in the 
imaging of transfection processes.
Naphthalimide conjugates 93 and 94 are spermine equivalents with 3.4 positive 
charges at physiological pH (Geall et al 2000). These vectors are more efficient than spermine 
(3.8 positive charges) in the condensation of calf thymus DNA. Naphthalimide 94 has a C18 
lipid chain. Therefore, steric hindrance of ligand binding may be responsible for less efficient 
DNA condensation processes than observed with the n-butyl derivative 93. Naphthalimides are 
known to be DNA intercalators (Tao et al 1996, Chang et al 1999). However, the absorbance 
for the naphthalimide band at 530 nm displayed linear hyperchromicity as a function of 
increased drug load, and no evidence for intercalation of this chromophore was observed. 
Naphthalimides 93 and 94 are substituted with bulky steroid and alkyl chains. These groups, 
especially the long octadecyl chain in conjugate 94, may perturb insertion of the naphthalimide 
moiety into intercalation sites.
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Conclusions
The synthesis of steroid based lipopolyamines has been investigated, with a design 
brief set in the area of efficient DNA condensation and non-viral gene delivery. We report the 
synthesis of spermidine and spermine polyammonium conjugates of cholesterol, lithocholic acid 
and ergosterol, a novel lipid moiety in the area of non-viral gene delivery. Using protecting- 
group strategies established in this research group and further refined here, spermine has been 
acylated, under regiochemical control, with the naturally occurring steroids cholesterol, 
lithocholic acid and ergosterol. These steroids afforded alkyl spermidine conjugates with 
variation in shape and hydrophobicity. In order to generate spermine-based polyammonium 
moieties for incorporation into lipopolyamines, spermine has been alkylated using a reductive 
alkylation route to extend unsymmetrically a polyamine chain. Also, the reduction of lithocholic 
acid amides to amines, as a route for retaining the pKa of spermine moieties, has been 
successfully applied.
Using steroidal cationic lipids as analytical tools for the study of DNA condensation, we 
have investigated particle formation by studying the light scattering effect and also by EtBr 
displacement fluorescence assay. By applying such spectroscopic techniques, cholesteryl 
spermidine mimic 7 and poly-L-lysine (PLL) have been show to bind preferentially to A-T rich 
DNA sequences. PLL of various average molecular weights have been shown to condense 
DNA with different affinities (a 120-mer being more efficient than the 38-mer and 255-mer PLL), 
but generally are all suitable for efficient DNA condensation at physiological salt concentration 
(150 mM NaCI).
A synthetic monocationic ergosteryl carbamate, a model for DC-Chol, the first steroidal 
cationic lipid, has been synthesised and shown to condense calf thymus DNA with a greater 
efficiency than simple polyamines such as spermine. Also, lipoputrescine and lipospermidine
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conjugates of other steroids have been assayed for their condensation of calf thymus DNA. 
Lipids possessing trans-AB ring junctions were more efficient than their c/'s-AB counterparts.
A synthetic route to fluorescent lipopolyamines has been established, via key Fmoc 
protected intermediates based on cis- and trans-AB steroid moieties. Using fluoride reagents to 
deprotect the Fmoc protecting group, we were able to introduce regioselectively fluorophores of 
choice to cholesterol and lithocholic based lipopolyamines. A crucial step in these 
achievements was the hydroboration of the alkene in cholesterol conjugates, in the presence of 
up to five carbamate functional groups. The major product was the trans-AB steroid, and it was 
separable from the minor product, the cis-AB diastereoisomer. Oregon Green and dansyl 
conjugates of cholesteryl spermine mimics have been prepared, each with the potential to be 
used together or independently in multicolour fluorescence studies related to DNA 
condensation and gene delivery.
Two naphthalimide-labelled conjugates of lithocholic acid-spermine mimics have been 
prepared. One incorporated both a C18 alkyl chain and a steroid moiety. Both conjugates 
were shown by normal absorption spectroscopy to condense calf thymus DNA and to be 
incorporated into a fluorescent DNA-lipopolyamine particle. We have designed, prepared, 
purified and analysed a series of complex small molecules, lipopolyamines that are capable of 
condensing DNA. We have made some of these efficient DNA-condensing agents fluoresce, 






Chemicals were purchased from Sigma-Aldrich-Fluka with the exception of fluorescein 
isothiocyanate (isomer I) and Oregon Green 488 NSE, which were purchased from Molecular 
Probes (Eugene OR, U.S.A.). Naphthalimide fluorophores were kindly supplied by Professor 
David Lewis (University of Wisconsin-Eau Claire Wl, U.S.A.). Lipopolyamines NP-1, NP-2, NP- 
3, NP-4 and NP-5 were kindly supplied by Professor Hong-Seok Kim (Kyungpook National 
University, South Korea). All chemicals were used without further purification. Solvents were 
GPR or HPLC grade and purchased from BDH or Fisher. Anhydrous CH2CI2 was distilled from 
calcium hydride and anhydrous MeOH was distilled from magnesium and iodine. Analytical 
thin layer chromatography (TLC) was performed on pre-coated plates (Merck TLC aluminium 
sheets silica 60 F254). Chromatograms were visualised with either UV light (254 or 366 nm), or 
stained with ninhydrin (0.3 % w/v solution in /7-butanol-acetic acid 97:3 v/v), phosphomolybdic 
acid (5 % w/v solution in ethanol) or 2,4-dinitrophenylhydrazine (3.5 % w/v solution in ethanol- 
water-sulfuric acid 10:4:3 v/v/v) as appropriate. “Purified over silica gel” refers to preparative 
column chromatography with slurry packed silica gel 60 (35-75 (am) purchased from BDH, 
performed either under gravity or under pressure with hand bellows (flash chromatography) 
(Stille et al 1978). Sand (acid washed), purchased from BDH was used to seal the column of 
silica gel and was used after washing with acetone, ethyl acetate, methanol and 
CH2Cl2/MeOH/conc. aq. NH3 (100:10:1 v/v/v). Solvents were “evaporated in vacuo” using a 
Buchi rotary evaporator under partial vacuum with a water pump.
Infra-red spectra were recorded as a KBr disc unless otherwise stated using a Perkin 
Elmer Spectrum RXI FT-IR instrument. 1H NMR and 13C NMR spectra were recorded on a 
JEOL EX400 instrument at 400 MHz and 100.8 MHz respectively. Chemical shifts (6, in parts 
per million) are relative to tetramethylsilane in 1H NMR spectra and solvent resonance in 13C 
NMR spectra. Coupling constants (line separations) (J) are expressed in Hertz as absolute
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values and multiplicities are recorded as s (singlet), d (doublet), t (triplet), q (quartet), quin 
(quintet), m (multiplet) and b (broad). High and low resolution FAB mass spectra (positive ion 
mode, unless otherwise stated) were measured on a VG AutoSpec Q spectrometer, using 
mefa-nitrobenzyl alcohol as the matrix. Polyamines are hygroscopic with varying salt content, 
therefore elemental analysis and melting points are unsuitable means of assessing the purity of 
these compounds (Byk et al 1997, Byk et al 1998). Semi-preparative RP-HPLC was performed 
with a Jasco PU-980 pump with a Jasco UV-975 detector. The stationary phase was a 
Supelcosil ABZ+Plus, 5 ^m  (25 cm x 10 mm) column. UV spectra were recorded on Perkin 
Elmer Lambda 40 or Unicam Helios y spectrometers. Fluorescence measurements were made 
on a Perkin Elmer LS 50B fluorimeter.
Ethidium bromide displacement assay
DNA (calf thymus, poly [d(A-T)]2, or poly [d(G-C)]2 , 6  pi, 1 mg/ml) in MilliQ water was 
added to buffer (20 mM or 150 mM NaCI, 2 mM HEPES, 0.05 mM EDTA, pH 7.4, 3000 pi) in a 
cuvette (quartz, 1 cm path length) followed by the addition of ethidium bromide (3 pi, 0.5 
mg/ml). This solution was mixed (using a microflea) for 1 min and fluorescence intensity 
measured (tax = 260 nm, tam = 600 nm). Aliquots of ligand (5 pi, typically 1 mg/ml stock 
solutions of polyamines, 0.1  mg/ml solutions of cationic polymers) were added with mixing, 
allowing 1 min equilibration time before measuring fluorescence. Curves were plotted as a 
function of ligand/DNA charge ratio, that is the ammonium/phosphate ion (HIP) ratio (Feigner et 
al 1997).
134
Light scattering assay (A320)
DNA (calf thymus, poly [d(A-T)]2 , or poly [d(G-C)]2 , 6  nl, 1 mg/ml) in MilliQ water was 
added with mixing to buffer (20 mM or 150 mM NaCI, 2 mM HEPES, 0.05 mM EDTA, pH 7.4, 
3000 jil) in a cuvette (quartz, 1 cm path length). Absorbance at X = 320 nm was measured. 
Aliquots of ligand (5 |il, typically 1 mg/ml solutions of cationic polymers) were added with 
mixing, allowing 1 min equilibration time before measuring the absorbance. Curves were 
plotted as a function of ligand/DNA charge ratio.
AP.AfSAP-JT ri-ferf-butyloxycarbonyl)-1,12-diamino-4,9-diazadodecane 5
A solution of ethyl trifluoroacetate (3.09 g, 21.7 mmol) in MeOH (50 ml) was added dropwise 
over 30 min to a stirred solution of 1,12-diamino-4,9-diazadodecane 1 (4.00 g, 19.8 mmol) in 
MeOH (300 ml) at -78 °C, under nitrogen. The temperature was increased to 0 °C over 1 h, 
then di-terf-butyl dicarbonate (17.23 g, 79 mmol) in MeOH (50 ml) was added dropwise over 5 
min. The reaction mixture was allowed to warm to 25 °C, then stirred for a further 18 h. After 
this time, the solution was basified (pH > 11) with conc. aq. ammonia and stirred for a further 
18 h. The solution was then concentrated in vacuo and the residue purified over silica gel 
(CH2Cl2-MeOH-conc. aq. N H 3 75:10:1 v/v/v) to afford the title compound as a colourless oil 
(4.86 g, 49 %). Ri 0.20 (CH2CI2-MeOH-conc. aq. N H 3 100:10:1 v/v/v). 1H NMR (C D C I3 ): 1.43- 
1.48 (31 H, m, 6 -CH2, 7-CH2i 0-C(CH3) 3 x 3), 1.60-1.66 ( 2  H, m, 2-CH2), 1.74-1.80 ( 2  H, m, 1 1 - 
CH2), 2.72-2.81 ( 2  H, m, 12-CH2), 3.05-3.32 (10 H, m, 1-CH2l 3-CH2,5-CH2,8-CH2,10-CH2),
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4.12 (2 H, s, NH2). 13C NMR: 25.9 (6 -CH2l 7-CH2), 28.3, 28.4, 28.4 (2-CH2, 0-C(CH3)3 x 3, 
overlapping), 37.5 (1-CH2), 38.9 (12-CH2), 43.9,44.3 (3-CH2,10-CH2), 46.8 (5-CH2, 8 -CH2, 
overlapping), 78.8,79.4 (0-C(CH3)3 x 3, overlapping), 155.7 (N-C0-0-C(CH3) 3 x 3). FAB-MS 




Cholesteryl chloroformate (738 mg, 1.6 mmol) in CH2CI2 (10 ml) was added over 5 min to a 
stirred solution of tri-Boc protected polyamine 5 (750 mg, 1.5 mmol) in CH2CI2 (20 ml) with TEA 
(0.5 ml) at 25 °C, under nitrogen. The solution was stirred for 6  h then evaporated to dryness 
in vacuo and the residue purified over silica gel (EtOAc-hexane 1:9 to 4:6 v/v) to afford the title 
compound as a white solid (1.17 g, 8 6  %). Rf 0.65 (EtOAc-hexane 7:3 v/v). 1H NMR (CDCI3): 
0.68 (3 H, s, 18’-CH3), 0.86,0.87 (6  H, 2 x d, J = 7, overlapping 2 Hz, 26'-CH3 and 27’-CH3), 
0.91 (3 H, d, J = 6 , 21’-CH3), 1.01 (3 H, s, 19’-CH3), 1.04-2.02 (61 H, m, 2-CH2, 6 -CH2,7-CH2,
11-CH2,1 ’-CH2, 2’-CH2i 4’-CH2, 7’-CH2i 8 ’-CH, 9’-CH, 11’-CH2,12’-CH2,14’-CH2, 15’-CH2, 16’- 
CH2,17’-CH, 20’-CH, 22’-CH2i 23’-CH2,25’-CH, 0-C(CH3)3 x 3), 2.27-2.36 (2 H, m, 24’-CH2), 
3.05-3.35 (12 H, m, 1-CH2, 3-CH2, 5-CH2, 8 -CH2,10-CH2,12-CH2), 4.43-4.53 (1 H, m, 3-CH), 
5.37 (1 H ,m, 6 '-CH), 5.60-5.65 (2 H, m, CH2-NH-CO x 2). 13C NMR: 11.6 (18’-CH3), 18.5 (21- 
CH3), 19.1 (19’-CH3), 20.8 (11’-CH2), 22.4 (27’-CH3), 22.6 (26’-CH2), 23.6 (23’-CH2), 24.1 (15- 
CH2), 25.5,25.8 (6 -CH2, 7-CH2), 27.8, 28.0, 28.0,28.2, 28.7 (2-CH2) 11-CH2, 2’-CH2,16’-CH2, 
25’-CH, 0-C(CH3)3 x 3, overlapping), 31.7 (7’-CH2, 8 ’-CH), 35.6 (20’-CH), 36.0 (22’-CH2), 36.3 
(10'-C), 36.8 (1’-CH2), 37.3 (1-CH2,12-CH2), 38.4 (24’-CH2), 39.3, 39.5 (4’-CH2,12’-CH2), 42.1 
(13’-C), 43.7,44.0 (3-CH2,10-CH2), 46.1,46.6 (5-CH2, 8 -CH2), 49.8 (9-CH), 55.9 (17’-CH),
56.5 (14’-CH2), 73.9 (3’-CH), 79.4 (0-C(CH3)3 x 3), 122.1 (6 ’-CH), 139.8 (5’-C), 155.9 (N-CO-O-
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C(CH3)3 x 3, NH-CO-O-CH, overlapping). FAB-MS m/z 915 (MH+), C53H94N4O8 requires 914; 
FAB-HRMS calculated 915.7150 (MH+), found 915.7152.
Me
Me
AP-tCholesteryl-S’-oxycarbonyty-l^-diamino^d-diazadodecane tritrifluoroacetate salt 
7
Tri-Boc protected polyamine 5 (215 mg, 0.23 mmol) in anhydrous CH2CI2 (18 ml) and TFA (2 
ml) was stirred at 25 °C for 4 h, then the solvent was evaporated in vacuo to afford the title 
compound as a white solid (114 mg, 79 %). 10 mg of this material was purified by semi­
preparative RP-HPLC (Supelcosil ABZ+Plus, 5 jum, 25 cm x 10 mm, X = 220 nm, MeCN-0.1 % 
aq. TFA 6:4 v/v), tR 7.7 min. NMR (d6-DMSO): 0.65 (3 H, s, 18'-CH3), 0.84 (6  H, d, J = 6 , 
26’-CH3,27-CH3), 0.90 (3 H, d, J = 6 , 21’-CH3), 0.97 (3 H, s, 19’-CH3), 0.97-2.00 (35 H, m, 2- 
CH2, 6 -CH2, 7 -CH2, H-CH2,1 ’-CH2, 2 -CH2,4 ’-CH2, 7 -CH2, 8 ’-CH, 9’-CH, 11’-CH2,12’-CH2, 
14’-CH2,15’-CH2, 16’-CH2i 17’-CH, 20’-CH, 22’-CH2, 23’-CH2, 25’-CH), 2.16-2.32 (2 H, m, 24’- 
CH2), 2.80-3.07 (1 2  H, m, 1-CH2, 3-CH2,5-CH2, 8 -CH2, IO-CH2,12-CH2), 4.22-4.38 (1 H, m, 3’- 
CH), 5.26-5.38 (1 H, m, 6 ’-CH), 8.00-8.95 (bs, ammonium NH). 13C NMR: 12.0 (18’-CH3), 18.8 
(21 ’-CH3), 19.3 (19'-CH3), 20.8 (11’-CH2), 2 2 .6  (26’-CH3), 22.9, 22.9 (6 -CH2,7-CH2, 27’-CH2),
23.5 (23’-CH2), 23.9,24.0 (2-CH2,15’-CH2), 26.5 (11-CH2), 27.7 (16’-CH2), 31.6 (7’-CH2, 8 ’- 
CH), 35.5 (20’-CH), 35.9 (22’-CH2), 36.3 (10’-C), 36.4 (1’-CH2), 36.8 (1-CH2), 37.6 (12-CH2),
38.5 (24’-CH2), 39.1, 39.1 (4’-CH2,12’-CH2), 42.1 (13’-C), 44.1 (3-CH2), 44.8 (10-CH2), 46.3,
4 6 .5  ( 5 - C H 2, 8 - C H 2), 4 9 . 7  ( 9 ’- C H ) ,  5 5 .8  ( 1 7 ’- C H ) ,  5 6 .3  ( 1 4 ’- C H 2), 7 3 .2  ( 3 ’- C H ) ,  1 2 1 .9  ( 6 ’- C H ) ,  
1 3 9 .7  ( 5 ’-C ) ,  1 5 5 .8  ( N H - C O - O - C H ) .  F A B - M S  m/z 6 1 5  ( M H +), C 38 H 7o N 40 2 requires 6 1 4 .
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A71,/V12-Ditrifluoroacetyl-1,12-diamino-4,9-diazadodecane ditrifluoroacetate salt 8
Ethyl trifluoroacetate (7.19 g, 50.65 mmol) was added to a stirred solution of 1,12-diamino-4,9- 
diazadodecane 1 (2.05 g, 10.13 mmol) and water (0.36 ml, 20.26 mmol) in MeCN (45 ml) at 25 
°C. The solution was heated at reflux for 18 h, then cooled to 25 °C and filtered to give a white 
solid. Recrystallisation from EtOAc afforded the title compound as a white solid (5.99 g, 93 %). 
IR 1684 cm-1 (CO). 1H NMR (de-DMSO): 1.60-1.70 (4 H, m, 6 -CH2,7-CH2), 1.85 (4 H, quin, J = 
7, 2 -CH2, H-CH2), 2.88-3.00 (8  H, m, 3-CH2l 5-CH2l 8 -CH2, IO-CH2), 3.27 (4 H, q, J = 6 , 1-CH2, 
I 2 -CH2), 8.80-9.00 (4 H, m, NH2+x 2), 9.66 (2 H, br t, J = 5, CF3-CO-NH x 2). 13C NMR: 22.8 
(6 -CH2, 7 -CH2), 25.1 (2-CH2, H-CH2), 36.7 (5-CH2, 8 -CH2), 44.5 (3-CH2,10-CH2), 46.1 (1-CH2,
I 2 -CH2), 113.4-120.1 (m, CF3CO-NH x 2, CF3CO-O x 2, overlapping), 156.3 (q, 2J c f = 36, 




A solution of ethyl trifluoroacetate (1.81 g, 10.6 mmol) in CH2CI2 (20 ml) was added dropwise 
over 30 min to a stirred solution of 1,12-diamino-4,9-diazadodecane 1 (1.00 g, 4.9 mmol) in 
CH2CI2 (30 ml) at -78 °C, under nitrogen. The temperature was increased to 0 °C over 1 h, 
then TEA (2.3 ml, 15.9 mmol) was added. Cholesteryl chloroformate (2.39 g, 5.3 mmol) in 
CH2CI2 (25 ml) was added dropwise over 30 min. The reaction mixture was allowed to warm to 
25 °C, then stirred for a further 18 h. The solvent was evaporated to dryness in vacuo  and the 
residue purified over silica gel (ChhCb-MeOH-conc. aq. NH3 100:10:1 v/v/v) to afford the title 
compound as a white wax (3.03 g, 76 %). Ri 0.38 (ChbCb-MeOH-conc. aq. NH3 100:10:1 
v/v/v). 1H NMR (CDCI3): 0.68 (3 H, s, I 8 -CH3), 0.86, 0.87 (6  H, 2 xd, J = 7, overlapping 2
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Hz, 26’-CH3 and 27'-CH3), 0.92 (3 H, d, J -  6 , 21’-CH3), 1.02 (3 H, s, 19’-CH3), 1.04-2.03 (35 H, 
m, 2-CH2) 6 -CH2, 7-CH2, 11-CH2i 1’-CH2i 2'-CH2j 4'-CH2, 7’-CH2i 8 ’-CH, 9’-CH, 11’-CH2i 12- 
CH2i 14’-CH2i 15’-CH2, 16’-CH2i 17’-CH, 20’-CH, 22’-CH2, 23’-CH2i 25’-CH), 2.25-2.38 (2 H, m, 
24’-CH2), 3.17-3.50 (8  H, m, 1-CH2, 3-CH2, 5-CH2, 8 -CH2), 4.48-4.58 (1 H, m, 3’-CH), 5.37-5.41 
(1 H, m, 6 ’-CH), 8.20-8.51 (bs, NH-CO). 13C NMR: 11.9 (18’-CH3), 18.7 (21’-CH3), 19.3 (19’- 
CH3), 21.0 (11’-CH2), 22.6 (27’-CH3), 22.8 (26’-CH3), 23.8 (23’-CH2), 24.3 (15’-CH2), 26.2,26.8,
27.1,28.0, 28.2, 28.2 (2-CH2,6-CH2,7-CH2,11-CH2,2 ’-CH2,16’-CH2, 25’-CH), 31.9 (8 ’-CH),
32.0 (7’-CH2, 8 -CH2), 35.8 (20’-CH), 36.0 (5-CH2), 36.2 (22’-CH2), 36.6 (10’-C), 36.9 (1’-CH2),
38.6 (24’-CH2), 39.5, 39.7 (4’-CH2,12’-CH2), 40.9 (3-CH2), 42.3 (13’-C), 43.5 (10-CH2), 46.7 (1- 
CH2), 49.4 (12-CH2), 50.0 (9’-CH), 56.1 (17’-CH), 56.7 (14’-CH2), 75.3 (3’-CH), 116.0,116.1 (2 
x q, 1J c f = 289, overlapping 13 Hz, CF3-CONH x 2), 122.8 (6 ’-CH), 139.5 (5’-C), 155.7-157.9 
(m, CF3-CONH x 2, NH-CO-O-CH overlapping). FAB-MS m/z 807 (MH+), C42H68N4O4F6 
requires 806; FAB-HRMS calculated 807.5223 (MH+), found 807.5227.
W-fCholesteryl-S’-oxycarbonyll-W.A/s-ditrifluoroacetyM.S-diamino^-azaoctcane 12
A solution of ethyl trifluoroacetate (525 mg, 3.7 mmol) in CH2CI2 (10 ml) was added dropwise
over 30 min to a stirred solution of 1,8-diamino-4-azaoctcane 2 (244 mg, 1.7 mmol) in CH2CI2 
(30 ml) at -78 °C, under nitrogen. The temperature was increased to 0 °C over 1 h, then TEA 
(0.7 ml, 5.1 mmol) was added. Cholesteryl chloroformate (829 mg, 1.8 mmol) in CH2CI2 (15 ml) 
was added dropwise over 30 min. The reaction mixture was allowed to warm to 25 °C, then 
stirred for a further 18 h. The solvent was evaporated to dryness in vacuo and the residue 
purified over silica gel (CH2CI2-hexane 4:1 to 100:1 v/v) to afford the title compound as a white 
powder (1.16 g, 92%). f t  0.68 (CH2CI2). 1H NMR (CDCI3): 0.68 (3 H, s, 18'-CH3), 0.86,0.87 
(6  H, 2 x d, J = 7, overlapping 2 Hz, 26’-CH3 and 27’-CH3), 0.92 (3 H, d, J = 6 , 21 ’-CH3), 1.02 (3 
H, s, 19'-CH3), 1.04-2.02 (33 H, m, 2-CH2, 6 -CH2, 7-CH2,1 ’-CH2, 2’-CH2,4 ’-CH2, 7’-CH2, 8 ’-CH,
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9-CH, 1 1 -C H 2 , 12'-CH2, 14'-CH2, 15’-CH2i 16'-CH2) 17-CH, 20’-CH, 22’-CH2i 23’-CH2) 25- 
CH), 2.23-2.37 (2 H, m, 24’-CH2), 3.19-3.44 (8  H, m, 1-CH2, 3-CH2l 5-CH2, 8 -CH2), 4.48-4.58 (1 
H, m, 3’-CH), 5.38 (1 H, m, 6 ’-CH), 6.67, 8.13 (2 H, 2 x m, NH-CO x 2). NMR: 12.0 (18’- 
CH3), 18.8 (21,-CH3), 19.4 (19’-CH3), 21.1 (11’-CH2), 22.6 (27’-CH3), 22.9 (26’-CH2), 23.9 (23’- 
CH2), 24.4 (15’-CH2), 25.8,25.8 (6 -CH2,7-CH2), 27.4, 27.5, 28.1, 28.3 (2-CH2, 2’-CH2,16’-CH2, 
25’-CH), 31.9, 32.0 (7’-CH2, 8 ’-CH), 35.8 (20’-CH), 36.2 (22’-CH2), 36.6 (10’-C), 37.0 (1’-CH2),
38.6 (24’-CH2), 39.2 (3-CH2,5-CH2), 39.4, 39.6 (4’-CH2,12’-CH2), 42.4 (13'-C), 43.8 (1-CH2, 8 - 
CH2), 50.0 (9’-CH), 56.1 (17’-CH), 56.7 (14’-CH2), 75.5 (3’-CH), 122.7 (6 ’-CH), 139.3 (5’-C),
157.0,157.4 (CF3-CONH x 2, NH-CO-O-CH overlapping). FAB-MS m/z 772 (M+Na+), 




To a stirred solution of triacylated polyamine 9 (478 mg, 0.59 mmol) in CH2CI2 (10 ml), was 
added di-ferf-butyl dicarbonate (142 mg, 0.65 mmol) and TEA (1 ml, 7.7 mmol) in CH2CI2 (2 ml) 
at 25 °C. The solution was stirred for 1 h then evaporated to dryness in vacuo and the residue 
purified over silica gel (CH2CI2-hexane 1:1 to 100:1 v/v) to afford the title compound as a white 
foam (329 mg, 64 %). f t  0.46 (CH2CI2-hexane 7:3 v/v). 1H NMR (CDCI3): 0.68 (3 H, s, 18’- 
CH3), 0.86,0.87 (6  H, 2 x d, J = 7, overlapping 2 Hz, 26’-CH3 and 27’-CH3), 0.92 (3 H, d, J = 6 , 
21’-CH3), 1.02 (3 H, s, 19’-CH3), 1.03-2.05 (44 H, m, 2-CH2, 6 -CH2, 7-CH2,11-CH2,1 ’-CH2, 2’- 
CH2, 4’-CH2i 7’-CH2i 8 ’-CH, 9’-CH, 11’-CH2i 12’-CH2i 14’-CH2i 15'-CH2i 16’-CH2,17’-CH, 20’- 
CH, 22’-CH2, 23’-CH2i 25’-CH, 0-C(CH3)3), 2.23-2.38 (2 H, m, 24’-CH2), 3.20-3.40 (8  H, m, 1- 
CH2, 3-CH2,5-CH2, 8 -CH2), 4.48-4.59 (1 H, m, 3’-CH), 5.35-5.40 (1 H, m, 6 '-CH), 8.10-8.38 (bs, 
NH-CO). 13C NMR: 12.0 (18’-CH3), 18.8 (21’-CH3), 19.4 (19’-CH3), 21.1 (11’-CH2), 22.7 (27’-
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CH3), 22.9 (26,-CH3), 23.9 (23’-CH2), 24.4 (15’-CH2), 26.2, 26.3,27.5,27.6 (2-CH2, 6 -CH2, 7- 
CH2, 11-CH2i), 28.4 (25’-CH), 28.6 (2’-CH2,16’-CH2), 28.8 (0-C(CH3)3), 31.9 (8 ’-CH), 32.0 (7’- 
CH2, 8 -CH2), 35.9 (20’-CH), 36.0 (5-CH2), 36.2 (22’-CH2), 36.6 (10’-C), 37.0 (1’-CH2), 38.7 (24’- 
CH2), 39.6, 39.8 (4’-CH2,12’-CH2), 42.4 (13’-C), 43.6,43.6 (3-CH2,10-CH2), 46.7,46.8 (1-CH2, 
12-CH2), 50.0 (9'-CH), 56.1 (17’-CH), 56.7 (14’-CH2), 75.4 (3’-CH), 80.9 (0-C(CH3)3), 122.8 (6 ’- 
CH), 139.2 (5’-C), 157.2,157.6 (CF3-CONH x 2, 0-C(CH3)3, NH-CO-O-CH overlapping).
N^./V^-ITri-fert-butyloxycarbonyO-W-P’ct-hydroxy-S’p-cholan^’-carbonyl)-!,^- 
diamino-4,9-diazadodecane 16
EDC (328 mg, 1.71 mmol) and lithocholic acid (321 mg, 0.85 mmol) were dissolved in CH2CI2 
(5 ml) and HOBt (58 mg, 0.43 mmol) was added with stirring at 25 °C under nitrogen. Tri-Boc 
protected polyamine 5 (428 mg, 0.85 mmol) was added and the solution stirred for 16 h. 
CH2CI2 (30 ml) was added and the solution was washed with water (50 ml) and saturated 
NaHC03 solution (60 ml). The organic layers were dried (MgS0 4 ), evaporated to dryness in 
vacuo and the residue purified over silica gel (CH2CI2-MeOH 30:1 to 20:1 v/v) to afford the title 
compound as a white foam (700 mg, 95%). Rf 0.24 (CH2CI2-MeOH 20:1 v/v). 1H NMR 
(CDCh): 0.61 (3 H, s, 18’-CH3), 0.89-2.29 (69 H, m, 2-CH2, 6 -CH2,7-CH2,11-CH2,1 ’-CH2, 2’- 
CH2, 4’-CH2i 5’-CH, 6 ’-CH2,7 ’-CH2, 8 ’-CH, 9’-CH, 11'-CH2,12'-CH2,14’-CH, 15’-CH2,16’-CH2, 
17-CH, 19’-CH3,20’-CH, 21’-CH3i 22’-CH2i 23’-CH2i 0-C(CH3)3x 3), 3.02-3.34 (12 H, m, 1-
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CH2, 3-CH2,5-CH2, 8 -CH2i 10-CH2i 12-CH2), 3.55-3.64 (1 H, m, 3’-CH), 5.27-5.36 (1 H, m, NH- 
CO-O), 6.71-6.86 (1 H, bs, 1-CH2-NH-C0). 13C NMR: 12.5 (18’-CH3), 18.8 (21’-CH3), 21.2 ( IT ­
CH;?), 23.8 (19’-CH3), 24.6 (15'-CH2), 25.5,26.2 (6 -CH2,7-CH2), 26.8 (7’-CH2), 27.6 (6 ’-CH2), 
27.6, 27.6 (2-CH2, 11-CH2), 28.6 (16’-CH2), 28.8 (0-C(CH3)3 x 3), 30.9 (2’-CH2), 32.2 (22’-CH2),
34.9 (10’-C, 23’-CH2, overlapping), 35.8 (1’-CH2), 35.9 (20-CH), 36.2 (8 ’-CH), 36.8 (4’-CH2)
37.4, 37.4 (1-CH2,12-CH2), 40.6 (12’-CH2), 40.8 (9’-CH), 42.5 (5’-CH), 43.1 (13’-C), 44.4,44.8,
46.4.46.6.46.9 (3-CH2, 5-CH2, 8 -CH2,10-CH2), 56.4 (17’-CH), 56.8 (14'-CH), 72.1 (3’-CH),
80.0 (0-C(CH3)3 x 3), 156.2 156.4 (O-CO-NH x 3), 174.0 (NH-CO). FAB-MS m/z 862 (MH+), 
C49H88N4O8 requires 862; FAB-HRMS calculated 861.6680 (MH+), found 861.6667.
f/1-(3’a-Trifluoroacetoxy-5’p-cholan-24’-carbonyl)-1,12-diamino-4,9-diazadodecane 
tritrifluoroacetate salt 18 (Attempted synthesis of A/1-(3a-Hydroxy-5p-cholan-24-carbonyl)-
1,12-diamino-4,9-diazadodecane trifluoroacetate salt 17)
Tri-Boc protected polyamine 16 (500 mg, 0.58 mmol) in anhydrous CH2CI2 (18 ml) and TFA (2 
ml) was stirred at 0 °C for 4 h, then the solvent was evaporated in vacuo. The residue was 
washed with diethyl ether (3x10 ml) then recrystallised from EtOAc to afford the title 
compound as a white solid (266 mg, 70 %). 1H NMR (d6-DMSO): 0.60 (3 H, s, 18’-CH3), 0.86 
(3 H, d, J = 6 , 21’-CH3), 0.90 (3 H, s, 19’-CH3), 0.92-2.12 (35 H, m, 2-CH2, 6 -CH2,7-CH2, 11- 
CH2,1'-CH2, 2’-CH2i 4’-CH2,5 ’-CH, 6 ’-CH2i 7’-CH2i 8 ’-CH, 9’-CH, 11’-CH2, 12’-CH2i 14-CH, 
15’-CH2i 16’-CH2i 17'-CH, 20’-CH, 22'-CH2i 23’-CH2), 2.80-3.02 (10 H, m, 3-CH2, 5-CH2, 8 -CH2, 
10-CH2,12-CH2), 3.08 (2 H, q, J = 6 , 1-CH2), 4.87-4.98 (1 H, m, 3’-CH), 7.29 (1:1:1, t, U h h -  
52, NH), 8.04,8.77, 8.94 (7 H, 3 x bs, ammonium NH). NMR: 12.1 (18’-CH3), 18.5 (21’- 
CH3), 20.7 (11’-CH2), 22.9, 23.0 (6 -CH2,7-CH2), 23.1 (19’-CH3), 24.6 (2-CH2,15’-CH2), 26.1,
26.3 (11-CH2,7 ’-CH2), 26.7 (6 ’-CH2), 28.0 (16’-CH2), 31.4 (2’-CH2), 31.8 (22’-CH2), 32.6 (23’- 
CH2), 34.3 (10’-C), 35.3 (1’-CH2,20’-CH), 35.5 (8 '-CH), 35.8 (1-CH2) 36.4 (4’-CH2,12-CH2),
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39.7 (12'-CH2), 40.1 (9'-CH), 41.3 (5’-CH), 42.5 (13'-C), 44.1,44.9,46.3 (3-CH2,5-CH2, 8 -CH2,
10-CH2 overlapping), 55.8 (17’-CH), 56.0 (14-CH), 79.5 (3-CH), 113.5-119.0 (m, CF3CO-O- 
CH, CF3CO-O x 3, overlapping), 156.0-159.9 (m, CF3CO-O-CH, CF3CO-O x 3, overlapping),
173.0 (NH-CO). FAB-MS m/z 657 (MH+), C36H63N4O3F3 requires 656; FAB-HRMS calculated 
657.4931 (MH+), found 657.4961.
6-Benzyloxycarbonylaminohexanyl-1-oxycarbonylpropylamine 28
To a stirred solution of 6-benzyloxycarbonylaminohexan-1-ol 41 (1.05 g, 4.18 mmol) and 1,1- 
carbonyldiimidazole (1.02 g, 6.27 mmol) in CH2CI2 (20 ml) was added TEA (1 ml). The solution 
was heated to reflux for 2 h, then cooled to 25 °C. 1-Propylamine (493 mg, 8.36 mmol), was 
added and the solution stirred for 2 h, then evaporated to dryness in vacuo. The residue was 
purified over silica gel (CH2CI2-MeOH-conc. aq. NH3 300:10:1 v/v/v) to afford the title 
compound as a white solid (900 mg, 64 %). Rf 0.45 (CH2CI2-MeOH-conc. aq. NH3 200:10:1 
v/v/v). IR 1684 cm-1 (N-CO). 1H NMR (CDCb): 0.93 (3 H, t, J = 7, CH2-CH3), 1.28-1.40 (4 H, 
m, 3-CH2,4-CH2), 1.42-1.54 (6  H, m, 2-CH2, 5-CH2, CH2-CH3), 3.12, 3.18 (4 H, 2 x q, J = 7, 
overlapping 23 Hz, 6 -CH2, N-CH2-CH2-CH3), 4.03 (2 H, t, J = 7 ,1-CH2), 4.87-4.94 (1 H, bs, 6 - 
CH2-NH-CO-0), 4.76-4.83 (1 H, bs, CH3-CH2-CH2-NH-C0-0), 5.09 (2 H, s, 0-CH2-Ph), 7.28- 
7.38 (5 H, m, Ph). 13C NMR: 11.3 (3’-CH3), 23.2 (CH2-CH3), 25.5 (3-CH2), 26.3 (4-CH2),28.9 
(2-CH2), 29.8 (5-CH2), 40.9 (6 -CH2), 42.7 (CH3-CH2-CH2), 64.5 (1-CH2), 66.5 (0-CH2-Ph), 
127.9,128.3 (Ph), 136.4 (C Ph), 156.2,156.5 (6-CH2-NH-C0-0, CH3-CH2-CH2-NH-C0-0). 













Phosgene (20 % solution in toluene, 10 ml, 20.4 mmol) was added dropwise to a stirred 
solution of ergosterol (1.37 g, 3.60 mmol) in THF (10 ml) at 25 °C. This solution was stirred for 
2  h then evaporated to dryness in vacuo. The residue was redissolved in anhydrous CH2CI2 (5 
ml) and added dropwise to a stirred solution of tri-Boc protected polyamine 5 (1.65 g, 3.29 
mmol) and TEA (1 ml 7.7 mmol) in anhydrous CH2CI2 (10 ml) and then stirred for 16 h. The 
solution was evaporated to dryness in vacuo and the residue purified over silica gel (EtOAc- 
hexane 3:7 to 7:3 v/v) to afford the title compound as a yellow foam (1.93 g, 60 %). Rf 0.62 
(EtOAc-hexane 7:3 v/v). IR 1694 cm-i (N-CO-O). 1H NMR (CDCI3): 0.63 (3 H, s, 18’-CH3), 
0.82,0.84 (6  H, 2 x d, J = 7 ,26’-CH3,27’-CH3), 0.92 (3 H, d, J = 7, 28’-CH3), 0.94 (3 H, s, 19’- 
CH3), 1.04 (3 H, d, J = 7, 21'-CH3), 1.20-2.57 (55 H, m, 2-CH2, 6 -CH2, 7-CH2, H-CH2,1 ’-CH2, 
2’-CH2, 4’-CH2i 9’-CH, 11’-CH2,12’-CH2,14’-CH, 15’-CH2i 16’-CH2i 17’-CH, 20’-CH, 24'-CH, 
25’-CH, 0-C(CH3)3 x 3), 3.02-3.34 (1 2  H, m, 1-CH2,3-CH2,5-CH2, 8 -CH2, IO-CH2,12-CH2), 
4.52-4.64 (1 H, m, 3’-CH), 5.13-5.26 (2 H, m, 22’-CH, 23’-CH), 5.34-5.40 (1 H, m, 7’-CH), 5.53- 
5.58 (1 H, m, 6 -CH). NMR: 12.5 (18’-CH3), 16.6 (19’-CH3), 18.0 (28’-CH3), 20.0,20.4 (26’- 
CH3, 27’-CH3), 21.4 ( ir-C H 2), 21.5 (21'-CH3), 23.4 (15’-CH2), 25.8, 26.4 (6 -CH2, 7-CH2), 28.7,
28.8, 28.9 (2-CH2, 11-CH2, 2’-CH2, 16’-CH2i 0-C(CH3)3 x 3), 33.4 (25’-CH), 37.4 (10’-C), 37.5 
(4’-CH2), 37.7 (I-CH2, 1 2 -CH2, overlapping), 38.3 (1'-CH2), 39.4 (12’-CH2), 40.8 (2 0 ’-CH), 43.1
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(13’-C, 24’-CH overlapping), 44.1,44.5 (3-CH2) 10-CH2), 46.4 (9’-CH), 46.6 (5-CH2, 8 -CH2, 
overlapping), 54.8 (14’-CH), 56.0 (17’-CH), 73.1 (3’-CH), 79.6 (0-C(CH3) 3 x 3), 116.5 (7’-CH),
119.6 (6 ’-CH), 132.0 (23’-CH), 135.7 (22’-CH), 140.0 (8 ’-C), 141.5 (5-C), 156.2 (N-CO-O). 






Phosgene (20 % solution in toluene, 5 ml, 10.2 mmol) was added dropwise to a stirred solution 
of ergosterol (800 mg, 2.02 mmol) in THF (10 ml) at 25 °C. This solution was stirred for 2 h 
then evaporated to dryness in vacuo. The residue was redissolved in anhydrous CH2CI2 (5 ml) 
and added dropwise to a stirred solution of A/,A/-dimethylamino-3-propylamine (413 mg, 4.04 
mmol) in anhydrous CH2CI2 (10 ml) and then stirred for 1 h. The solution was evaporated to 
dryness in vacuo and the residue purified over silica gel (CH2CI2-MeOH-conc. aq. NH3 75:10:1 
v/v/v) to afford the title compound as a buff solid (889 mg, 84 %). Rf 0.24 (CH2CI2-MeOH-conc. 
aq. NH3 100:10:1 v/v/v). NMR (CDCI3): 0.63 (3 H, s, 18’-CH3), 0.82,0.84 (6  H, 2 x d, J = 7, 
26’-CH3,27’-CH3), 0.92 (3 H, d, J = 7 ,28’-CH3), 0.94 (3 H, s, 19’-CH3), 1.04 (3 H, d, J = 7,21’- 
CH3), 1.21-2.56 (30 H, m, 1’-CH2, 2’-CH2,4 ’-CH2,9 ’-CH, 11’-CH2,12’-CH2,14’-CH, 15’-CH2, 
16’-CH2,17-CH, 20’-CH, 24’-CH, 25’-CH, (CH3)2N, 2-CH2i 3-CH2), 3.22-3.26 (2 H, m, 1-CH2), 
4.56-4.61 (1 H, m, 3’-CH), 5.14-5.25 (2 H, m, 22’-CH, 23’-CH), 5.37-5.38 (1 H, m, 7’-CH), 5.53-
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5.57 (2 H, m, 6 ’-CH, NH). 13C NMR: 12.1 (18’-CH3), 16.3 (19’-CH3), 17.7 (28’-CH3), 19.7 (27- 
CH3), 20.0 (26’-CH3), 21.1 (11’-CH2), 21.2 (21’-CH3), 23.1 (15’-CH2), 27.1 (2-CH2), 28.3 (16’- 
CH2), 28.6 (2’-CH2), 33.1 (25'-CH), 37.1 (10’-C), 37.2 (4’-CH2), 38.0 (1’-CH2), 39.1 (12’-CH2),
39.8 (1-CH2), 40.4 (20’-CH), 42.8 (13’-C, 24’-CH overlapping), 45.2 ((CH3)2N), 46.1 (9’-CH),
54.5 (14’-CH), 55.7 (17’-CH), 57.6 (3-CH2), 72.8 (3’-CH), 116.2 (7’-CH), 119.8 (6 ’-CH), 131.8 
(23’-CH), 135.4 (22’-CH), 138.7 (8 ’-C), 141.1 (5'-C), 156.0 (N-CO-O). FAB-MS m/z 525 (MH+), 
C34H56N20 2 requires 524; FAB-HRMS calculated 525.4420 (MH+), found 525.4421.
HO
W ^ -D i-P ’a-hydroxy-S’p-cholan^’-carbonyO-W^-fdi-te/f-butyloxycarbonyl)-!,^- 
diamino-4,9-diazadodecane 35
EDC (76 mg, 0.54 mmol) and lithocholic acid (142 mg, 0.38 mmol) were dissolved in anhydrous 
CH2CI2 (8  ml) and HOBt (10 mg, 74 |imol) was added with stirring at 25 °C under nitrogen. Di- 
Boc protected polyamine 34 (72 mg, 0.18 mmol) was added and the solution stirred for 16 h. 
CH2CI2 (30 ml) was added and the solution was washed with water (50 ml) and saturated 
NaHC03 solution (60 ml). The organic layers were dried (MgSC>4), evaporated to dryness in 
vacuo and the residue purified over silica gel (CH2CI2-MeOH 30:1 v/v) to afford the title 
compound as a white foam (134 mg, 67 %). Rf 0.21 (CH2CI2-MeOH 30:1 v/v). 1H NMR 
(CDCI3): 0.64 (6  H, s, 18’-CH3 x 2), 0.91 (6  H, s, 19’-CH3 x 2), 0.92 (6  H, d, J = 6 , 21'-CH3 x 2),
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0.94-2.40 (84 H, m, 2-CH2, 6 -CH2i 7-CH2, 11-CH2, 1’-CH2 x 2 ,2’-CH2 x 2 ,4’-CH2 x 2, 5-CH x 2, 
6 ’-CH2 x 2 ,7’-CH2 x 2 ,8 -CH x 2 ,9-CH x 2,11 ’-CH2 x 2 ,12'-CH2 x 2,14-CH x 2,15’-CH2 x 2, 
16’-CH2x 2 ,17’-CH x 2 ,20-CH x 2 ,22’-CH2 x 2, 23’-CH2x 2, 0-C(CH3)3 x 2), 3.10-3.30 (12 H, 
m, 1-CH2l 3-CH2i 5-CH2i 10-CH2( 9-CH2i 12-CH2), 3.58-3.66 (2 H, m, 3’-CH x 2), 6.83-6.93 (2 
H, m, CH2-NH-CO x 2). «C NMR: 12.1 (18’-CH3 x 2), 18.4 (21’-CH3 x 2), 20.9 (11’-CH2 x 2),
23.4 (19’-CH3 x 2), 24.2 (15’-CH2 x 2), 25.5,26.2 (6 -CH2i 7-CH2), 26.5 (7’-CH2 x 2), 27.2 (6 ’- 
CH2 x 2), 27.6, 27.6 (2-CH2, 11-CH2), 28.2 (16’-CH2 x 2), 28.4 (0-C(CH3)3 x 2), 30.5 (2’-CH2 x 
2), 31.9 (22’-CH2 x 2), 33.7 (23’-CH2x 2), 34.6 (10-C x 2), 35.4 (1’-CH2 x 2), 35.5 (20’-CH x 2),
35.9 (8 -CH x 2), 36.4 (4’-CH2 x 2), 37.4, 37.4 (1-CH2,12-CH2), 40.2 (12’-CH2 x 2), 40.4 (9’-CH 
x 2), 42.1 (5’-CH x 2), 42.7 (13’-C x 2), 44.8,44.8,46.5,46.6,46.8 (3-CH2, 5-CH2, 8 -CH2, 10- 
CH2), 56.0 (17’-CH x 2), 56.5 (14-CH x 2), 71.6 (3’-CH x 2), 79.7 (0-C(CH3)3 x 2), 156.0 156.0 
(O-CO-NH x 2), 173.6 (NH-CO x 2). FAB-MS m/z 1120 (MH+), CeaHnsN^s requires 1118; 









Amide 35 (105 mg, 0.09 mmol) in anhydrous CH2CI2 (9 ml) and TFA (1 ml) was stirred at 25 °C 
for 2  h, then the solvent was evaporated in vacuo and the residue was recrystallised once from 
ethyl acetate to afford a crude white solid. To a refluxing solution of this solid in THF (20 ml)
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was added Borane-DMS complex (10 M solution in DMS, 1 ml, 10 mmol) dropwise over 5 min 
to a stirred. The solution was stirred at reflux for 12 h (a white precipitate formed), then dilute 
aq. HCI (5 M, 10 ml) was added slowly (precipitate dissolved). The solution was stirred at 
reflux for a further 2 h then evaporated to dryness in vacuo. The residue was recrystallised 
from ethyl acetate to afford the title compound as a white solid (26 mg, 31 %). 1H NMR (d6- 
DMSO): 0.63 (6  H, s, 18'-CH3 x 2), 0.87-0.91 (12 H, m, 19’-CH3 x 2, 21’-CH3 x 2), 0.93-2.35 
(64 H, m, 2-CH2, 6 -CH2, 7 -CH2, 11-CH2,1 ’-CH2 x 2 , 2’-CH2 x 2 , 4’-CH2 x 2 , 5’-CH x 2 , 6 ’-CH2 x 
2 , 7’-CH2 x 2, 8 ’-CH x 2 9’-CH x 2 ,1 1  ’-CH2 x 2 , 12’-CH2 x 2,14’-CH x 2 ,15’-CH2 x 2,16’-CH2 x 
2 ,17’-CH x 2 ,20’-CH x 2 ,22’-CH2 x 2 ,23’-CH2 x 2), 2.82-3.36 (16 H, m, 1-CH2, 3-CH2, 5-CH2, 
8 -CH2, IO-CH2,12-CH2,24-CH2x2), 3.32-3.42 (2  H, m, 3-CH x 2 ), 9.02-9.30 (2 x bs, 
ammonium NH). FAB-MS m/z 892 (MH+), C58H106N4O2 requires 891; FAB-HRMS calculated 
891.8382 (MH+), found 891.8394.
3-Benzyloxycarbonylaminopropan-1 -ol 40
To a stirred solution of 3-aminopropan-1-ol 38 (2.0 g, 27.4 mmol) in CH2CI2 (200 ml) and TEA 
(3.8 ml, 27.4 mmol) at 25 °C, benzyl chloroformate (5.1 g, 30.1 mmol) was added dropwise 
over 5 min. The solution was stirred for 4 h, then evaporated to dryness in vacuo and the 
residue was purified over silica gel (EtOAc-hexane 6:4 v/v) to afford the title compound as a 
white solid (5.27 g, 92 %). Rf 0.41 (EtOAc-hexane 8:2 v/v). mp: 50-51 °C. IR 3326 cm-1 (OH), 
1682 cm*1 (N-CO-O). 1H NMR (CDCI3): 1.68 (2 H, quin, J = 6 , 2-CH2), 3.10 (1 H, bs, CH2-OH), 
3.31 (2 H, q, J = 6 , 3-CH2), 3.64 (2 H, t, J = 6 , 1-CH2), 5.08 (2 H, s, 0-CH2-Ph), 5.27 (1 H, bs, 
CH2-NH-CO-O), 7.27-7.37 (5 H, m, Ph). 13C NMR: 32.9 (2-CH2), 38.2 (3-CH2), 59.9 (1-CH2),
67.2 (0-CH2-Ph), 128.3,128.4,128.7 (Ph), 136.6 (Cq Ph), 157.5 (N-CO-O). FAB-MS m/z 210 
(MH+), C iiH i5N0 3 requires 209; FAB-HRMS calculated 210.1130 (MH+), found 210.1136.
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6-Benzyloxycarbony laminohexan-1 -ol 41
To a stirred solution of 6-aminohexan-1-ol 39 (3.0 g, 26 mmol) in CH2CI2 (250 ml) and TEA (3.6 
g, 26 mmol) at 25 °C, benzyl chloroformate (4.85 g, 29 mmol) was added dropwise over 5 min. 
The solution was stirred for 18 h, then evaporated to dryness in vacuo and the residue was 
purified over silica gel (EtOAc-hexane 9:1 v/v) to afford the title compound as a white solid 
(6.31 g, 97 %). Rf 0.50 (EtOAc-hexane 8:2 v/v). mp: 78-80 °C. 1H NMR (CDCIs): 1.33-1.34 (4 
H, m, 3-CH2j 4-CH2), 1.48-1.56 (4 H, m, 2-CH2) 5-CH2), 1.95 (1 H, s, CH2-OH), 3.18 (2 H, q, J = 
7, 6 -CH2), 3.60 (2 H, t. J = 7 ,1-CH2), 4.91 (1 H, bs, CH2-NH-CO-O), 5.08 (2 H, s, 0-CH2-Ph),
7.30-7.35 (5 H, m, Ph). «C NMR: 25.2 (3-CH2), 26.3 (4-CH2), 29.8 (5-CH2), 32.4 (2-CH2), 40.8 
(6 -CH2), 62.5 (I-CH2), 66.5 (0-CH2-Ph), 128.0,128.4 (Ph), 136.5 (C Ph), 156.4 (N-CO-O). 
FAB-MS m/z 252, (MH+), C14H21NO3 requires 251; FAB-HRMS calculated found 252.1560 
(MH+), found 252.1604.
3-Benzyloxycarbonylaminopropanal 42
Oxalyl chloride (0.85 ml, 9.7 mmol) was dissolved in anhydrous CH2CI2 (35 ml) and stirred at - 
78 °C under nitrogen. Anhydrous DMSO (1.25 ml, 17.6 mmol) was added dropwise over 5 min 
and the mixture stirred for a further 10 min. Alcohol 40 (1.84 g, 8 .8  mmol) in anhydrous CH2CI2 
(40 ml) was added dropwise over 5 min. This gave a cloudy suspension which was allowed to 
warm to -20 °C until clear, then stirred at -78 °C for a further 10 min. TEA (6.1 ml, 44 mmol) 
was added and the solution warmed to 25 °C. Water (100 ml) was added and the organic 
layer was collected. The aqueous layer was extracted with CH2CI2 (2  x 60 ml) and the 
combined organic extracts were dried (MgS0 4 ) and then evaporated to dryness in vacuo and 
the residue purified over silica gel (EtOAc-hexane 3:1 v/v) to afford the title compound as a 
yellow oil (1.17 g, 64%). Rf 0.51 (EtOAc-hexane 8:2 v/v). IR (thin film) 1713 cm-1 (CHO), 1684
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cm-1 (N-CO-O). 1H NMR (CDCb): 2.71 (2 H, t, J = 7 ,2-CH2), 3.40-3.51 (2 H, m, 3-CH2), 5.08 
(2 H, s, 0-CH2-Ph), 5.27 (1 H, bs, CH2-NH-C0-0), 7.27-7.37 (5 H, m, Ph), 9.78 (1 H, s, CHO). 
13C NMR: 34.9 (2-CH2), 44.2 (3-CH2), 67.1 (0-CH2-Ph), 128.3,128.4,128.7 (Ph), 136.6 (C Ph),
156.4 (N-CO-O), 201.3 (CHO). FAB-MS m/z 208 (MH+), C11H13NO3 requires M+ = 207.
6-Benzyloxycarbonylaminohexanal 43
Oxalyl chloride (0.55 ml, 6.3 mmol) was dissolved in anhydrous CH2CI2 (25 ml) and stirred at - 
78 °C under nitrogen. Anhydrous DMSO (0.8 ml, 11 mmol) was added dropwise over 4 min 
and the mixture stirred for a further 10 min. Alcohol 41 (1.43 g, 5.7 mmol) in anhydrous CH2CI2 
(30 ml) was added dropwise over 5 min. This gave a cloudy suspension which was allowed to 
warm to -20 °C until clear, then stirred at -78 °C for a further 10 min. TEA (4 ml, 28 mmol) was 
added and the solution warmed to 25 °C. Water (100 ml) was added and the organic layer 
was collected. The aqueous layer was extracted with CH2CI2 (2 x 50 ml) and the combined 
organic extracts were dried (MgS0 4 > and then evaporated to dryness in vacuo and the residue 
purified over silica gel (EtOAc-hexane 3:7 v/v) to afford the title compound as a yellow oil 
(0.99g, 70 %). Rf 0.59 (EtOAc-hexane 8:2 v/v). IR (thin film) 1711 cm-1 (CHO), 1681 cm*1 (N- 
CO-O). 1H NMR (CDCb): 1.31 (2 H, m, 4-CH2), 1.50 (2 H, quin, J = 7, 5-CH2), 1.61 (2 H, quin,
J = 7 ,3-CH2), 2.40 (2 H, t, J = 7 ,2-CH2), 3.16 (2 H, q, J = 7 ,6 -CH2), 5.07-5.16 (3 H, m, 0-CH2- 
Ph, CH2-NH-CO-0), 7.28-7.34 (5 H, m, Ph), 9.72 (1 H, s, CHO). 13C NMR: 21.6 (3-CH2), 26.2 
(4-CH2), 29.7 (5-CH2), 40.7 (2-CH2), 43.6 (6 -CH2), 66.5 (0-CH2-Ph), 128.0,128.4 (Ph), 136.6 
(Cq Ph), 156.5 (N-CO-O), 202.6 (CHO). FAB-MS m/z 250 (MH+), C14H19NO3 requires 249; 
FAB-HRMS calculated 250.1443 (MH+), found 250.1443.
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yV1,/V4,A^9,A/13-(Tetra-ferf-butyloxycarbonyl)-1,16-diamino-4,9,13-triazahexadecane 46
Tri-Boc protected polyamine 5 (700 mg, 1.4 mmol) and aldehyde 42 (288 mg, 1.4 mmol) in 
anhydrous MeOH (25 ml) was stirred at 25 °C, under nitrogen, over 4 A molecular sieves for 5 
min. Glacial acetic acid (catalytic amount, 4 drops to pH 5) followed by sodium 
cyanoborohydride (151 mg, 2.4 mmol) were then added and the reaction mixture stirred for 24 
h. The reaction mixture was filtered and then evaporated to dryness in vacuo. The residue was 
purified over silica gel (CH2Cl2-MeOH-conc. aq. NH3 100:10:1 v/v/v) to give a colourless oil 
(312 mg, 32 %). Rf 0.32 (CH2Cl2-MeOH-conc. aq. NH3 100:10:1 v/v/v). This oil was dissolved 
in CH2CI2 (15 ml) then TEA (1 ml, 7.7 mmol) and di-ferf-butyl dicarbonate (144 mg, 0.66 mmol) 
were added and the solution stirred at 25 °C for 3 h. After this time, the solution was 
evaporated to dryness in vacuo and the residue redissolved in MeOH (15 ml) and Pearlman’s 
catalyst (1 g, Pd(OH)2, 20 % on carbon) was added. The reaction vessel was flushed with 
hydrogen (x 3) and stirred under an atmosphere of hydrogen for 18 h. The reaction mixture 
was then filtered and the filtrate concentrated in vacuo. The residue was purified over silica gel 
(CH2Cl2-MeOH-conc. aq. NH3 100:10:1 v/v/v) to afford the title compound as a yellow oil (304 
mg, 30%). Rf 0.26 (CH2CI2-MeOH-conc. aq. NH3 100:10:1 v/v/v). 1H NMR (C D C I3 ): 1.42-1.52 
(40 H, m, 6 -CH2, 7 -CH2, 0-C(CH3)3 x4), 1.60-1.80 (4 H, m, 2-CH2, H-CH2), 2.32-2.48 (2 H, bs, 
NH2), 2.72 (2  H, t, J = 6 , 1 6 -CH2), 3.05-3.35 (14 H, m, 1-CH2, 3-CH2, 5-CH2, 8 -CH2, IO-CH2, 
12-CH2,14-CH2), 5.30-5.40 (1 H, bs, I-CH2-NH-CO-O). 13C NMR: 25.6, 25.7, 25.7, 25.8, 25.9,
26.0 (6 -CH2, 7 -CH2, 11-CH2), 28.5, 28.5 (2-CH2, 0-C(CH3)3 x 4, overlapping), 32.0 (15-CH2), 
37.5, 37.6 (I-CH2), 38.6, 39.1 ( I6 -CH2), 43.9,44.2,44.6,44.8 (3-CH2,10-CH2,12-CH2, 14-
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CH2, overlapping), 46.8,46.8 (5 -CH2, 8 -CH2 overlapping), 79.7, 79.8 (0 -C(CH3)3 x 4), 155.2,
158.1 (N-CO-O x 4, overlapping). FAB-MS m/z 660 (MH-), C33H65N5O8 requires 659; FAB- 
HRMS calculated 660.4911 (MH+), found 660.4908.
fV^N^^/V^-ITetra-fe/t-butyloxycarbonylJ-I.IQ-diamino^&IS-triazanonadecane 47
Tri-Boc protected polyamine 5 (817 mg, 1.6 mmol) and aldehyde 43 (405 mg, 1.6 mmol) in 
anhydrous MeOH (25 ml) was stirred at 25 °C, under nitrogen, over 4 A molecular sieves for 5 
min. Glacial acetic acid (catalytic amount, 4 drops to pH 5) followed by sodium 
cyanoborohydride (153 mg, 2.4 mmol) were then added and the reaction mixture stirred for 24 
h. The reaction mixture was filtered and then evaporated to dryness in vacuo. The residue 
was purified over silica gel (CH2Cl2-MeOH-conc. aq. NH3 100:10:1 v/v/v) to give a colourless oil 
(494 mg, 41 %). Rf 0.35 (CH2Cl2-MeOH-conc. aq. NH3 100:10:1 v/v/v). This oil was dissolved 
in CH2CI2 (15 ml) then TEA (1 ml, 7.7 mmol) and di-ferf-butyl dicarbonate (218 mg, 1.0 mmol) 
were added and the solution stirred at 25 °C for 18 h. After this time, the solution was 
evaporated to dryness in vacuo and the residue (crude 45) redissolved in MeOH and conc. aq. 
ammonia (10 ml) was added and stirred for 1 h. The solvent was evaporated in vacuo and the 
residue redissolved in MeOH (15 ml) and Pearlman’s catalyst (1 g, Pd(OH)2, 20 % on carbon) 
was added. The reaction vessel was flushed with hydrogen (x 3) and stirred under an 
atmosphere of hydrogen for 18 h. The reaction mixture was then filtered and the filtrate 
concentrated in vacuo. The residue was purified over silica gel (CH2Cl2-MeOH-conc. aq. NH3 
100:10:1 v/v/v) to afford the title compound as a yellow oil (384 mg, 34 % overall). R f 0.28 
(CH2CI2-MeOH-conc. aq. NH3 100:10:1 v/v/v). 1H NMR (CDCb): 1.22-1.34 (4 H, m, I 6 -CH2, 
17-CH2), 1.41-1.52 (44 H, m, 6 -CH2, 7-CH2l 15-CH2, 18-CH2i 0 -C(CH3) 3 x 4), 1.56-1.80 (4 H, 
m, 2 -CH2, H-CH2), 2.35-2.49 (2  H, bs, NH2), 2.65 (2 H, t, J = 6 , 1 6 -CH2), 3.07-3.30 (14 H, m, 
I-CH2, 3 -CH2, 5-CH2) 8 -CH2, IO-CH2,12-CH2,14-CH2), 5.33-5.43 (1 H, bs, NH-CO-O). «c
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NMR: 25.5, 25.8 26.7,26.9 (6 -CH2,7-CH2, H-CH2,15-CH2,16-CH2,17-CH2l overlapping),
27.9, 28.0, 28.3,28.9 (2-CH2, 0 -C(CH3)3 x 4, overlapping), 32.9 ( I 8 -CH2), 37.6 (1-CH2), 41.5,
41.7 (19-CH2), 44.2,44.5,44.6 46.7,46.8,47.2 (3-CH2 ,5-CH2, 8 -CH2,10-CH2,12-CH2, 14- 
CH2), 79.8 (0-C-(CH3)3 x 4), 156.6,156.8 (N-CO-O x 4, overlapping). FAB-MS m/z 702 (MH+), 
CseHziNsOs requires 701; FAB-HRMS calculated 702.5381 (MH+), found 702.5390.
For characterisation, an analytical sample (100 mg) of 45 was purified over silica gel (EtOAc- 
hexane 6:4 v/v) to afford a yellow oil. Rf 0.84 (EtOAc v/v). 1H NMR (CDCI3): 1.23-1.34 (4 H, 
m, 3 -CH2, 4 -CH2), 1.39-1.54 (42 H, m, 2-CH2,5-CH2,13-CH2,14-CH2,0-C(CH3)3 x 4), 1.79- 
1.82 (4 H, m, 9 -CH2, 1 8 -CH2), 3.00-3.27 (16 H, m, 1-CH2, 6 -CH2, 8 -CH2, IO-CH2,12-CH2, 15- 
CH2,17-CH2,19-CH2), 5.04-5.10 (2 H, m, 0-CH2-Ph), 5.08-5.14 (1 H, s, 19-CH2-NH-C0-0),
5.30-5.38 (1 H, bs, I-CH2-NH-CO-O), 7.22-7.40 (5 H, m, Ph). NMR (CDCb): 26.4,27.2,
27.4, 27.6 (2-CH2, 3 -CH2,4-CH2, 5 -CH2,13-CH2,14-CH2,0-C-(CH3)3 x4, overlapping), 28.1, 
28.2, 28.5, 29.9 (13-CH2, 1 8 -CH2), 41.2,41.3,41.4,41.5,41.7 (1-CH2, 6 -CH2l 8 -CH2, IO-CH2, 
12-CH2,15-CH2,17-CH2,19-CH2), 66.5 (0-CH2-Ph), 79.7 (0 -C-(CH3)3 x 4), 128.1,128.5 (Ph),
136.7 (C Ph), 155.5,156.4 (N -C O -O  x 5, overlapping). FAB-MS m/z 836 (MH+), C44H77N5O10 
requires 835; FAB-HRMS calculated 836.5749 (MH+), found 836.5747.
^-(Cholesteryl-S’-oxycarbonylJ-^^^^^^ftetra-ferf-butyloxycarbonyl)-!,16-diamino- 
4,8,13-triazahexadecane 48
Cholesteryl chloroformate (323 mg, 0.72 mmol) in CH2CI2 (5 ml) was added over 5 min to a 
stirred solution of tetra-Boc protected polyamine 46 (431 mg, 0.65 mmol) in CH2CI2 (5 ml) with 
TEA (1 ml, 7.7 mmol) at 25 °C, under nitrogen. The solution was stirred for 18 h then 
evaporated to dryness in vacuo and the residue purified over silica gel (EtOAc-hexane 4:6 to 
5:5 v/v) to afford the title compound as a white solid (431 mg, 61 %). R f 0.70 (EtOAc-hexane 
7:3 v/v). 1H NMR (CDCb): 0.66 (3 H, s, 18’-CH3), 0.84,0.85 (6  H, 2 x d, J = 7, overlapping 2
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Hz, 26’-CH3 and 27’-CH3), 0.90 (3 H, d, J = 7, 21’-CH3), 0.99 (3 H, s, 19’-CH3), 1.02-2.03 (72 H, 
m, 2-CH2, 6 -CH2, IO-CH2, H-CH2,15-CH2, 1’-CH2, 2’-CH2,4 ’-CH2,7 ’-CH2, 8 ’-CH, 9’-CH, 11’- 
CH2> 12’-CH2i 14’-CH, 15’-CH2) 16’-CH2i 17’-CH, 20’-CH, 22’-CH2, 23’-CH2, 25’-CH, 0-C(CH3)3 
x 4), 2.22-2.37 (2  H, m, 24’-CH2), 3.00-3.34 (12 H, m, 1-CH2i 3-CH2,5-CH2) 7-CH2, 9-CH2i 12- 
CH2, 1 4 -CH2, 1 6 -CH2), 4.41-4.52 (1 H, m, 3’-CH), 5.35 (1 H, d, J = 4, 6 '-CH), 5.47-5.60 (2 H, m, 
CH2-NH-CO x 2). 13C NMR: 12.0 (18’-CH3), 18.8 (21’-CH3), 19.4 (19’-CH3), 21.1 (11,-CH2),
22.6 (27’-CH3), 22.9 (26’-CH2), 23.9 (23’-CH2), 24.4 (15’-CH2), 25.4, 25.6, 25,9 (6 -CH2, 10-CH2i 
H-CH2), 28.1, 28.2, 28.3, 28.5, 28.5 (2-CH2i 15-CH2) 2’-CH2,16’-CH2, 25’-CH, 0-C(CH3)3 x4, 
overlapping), 32.0 (7’-CH2, 8 ’-CH, overlapping), 35.7 (20’-CH), 36.2 (22’-CH2); 36.6 (10’-C),
37.1 (1’-CH2), 37.3 (1-CH2,16-CH2), 38.6 (24’-CH2), 39.6, 39.8 (4’-CH2,12’-CH2), 42.4 (13’-C),
44.8,46.6,46.9 (3-CH2, 5-CH2,7-CH2,9-CH2,12-CH2,14-CH2 overlapping), 50.1 (9’-CH), 56.2 
(17’-CH), 56.7 (14’-CH2), 74.1 (3’-CH), 79.2 (0-C(CH3)3 x 4), 122.3 (6 -CH), 139.7 (5'-C), 155.3,
156.0 (N-C0-0-C(CH3)3 x 4, NH-CO-O-CH, overlapping). FAB-MS m/z 1072 (MH+), 
C61H109N5O10 requires 1071; FAB-HRMS calculated 1072.8253 (MH+), found 1072.8272.
A/1-(Cholesteryl-3’-oxycarbonyl)-iV7,f/11,f/16,f/19-(tetra-fe/t-butyloxycarbonyl)-1J19-diamino-
7,11,16-triazanonadecane 49
Cholesteryl chloroformate (85 mg, 0.19 mmol) in CH2CI2 (5 ml) was added over 5 min to a 
stirred solution of tetra-Boc protected polyamine 47 (120 mg, 0.17 mmol) in CH2CI2 (5 ml) with 
TEA (1 ml, 7.7 mmol) at 25 °C, under nitrogen. The solution was stirred for 18 h then 
evaporated to dryness in vacuo and the residue purified over silica gel (EtOAc-hexane 4:6 v/v) 
to afford the title compound as a white solid (190 mg, 95 %). Rf 0.72 (EtOAc-hexane 7:3 v/v).
1H NMR (CDCb): 0.68 (3 H, s, 18’-CH3), 0.86,0.87 (6  H, 2 x d, J = 7, overlapping 2 Hz, 26'-CH3 
and 27'-CH3), 0.91 (3 H, d, J = 6 , 21’-CH3), 1.01 (3 H, s, 19’-CH3), 1.04-2.04 (78 H, m, 2-CH2,
3-CH2, 4-CH2i 5-CH2i 9-CH2i 13-CH2i 14-CH2,18-CH2,1 ’-CH2, 2’-CH2,4 ’-CH2i 7’-CH2, 8 ’-CH,
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9’-CH, ir -C H 2) 12’-CH2,14’-CH, 15'-CH2i 16'-CH2,17’-CH, 20’-CH, 22'-CH2, 23’-CH2i 25’-CH, 
0-C(CH3)3 x 4), 2.22-2.39 (2 H, m, 24’-CH2), 3.02-3.35 (16 H, m, 1-CH2i 6-CH2> 8-CH2i 10-CH2) 
12-CH2i 15-CH2i 17-CH2i 19-CH2), 4.43-4.55 (1 H, m, 3’-CH), 4.60-4.80 (2 H, m, CH2-NH-CO x 
2), 5.37 (1 H, d, J = 5 ,6’-CH). 13C NMR: 12.0 (18’-CH3), 18.8 (21’-CH3), 19.4 (19’-CH3), 21.1 
(11’-CH2), 22.6 (27’-CH3), 22.9 (26’-CH2), 23.9 (23’-CH2), 24.4 (15’-CH2), 28.1,28.3, 28.5,28.6 
(9-CH2,18-CH2,2 ’-CH2, 16’-CH2i 25'-CH, 0-C(CH3)3 x 3, overlapping), 32.0 (7’-CH2,8 ’-CH, 
overlapping), 35.8 (20’-CH), 36.2 (22’-CH2); 36.6 (10’-C); 37.1 (1’-CH2), 37.3 (19-CH2), 38.6 
(24’-CH2), 39.6, 39.8 (4’-CH2,12’-CH2), 40.8 (1-CH2), 42.4 (13'-C), 44.8,46.6,46.9 (6-CH2, 8- 
CH2,10-CH2,12-CH2,15-CH2,17-CH2 overlapping), 46.9 (5-CH2,8-CH2, overlapping), 50.1 
(9'-CH), 56.2 (17’-CH), 56.7 (14’-CH2), 74.1 (3-CH), 79.2 (0-C-(CH3)3 x 3), 122.3 (6-CH),
139.7 (5’-C), 155.3,156.0 (N-C0-0-C(CH3)3 x 3, NH-CO-O-CH, overlapping). FAB-MS m/z 




EDC (235 mg, 1.2 mmol) and lithocholic acid (231 mg, 0.61 mmol) were dissolved in CH2CI2 (5 
ml) and HOBt (17 mg, 0.13 mmol) was added with stirring at 25 °C under nitrogen. Tetra-Boc 
protected polyamine 46 (405 mg, 0.61 mmol) was added and the solution stirred for 16 h. 
CH2CI2 (30 ml) was added and the solution was washed with water (50 ml) and saturated 
NaHC03 solution (60 ml). The organic layers were dried (MgS04), evaporated to dryness in 
vacuo and the residue purified over silica gel (CH2CI2-MeOH 30:1 to 20:1 v/v) to afford the title 
compound as a white foam (590 mg, 95%). Rf 0.30 (CH2CI2-MeOH 20:1 v/v). 1H NMR 
(CDCb): 0.64 (3 H, s, 18’-CH3), 0.91 (3 H, s, 19’-CH3), 0.92 (3 H, d, J = 6 ,21'-CH3), 0.95-2.30 
(74 H, m, 2-CH2,6-CH2, 10-CH2i 11-CH2,15-CH2,1 ’-CH2,2'-CH2,4 ’-CH2, 5’-CH, 6’-CH2, 7’-
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CH2) 8 ’-CH, 9-CH, 11’-CH2, 12’-CH2i 14’-CH, 15'-CH2i 16’-CH2, 17-CH, 20’-CH, 22’-CH2i 23’- 
CH2) 0-C(CH3)3 x 4), 3.04-3.33 (16 H, m, 1-CH2( 3-CH2i 5-CH2) 7-CH2) 9-CH2) 12-CH2) 14-CH2) 
16-CH2), 3.57-3.66 (1 H, m, 3’-CH), 5.31-5.40 (1 H, m, CH2-NH-C0-0), 6.78-6.87 (1 H, m, CH2- 
NH-CO). 13C NMR: 12.1 (18’-CH3), 18.4 (21’-CH3), 20.9 (11’-CH2), 23.4 (19’-CH3), 24.3 (15’- 
CH2), 25.5, 26.2 (10-CH2,11-CH2), 26.5 (7'-CH2), 27.2 (6 ’-CH2), 27.6, 27.6 (2-CH2, 6-CH2, 15- 
CH2), 28.3 (16’-CH2), 28.5,28.5 (0-C(CH3)3 x 4), 30.5 (2’-CH2), 31.8 (22’-CH2), 33.8 (23’-CH2),
34.6 (10’-C), 35.4 (1’-CH2), 35.5 (20’-CH), 35.9 (8 ’-CH), 36.4 (4’-CH2) 37.4, 37.4 (1-CH2, 16- 
CH2), 40.2 (12’-CH2), 40.4 (9’-CH), 42.1 (5’-CH), 42.7 (13’-C), 44.8,44.8,46.5,46.6,46.8 (3- 
CH2, 5-CH2i 7-CH2,12-CH2,14-CH2), 56.0 (17’-CH), 56.4 (14’-CH), 71.7 (3'-CH), 79.4 (0- 
C(CH3)3 x 4), 156.0 156.1 (O-CO-NH), 173.5 (CO-NH). FAB-MS m/z 1018 (MH-), C49H88N4O8 
requires 1017; FAB-HRMS calculated 1018.7783 (MH+), found 1018.7827.
Di-(3-benzyloxycarbonylaminopropan-1-yl) oxalate 51 (Attempted synthesis of 3- 
benzyloxycarbonylaminopropanal 42)
Oxalyl chloride (0.92 ml, 10.6 mmol) was dissolved in anhydrous CH2CI2 (30 ml) and stirred at - 
78 °C under nitrogen. DMSO (1.36 ml, 19.2 mmol) was added dropwise over 5 min and the 
mixture stirred for a further 10 min. Alcohol 40 (2.0 g, 9.6 mmol) in anhydrous CH2CI2 (50 ml) 
was added dropwise over 5 min. This solution was stirred for a further 20 min. TEA (6 .6  ml, 48 
mmol) was added and the solution warmed to 25 °C. Water (100 ml) was added and the 
organic layer was collected. The aqueous layer was extracted with CH2CI2 (3 x 80 ml) and the 
combined organic extracts were dried (MgS0 4 ) and then evaporated to dryness in vacuo and 
the residue purified over silica gel (EtOAc-hexane 7:3 v/v) to afford the title compound as a 
white solid (3.3 g, 73 %). Rf 0.52 (EtOAc-hexane 8:2 v/v). 1H NMR (CDCb): 1.85-1.95 (4 H, 
m, 2-CH2 x 2), 3.20-3.32 (4 H, m, 3-CH2 x 2), 4.28 (4 H, t, J = 6 , 1-CH2 x 2), 5.06 (4 H, s, O-
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CH2-Ph x 2), 5.30-5.38 (2 H, m, CH2-NH-C0-0 x 2), 7.28-7.37 (10 H, m, Ph x 2). FAB-MS m/z 





Borane-DMS complex (10 M solution in DMS, 0.6 ml, 5.6 mmol) was added dropwise over 5 
min to a stirred solution of cholesteryl acetate (950 mg, 2.2 mmol) in anhydrous CH2CI2 (10 ml), 
and EtOAc (1 ml) at 25 °C under nitrogen. The solution was stirred for 4 h then cooled to 0 °C 
in ice. Water (5 ml) was added and stirred for 5 min after which time H2O2 (30 % w/v aq. 
solution, 5 ml) and NaHCC>3 (saturated aq. solution, 5 ml) were added. The reaction mixture 
was stirred for 30 min then extracted with EtOAc (3 x 40 ml). The organic layers were 
combined, dried (MgSO^, and evaporated to dryness in vacuo. The residue was purified over 
silica gel (EtOAc-hexane 4:6 v/v) to afford the title compound as a white foam (672 g, 68 %). R f 
0.47 (EtOAc-hexane 4:6 v/v). 1H NMR (CDCb): 0.64 (3 H, s, I 8 -CH3), 0.83 (3 H, s, 19’-CH3), 
0.86, 0.86 (6 H, 2 x d, J = 7, overlapping 2 Hz, 26’-CH3 and 27,-CH3), 0.90 (3 H, d, J = 7, 21- 
CHs). 0.95-2.24 (33 H, m, 1’-CH2, 2’-CH2) 4’-CH2, 5’-CH, 7’-CH2, 8’-CH, 9’-CH, ir -C H 2, 12’- 
CH2( 14'-CH2,15’-CH2,16’-CH2) 17’-CH, 20’-CH, 22’-CH2, 23’-CH2i 24'-CH2 25'-CH, CH3-CO), 
3.39(1 H ,dt,J = 4 and 10,6 '-CH), 4.62-4.73(1 H, m, 3’-CH). 13CNMR: 12.1 (18’-CH3), 13.5 
(19’-CH3), 18.6 (21’-CH3), 2 1 .2  ( ir-C H 2), 22.7 (27’-CH3), 22.9 (26,-CH2), 23.9 (23’-CH2), 24.3 
(15’-CH2), 27.3,28.1, 28.3 (2’-CH2) 16’-CH2) CH3-CO-O), 34.4 (8 ’-CH), 35.8 (20’-CH), 36.2,
3 6 .3  ( 1 0 ’-C ,  2 2 - C H 2) , 3 7 .1  ( 1 ’- C H 2), 3 8 .0  ( 2 4 ’- C H 2), 3 9 .6 ,  3 9 .8  ( 7 ’- C H 2 , 1 2 ’- C H 2), 4 1 .8  ( 4 ' - C H 2),
4 2 . 6  ( 1 3 ’-C ) ,  5 1 .7  ( 5 ’- C H ) ,  5 3 .7  ( 9 ’- C H ) ,  5 6 .1 ,  5 6 .2  ( 1 4 ’- C H ,  1 7 ’- C H ) ,  6 9 .5  ( 6 ’- C H )  7 3 .6  ( 3 ’- C H ) ,
1 7 0 .4  ( C H 3- C O - O ) .
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^1-(6’a-Hydroxy-5,a-cholesteryl-3,-oxycarbonyl)-^4,A/9,A/12-(tri-feft-butyloxycarbonyl)-
1,12-diamino-4,9-diazadodecane 54 and W -^ ’p-Hydroxy-S’p-cholesteryl-S’-oxycarbonyl)- 
N^.N^tri-fe/t-butyloxycarbonyO-l^-diamino^-diazadodecane 55
Borane-DMS complex (10 M solution in DMS, 0.3 ml, 2.6 mmol) was added dropwise over 5 
min to a stirred solution of steroid 6  (950 mg, 1.0 mmol) in anhydrous CH2CI2 (8  ml), at 25 °C 
under nitrogen. The solution was stirred for 4 h then cooled to 0 °C in ice. Water (5 ml) was 
added and stirred for 5 min after which time H2O2 (30 % aq. solution, 5 ml) and NaHCC>3 
(saturated aq. solution, 5 ml) were added. The reaction mixture was stirred for 30 min then 
extracted with EtOAc (3 x 40 ml). The organic layers were combined, dried (MgS0 4 ), and 
evaporated to dryness in vacuo. The residue was purified over silica gel (EtOAc-hexane 4:6 
v/v) to afford compound 54 as a white foam (630 mg, 65 %). R f 0.55 (EtOAc-hexane 7:3 v/v). 
1H NMR (CDCb): 0.61 (3 H, s, 18'-CH3), 0.78 (3 H, s, 19’-CH3), 0.82,0.83 (6  H, 2 x d, J = 6 , 
overlapping 2 Hz, 26’-CH3 and 27’-CH3), 0.86 (3 H, d, J = 7 ,21’-CH3), 0.94-2.22 (64 H, m, 2- 
CH2, 6 -CH2, 7 -CH2, 1 1 -CH2,1 ’-CH2, 2’-CH2, 4’-CH2i 5’-CH, 7’-CH2, 8 -CH, 9-CH, 11’-CH2, 12- 
CH2,14’-CH, 15’-CH2,16’-CH2,17’-CH, 20’-CH, 22’-CH2j 23’-CH2, 24’-CH2, 25’-CH, 0-C(CH3) 3 
x 3), 3.10-3.22 (1 2  H, m, 1-CH2, 3-CH2, 5-CH2, 8 -CH2, IO-CH2,12-CH2), 3.34 (1 H, dt, J = 4 
and 10,6 ’-CH), 4.46-4.58 (1 H, m, 3’-CH), 5.45-5.60 (2 H, m, CH2-NH-CO x 2). NMR: 12.1 
(18’-CH3), 13.4 (19’-CH3), 18.7 (21’-CH3), 21.1 ( ir-C H 2), 22.6 (27’-CH3), 22.9 (26’-CH2), 23.9 
(23’-CH2), 24.2 (15’-CH2), 25.5,26.1 (6 -CH2,7-CH2), 27.7, 28.0,28.2,28.5,28.8 (2-CH2, 11- 
CH2, 2’-CH2i 16’-CH2i 25’-CH, 0-C(CH3)3 x 3, overlapping), 34.4 (8 ’-CH), 35.8 (20’-CH), 36.2 
(10'-C), 36.3 (22’-CH2), 37.1 (1’-CH2), 37.3, 37.4 (1-CH2,12-CH2), 38.9 (24’-CH2), 39.5, 39.8 
(7’-CH2,12’-CH2), 42.8 (13’-C), 42.6 (4’-CH2), 43.8,44.0 (3-CH2,10-CH2, overlapping), 46.7,
46.8 (5-CH2, 8 -CH2, overlapping), 51.7 (5’-CH), 53.7 (9’-CH), 56.1 (14'-CH, 17’-CH2), 69.4 (6 - 
CH), 73.8 (3’-CH), 79.5 (0-C(CH3)3 x 3), 155.9 (N-C0-0-C(CH3) 3 x 3, NH-CO-O-CH,
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overlapping). FAB-MS m/z 933 (MH+), C53H94N4O8 requires 932; FAB-HRMS calculated 
933.7256 (MH+), found 933.7274.
Further elution gave compound 55 as a white foam (30 mg, 3 %). Rf 0.14 (EtOAc-hexane 7:3 
v/v). FAB-MS m/z 933 (MH+), C53H94N4O8 requires 932; FAB-HRMS calculated 933.7256 
(MH+), found 933.7274.
5” -(Fluorescein-thioureido)-pentanoic acid 63
A solution of 5-aminopentanoic acid (66 mg, 0.51 mmol) in aq. NaOH (1M, 10 ml) was added 
dropwise over 5 min to a suspension of fluorescein isothiocyanate (200 mg, 0.51 mmol) in 
ethanol (4 ml). The solution was stirred for 5 h, then acidified to pH 3 with dilute aq. HCI to give 
a yellow precipitate which was collected by filtration and dried over P2O5 to afford the title 
compound as an orange-brown solid (252 mg, 95 %). fo 12.9 min (Supelcosil ABZ+Plus, 5 pm, 
25 cm x 10 mm, X = 495 nm, MeCN-0.1 % aq. TFA 8:2 v/v). 1H NMR (CD3OD): 1.14-1.16 (4 H, 
m, 3"-CH2,4 ”-CH2), 2.37 (2 H, t, J = 7 ,2”-CH2), 3.60-3.67 (2 H, m, 5”-CH2), 6.65 (2 H, dd, J = 9, 
2, 2-CH, 7-CH), 6.78 (2 H, d, J = 2, 4-CH, 5-CH), 6.83 (2 H, d, J = 9 ,1-CH, 8-CH), 7.18 (1 H, d, 
J = 8, 3-CH), 7.80 (1 H, dd, J = 8, 2, 4-CH), 8.22 (1 H, s, 6’-CH). NMR: 24.2 (3"-CH2),
26.1 (4”-CH2), 30.2 (2”-CH2), 35.3 (5"-CH2), 104.2,113.3,115.6,122.0,127.3,130.1,131.4,
131.6,132.5,143.0,143.3,155.9,163.9 (1-CH, 2-CH, 3-C, 4-CH, 4a-C, 5-CH, 5a-C, 6-C, 7-
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CH, 8-CH, 8a-C, 9-C, 9a-C, 1’-C, 2’-C, 3’-CH, 4’-CH, 5’-C, 6’-CH) 171.1 (1-C-COOH), 177.9
(1"-C00H), 183.2 (C=S). FAB-MS m/z 507 (MH+), C26H22N2O7S requires 506; FAB-HRMS 
calculated 507.1226 (MH+), found 507.1218.
5”-(Ussamine rhodamine B sulfonamido)-pentanoic acid 64
5-Aminopentanoic acid (61 mg, 0.52 mmol) in aq. NaOH (96.9 mM, 5.8 ml, 0.52 mmol) was 
added dropwise over 30 min to a stirred solution of lissamine rhodamine B sulfonyl chloride 
(300 mg, 0.52 mmol) in acetone (10 ml) at 25 °C. The solution was stirred for 16 h, then 
acidified to pH 3 with dilute aq. HCI. The solvent was evaporated in vacuo and the residue 
purified over silica gel (CH2Cl2-MeOH 3:1 v/v) to afford the title compound as a purple solid 
(212 mg, 62 %). Rf 0.22 (CH2Cl2-MeOH 3:1 v/v). Absorption A,max (MeCN): 554 nm (emax 
57,416 M-1cm-1). 1H NMR (D20): 1.08-1.21 (12 H, m, CH3 x 4), 1.67-1.76 (4 H, m, 3”-CH2, 4”- 
CH2), 2.42-2.49 (2 H, m, 2”-CH2), 3.00-3.06 (2 H, m, 5"-CH2), 3.41-3.56 (8 H, m, CH2-CH3 x 4), 
6.61 (2 H, s, 4-CH, 5-CH), 6.81 (2 H, d, J = 9, 2-CH, 7-CH), 6.94 (2 H, d, J = 9 ,1-CH, 8-CH), 
7.35 (1 H, d, J = 8, 3’-CH), 8.17 (1 H, d, J = 8 ,4’-CH), 8.52 (1 H, s, 6-CH). FAB-MS m /z658 
(MH+), C32H39N3O8S2 requires 657.
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5”-Benzyloxycarbonylaminopentanoic acid 65
Benzyl chloroformate (2.00 g, 11.7 mmol) was added dropwise over 5 min to a stirred solution 
of 5-aminopentanoic acid (1.25 g, 10.7 mmol) in aq. NaOH (2 M, 100 ml) at 0 °C. The solution 
was stirred for 18 h, then acidified to pH 3 with dilute aq. HCI to give a white precipitate which 
was collected by filtration and dried over P2O 5 to afford the title compound as a white solid 
(2.06 g, 77%). mp: 98-99 °C. IR 1700 cm-1 (COOH), 1690 cm-1 (N-CO-O). 1H NMR (d6- 
DMSO): 1.41,1.49 (4 H, 2x  quin, J = 7, overlapping 34 Hz, 3”-CH2) 4”-CH2), 2.21 (2 H, t, J =
7, 2”-CH2), 2.99 (2 H, q, J = 6 ,5”-CH2), 3.60 (2 H, m, CH2-NH-CO-0, COOH exchanged), 5.01 
(s, 2 H, 0-CH2-Ph), 7.26-7.39 (5 H, m, Ph). 13C NMR: 22.6 (3”-CH2), 29.7 (4"-CH2), 34.1 (2”- 
CH2), 40.8 (5"-CH2), 65.9 (0-CH2-Ph), 128.3,128.4,129.0 (Ph), 137.9 (C Ph), 156.7 (N-CO-O),
175.0 (COOH). FAB-MS m/z 252 (MH+), C13H17NO4 requires 251; FAB-HRMS calculated 
252.1236 (MH+), found 252.1238.
5”-Benzyloxycarbonylaminopentanoyl chloride 65a
Oxalyl chloride (1.25 ml, 14.2 mmol) was added dropwise to a stirred solution of acid 65 (722 
mg, 2.88 mmol) in toluene (10 ml) at 25 °C. The solution was stirred for 1 h then evaporated to 
dryness in vacuo to afford the title compound as a yellow oil (785mg, 86 % by 13C NMR). IR 
(thin film) 1770 crrr1 (COCI), 1690 cm-1 (N-CO-O). 13C NMR (d6-DMSO): 19.9 (3”-CH2), 22.2 
(4”-CH2), 34.5 (2"-CH2), 46.2 (5”-CH2), 67.6 (0-CH2-Ph), 127.8,128.4,128.9 (Ph), 135.8 (C 
Ph), 153.8 (N-CO-O), 170.7 (COCI).
161
4a'
5” -(9,M-Fluorenylmethoxycarbonyl)-aminopentanoic acid 68
A solution of 5-aminopentanoic acid (930 mg, 8.0 mmol), A/-(9-fluorenylmethoxycarbonyloxy)- 
succinimide (2.69 g, 8 .0  mmol), NaHCC>3 (2 .0  g) in water (20 ml) and dioxane (30 ml) was 
stirred for 16 h at 25 °C. The solution was washed with diethyl ether (3 x 50 ml). The aqueous 
layer was acidified to pH 3 with dilute aq. HCI, then extracted with EtOAc (3 x 60 ml). The 
combined organic extracts were evaporated to dryness in vacuo. The residue was 
recrystallised from EtOAc to afford the title compound as white crystals (2.22 g, 82 %). 1H 
NMR (de-DMSO): 1.40 (2 H, quin, J = 7, 3”-CH2), 1.48 (2 H, quin, J = 7 ,4”-CH2), 2.21 (2 H, t, J 
= 7, 2”-CH2), 2.98 (2 H, q, J =  6 , 5”-CH2), 4.20 (1 H, t, J = 7, 9,M-CH), 4.29 (2 H, d, J =  7 ,10 ’"- 
CH2), 7.32 (2 H, t, J = 7, 2"’-CH and 7” ’-CH), 7.40 (2 H, t, J = 7, 3” ’-CH and 6 ” ’-CH), 7.68 (2 H, 
d, J = 7, T -C H  and 8 ” ’-CH), 7.88 (2 H, d, J = 7 ,4” ’-CH and 5” ’-CH), 12.05 (1H, bs, COOH). 
13C NMR: 21.8 (3” -CH2), 28.9 (4”-CH2), 33.3 (2"-CH2), 40.1 (5"-CH2), 47.4 (9” ’-CH), 65.1 (10"’- 
CH2), 119.9 (2” ’-CH and 7m-CH), 125.0 (3’” -CH and 6 ” ’-CH), 126.9 (1IM-CH and 8 ’” -CH), 127.4 
(4” ’-CH and 5m-CH), 140.5 (4” ’a-C and 5” ’a-C), 143.7 (1ma-C and 8 ma-C), 155.9 (O-CO-NH),
174.1 (COOH). FAB-MS m/z 340 (MH+), C20H2iNO4 requires 339; FAB-HRMS calculated 
340.1549 (MH+), found 340.1547.
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A/-(3’a-hydroxy-5’p-cholan-24’-carbonyl)-1-aminopropane 5”-(9m- 
fluorenylmethoxycarbonyl)-aminopentanoic acid ester 69
5"-(9m-Fluorenylmethoxycarbonyl)-aminopentanoic acid 68 (259 mg, 0.76 mmol) and DCC 
(174 mg, 0.84 mmol) were stirred in anhydrous CH2CI2 (5 ml) and DMAP (20 mg, 0.16 mmol) 
was added. The solution was stirred for 1 min then secondary alcohol 67 (320 mg, 0.76 mmol) 
was added and the solution stirred for 6 h at 25 °C, and then evaporated to dryness in vacuo. 
The residue was purified over silica gel (EtOAc-hexane 4:6 v/v) to afford the title compound as 
a white solid (482 mg, 85 %). Rf 0.62 (EtOAc-hexane 8:2 v/v). 1H NMR (CDCb): 0.63 (3 H, s, 
18’-CH3), 0.89-0.94 (9 H, m, 3-CH3,21’-CH3,19’-CH3 overlapping), 0.97-2.34 (36 H, 2-CH2, 1- 
CH2, 2’-CH2) 4’-CH2, 5’-CH, 6’-CH2i 7’-CH2i 8’-CH, 9’-CH, 11’-CH2,12’-CH2,14’-CH, 15’-CH2, 
16’-CH2,17-CH, 20’-CH, 22'-CH2i 23’-CH2i 2”-CH2i 3"-CH2,4"-CH2), 3.17-3.25 (4 H, m, 1-CH2, 
5"-CH2)) 4.21 (1 H, t, J = 7, CH-CH2), 4.39 (2 H, d, J = 7, CH-CH2), 4.69-4.80 (1 H, m, 3’-CH), 
4.88-4.94 (1 H, m, CH2-NH-CO-O), 5.46-5.52 (1 H, m, CH2-NH-CO-CH2), 7.31 (2 H, t, J = 7, 
2” ’-CH, 7” ’-CH), 7.40 (2 H, t, J = 7, 3m-CH, 6” ’-CH), 7.59 (2 H, d, J = 7 ,1m-CH, 8"’-CH), 7.76 (2 
H, d, J = 7 ,4” ’-CH, 5” ’-CH). 13C NMR: 11.5 (3-CH3), 12.1 (18’-CH3), 18.5 (21’-CH3), 20.9 (11- 
CH2), 22.2 (3”-CH2), 23.2 (2-CH2), 23.4 (19’-CH3), 24.2 (15’-CH2), 26.4,26.8, (7’-CH2,4 ”-CH2),
27.1 (6’-CH2), 28.3 (16’-CH2), 29.4 (2’-CH2), 31.9 (22’-CH2), 32.4 (4’-CH2), 34.0 (23’-CH2), 34.3 
(2”-CH2), 34.6 (10’-C), 35.1 (1’-CH2), 35.5 (20’-CH), 35.8 (8’-CH), 40.2 (12’-CH2), 40.5 (9’-CH),
40.7 (5”-CH2), 41.2 (1-CH2), 42.0 (5’-CH), 42.8 (13-C), 49.1 (0-CH2-CH), 56.1 (17’-CH), 56.5 
(14’-CH), 66.5 (0-CH2-CH), 74.4 (3'-CH), 119.8 (2m-CH, 7,,,-CH), 124.9 (3m-CH, 6” ’-CH), 126.9 
(T”-CH, 8” ’-CH), 127.5 (4”’-CH, 5"’-CH), 141.1 (4” ’a-C, 5ma-C), 143.8 (1ma-C, 8ma-C), 156.2 
(O-CO-NH), 172.7 (0-CO-CH2), 173.2 (CH2-CO-NH). FAB-MS m/z 739 (MH+), C47H66N A  
requires 738; FAB-HRMS calculated 739.5050 (MH+), found 739.5066.
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4-Nitrophenyl 5” -(9’-fluorenylmethoxycarbonyl)-aminopentanoate 71
4-Nitrophenol (395 mg, 2.84 mmol) in EtOAc (5 ml) was added to a solution of DCC (586 mg, 
2.84 mmol) and acid 68 (964 mg, 2.84 mmol) in EtOAc (30 ml) at 25 °C. The solution was 
stirred for 16 h then filtered. Then the filtrate was evaporated to dryness in vacuo and the 
residue was recrystallised once from EtOAc to afford the title compound as yellow crystals (967 
mg, 74 %). 1H NMR (CDCb): 1.65,1.78 (4 H, 2 x quin, J = 7, 3”-CH2,4 ” -CH2), 2.63 (2 H, t, J = 
7, 2"-CH2), 3.25 (2 H, q, J = 6 , 5”-CH2), 4.20 (1 H, t, J = 7, CH2CH), 4.41 (2 H, d, J = 7, CH2- 
CH), 7.25 (2 H, d, J = 9, 2-CH, 6 -CH), 7.30 (2 H, t, J = 7, 2’” -CH, 7” ’-CH), 7.39 (2 H, t, J = 7, 
3’” -CH, 6 ” ’-CH), 7.58 (2 H, d, J =  7, T ’-CH, 8 ” ’-CH), 7.75 (2 H, d, J = 7, 4m-CH, 5m-CH), 8.24 
(2 H, d, J = 9, 3-CH, 5-CH). NMR: 21.8 (3”-CH2), 29.4 (4”-CH2), 33.8 (2”-CH2), 40.5 (5"- 
CH2), 47.3 (0-CH2-CH), 6 6 .6  (0-CH2-CH), 119.8 (2” ’-CH, 7” ’-CH), 122.2 (2-CH, 6 -CH), 124.8 
(3-CH, 5-CH), 124.8 (3m-CH, 6 m-CH), 126.9 (1” ’-CH, 8 ’” -CH), 127.5 (4,,,-CH, 5m-CH), 141.1 
(4” ’a-C, 5” ’a-C), 143.7 ( r ’a-C, 8 ” ’a-C), 145.1 (4”-C), 155.1,156.3 (1” -C, O-CO-NH), 170.6 (O- 
CO-CH2).
A/4,A/9,A/12-(Tri-ferf-butyloxycarbonyl)-A/1-(3’cx-hydroxy-5’P-cholan-24’-carbonyl)-1,12- 
diamino-4,9-diazadodecane 5” -(9’” -fluorenylmethoxycarbonyl)-aminopentanoic acid 
ester 72
5-(9-Fluorenylmethoxycarbonyl)-aminopentanoic acid 68 (70 mg, 0.21 mmol) and DCC (43 mg, 
0.21 mmol) were stirred in anhydrous CH2CI2 (5 ml) and DMAP (5 mg, 40 pmol) was added.
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The solution was stirred for 1 min then secondary alcohol 16 (178 mg, 0.21 mmol) was added 
and the solution stirred for 18 h at 25 °C, and then evaporated to dryness in vacuo. The 
residue was purified over silica gel (EtOAc-hexane 4:6 v/v) to afford the title compound as a 
white solid (195 mg, 80 %). Rf 0.45 (EtOAc-hexane 7:3 v/v). 1H NMR (CDCb): 0.63 (3 H, s, 
18’-CH3), 0.91 (3 H, d, J = 6 ,21’-CH3), 0.92 (3 H, s, 19’-CH3), 0.98-2.34 (69 H, m, 2-CH2, 6- 
CH2i 7-CH2,11-CH2, 1’-CH2, 2’-CH2, 4’-CH2i 5’-CH, 6’-CH2i 7’-CH2,8 ’-CH, 9’-CH, 11’-CH2, 12- 
CH2,14’-CH, 15’-CH2,16’-CH2,17’-CH, 20’-CH, 22’-CH2,23’-CH2, 2”-CH2i 3”-CH2, 4”-CH2i O- 
C(CH3)3 x 3), 3.00-3.32 (14 H, m, 1-CH2, 3-CH2,5-CH2,8-CH2,10-CH2,12-CH2, 5”-CH2), 4.21 
(1 H, t, J = 7, CH-CH2), 4.39 (2 H, d, J = 7, CH-CH2), 4.69-4.78 (1 H, m, 3’-CH), 5.25-5.36 (1 H, 
m, CH2-NH-CO-0), 6.73-6.82 (1 H, m, CH2-NH-CO-CH2), 7.31 (2 H, t, J = 7, 2’-CH, 7-CH), 
7.40 (2 H, t,J  = 7, 3-CH, 6’-CH), 7.59 (2 H, d, J = 7, V-CH, 8’-CH), 7.76 (2 H, d, J = 7 ,4'-CH, 
5’-CH). 13C NMR: 12.1 (18’-CH3), 18.5 (21’-CH3), 20.9 (11’-CH2), 22.2 (3"-CH2), 23.4 (19’- 
CH3), 24.2 (15’-CH2), 25.7,26.3 (6-CH2,7-CH2), 26.8, 26.8, (7’-CH2,4 ”-CH2, overlapping), 27.1 
(6’-CH2), 27.6, 27.6 (2-CH2,11-CH2), 28.3, 28.5, 28.5 (16-CH2, 0-C(CH3)3 x 3,), 29.4 (2’-CH2),
31.9 (22’-CH2), 32.4 (4’-CH2), 34.0 (23’-CH2), 34.2 (2"-CH2), 34.6 (10’-C), 35.1 (1’-CH2), 35.5 
(20’-CH), 35.8 (8-CH), 37.4, 37.8 (1-CH2,12-CH2), 40.2 (12’-CH2), 40.4 (9’-CH), 40.5 (5”-CH2),
41.9 (5-CH), 42.8 (13-C), 44.3,46.7 (3-CH2,5-CH2,8-CH2,10-CH2, overlapping), 49.3 (O- 
CH2-CH), 56.1 (17’-CH), 56.4 (14-CH), 66.5 (0-CH2-CH), 74.3 (3’-CH), 79.7 (0-C(CH3)3x 3),
119.8 (2’-CH, 7’-CH), 124.9 (3’-CH, 6-CH), 126.8 (1’-CH, 8’-CH), 127.5 (4-CH, 5’-CH), 141.1 
(4a’-C, 5a’-C), 143.8 (1a’-C, 8a’-C), 156.2 (N-C0-0-C(CH3)3 x 3, N-CO-0-CH2 overlapping),
173.0 (0-CO-CH2), 173.7 (CH2-CO-NH). FAB-MS m/z 1182 (MH+), C69H107N5O11 requires 




1,16-diamino-4,8,13-triazahexadecane 5” -(9’” -fluorenylmethoxycarbonyl)- 
aminopentanoic acid ester 73
5-(9-Fluorenylmethoxycarbonyl)-aminopentanoic acid 68 (22 mg, 65 jLtmol) and DCC (19 mg,
93 nmol) were stirred in anhydrous CH2CI2 (8  ml) and DMAP (2 mg, 16 nmol) was added at 25 
°C. The solution was stirred for 1 min then secondary alcohol 50 (6 6  mg, 62 nmol) was added 
and the solution stirred for 28 h then evaporated to dryness in vacuo. The residue was purified 
over silica gel (EtOAc-hexane 2:8 to 9:1 v/v) to afford the title compound as a white solid (38 
mg, 44 %). f t  0.53 (EtOAc-hexane 7:3 v/v). 1H NMR (CDCb): 0.63 (3 H, s, 18’-CH3), 0.89-0.94 
(6  H, m, 2 I-CH 3 and 19’-CH3), 0.96-2.45 (80 H, m, 2-CH2, 6 -CH2, 10-CH2) H -C H 2,15-CH2, 1- 
CH2) 2 -CH2, 4 -CH2, 5’-CH2i 6 ’-CH2, 7 -CH2, 8 -CH, 9’-CH, H-CH 2, 12’-CH2,14-CH, 15’-CH2l 
I 6 -CH2,1 7 ’-CH, 20’-CH, 2 2 -CH2, 23’-CH2i 2”-CH2l 3” -CH2) 4”-CH2) 0 -C(CH3)3 x 4,), 3.00-3.34 
(18 H, m, 1-CH2) 3-CH2i 5-CH2, 7-CH2, 9-CH2,12-CH2,14-CH2, 16-CH2i 5” -CH2), 4.21 (1 H, t, J 
= 7, CH-CH2), 4.39 (2 H, d, J = 6 , CH-CH2), 4.69-4.78 (1 H, m, 3’-CH), 5.30-5.40 (1 H, m, CH2- 
NH-CO-O), 6.74-6.88 (1 H, m, CH2-NH-CO-CH2), 7.31 (2 H, t, J =  7, 2’-CH, 7’-CH), 7.40 (2 H, t, 
J = 7, 3’-CH, 6 ’-CH), 7.59 (2 H, d, J = 7,1 ’-CH, 8 ’-CH), 7.76 (2 H, d, J = 7, 4 ’-CH, 5’-CH).
NMR: 12.2 (18’-CH3), 18.5 (21’-CH3), 20.9 ( ir -C H 2), 22.2 (3"-CH2), 23.4 (19’-CH3), 24.3 (15’- 
CH2), 25.6, 26.2 (10-CH2, H -C H 2), 26.4, 26.8, (7’-CH2, 4 M-CH2), 27.1 (6 ’-CH2), 27.6, 27.6 (2 - 
CH2( 6-CH2,15-CH2), 28.3 (16’-CH2), 28.5, 28.5 (0-C(CH3)3 x 4), 29.4 (2'-CH2), 31.9 (22’-CH2),
32.3 (4-CH2), 33.9 (23’-CH2), 34.2 (2”-CH2), 34.6 (10’-C), 35.1 (1’-CH2), 35.6 (20’-CH), 35.8 (8 -
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CH), 37.4, 37.4 (1-CH2) 16-CH2), 40.1 (12’-CH2), 40.4 (9’-CH), 40.6 (5"-CH2), 41.9 (5’-CH),
42.7 (13’-C), 44.8, 44.8 (3-CH2l 5-CH2, 7-CH2, 9-CH2,12-CH2,14-CH2), 47.3 (0-CH2-CH), 56.1 
(17’-CH), 56.4 (14-CH), 66.5 (0-CH2-CH), 74.4 (3’-CH), 79.4, 79.8 (0-C(CH3)3 x 4), 119.8 (2’- 
CH, 7’-CH), 124.9 (3’-CH, 6-CH), 126.8 (1-CH, 8’-CH), 127.5 (4’-CH, 5’-CH), 141.1 (4a’-C, 5a- 
C), 143.8 (1a’-C, 8a’-C), 156.2 (N-C0-0-C(CH3)3 x 4, N-C0-0-CH2 overlapping), 172.7 (O-CO- 
CH2), 173.6 (CH2-CO-NH). FAB-MS m/z 1339 (MH+), C77H i22N6O i3 requires 1338.
A/1-(3’a-5’p-Cholan-24’-carbonyl)-1,12-diamino-4,9-diazadodecane 5” -(9’” - 
fluorenylmethoxycarbonyl)-aminopentanoic acid ester tristrifluoroacetate salt 74
Tri-Boc protected polyamine 72 (25 mg) in anhydrous CH2CI2 (18 ml) and TFA (2 ml) was 
stirred at 25 °C for 3 h, then the solvent was evaporated in vacuo and the residue purified by 
semi-preparative RP-HPLC (Supelcosil ABZ+Plus, 5 j^m, 25 cm x 10 mm, X = 265 nm, MeCN- 
0.1 % aq. TFA 8:2 v/v) to afford the title compound as a white solid (10 mg, 55 %). fo 8.2 min 
(Supelcosil ABZ+Plus, 5 jam, 25 cm x 10 mm, X = 265 nm, MeCN-0.1 % aq. TFA 8:2 v/v). 
Absorption ^max (H20): 262 nm. Fluorescence Xm * (Ex): 265 nm, ?imax (Em): 320 nm. FAB- 





Borane-DMS complex (10 M solution in DMS, 0.1 ml, 0.70 mmol) was added dropwise over 5 
min to a stirred solution of steroid 48 (300 mg, 0.28 mmol) in anhydrous CH2CI2 (8  ml), at 25 °C 
under nitrogen. The solution was stirred for 4 h then cooled to 0 °C in ice. Water (5 ml) was 
added and stirred for 5 min after which time H2O2 (30 % aq. solution, 5 ml) and NaHC03 
(saturated aq. solution, 5 ml) were added. The reaction mixture was stirred for 30 min then 
extracted with EtOAc (3 x 40 ml). The organic layers were combined, dried (MgSO^, and 
evaporated to dryness in vacuo. The residue was purified over silica gel (EtOAc-hexane 4:6 
v/v) to afford the title compound as a white foam (195 mg, 64 %). Rf 0.61 (EtOAc-hexane 7: 
v/v). 1H NMR (CDCb): 0.65 (3 H, s, 18’-CH3), 0.82 (3 H, s, 19’-CH3), 0.86,0.87 (6  H, 2 x d, J = 
6 , overlapping 2 Hz, 26’-CH3 and 27’-CH3), 0.90 (3 H, d, J = 7 ,21’-CH3), 1.04-2.26 (75 H, m, 2- 
CH2, 6 -CH2, 1 0 -CH2, 1 1 -CH2,15-CH2,1 ’-CH2, 2 -CH2, 4’-CH2, 5’-CH, 7’-CH2, 8 -CH, 9’-CH, 11'- 
CH2l 12-CH2,14-CH, 15’-CH2, 1 6 -CH2,17-CH, 20’-CH, 22’-CH2, 23’-CH2) 24’-CH2, 25-CH, 
0 -C(CH3)3 x 4), 3.02-3.30 (16 H, m, 1-CH2, 3-CH2, 5-CH2, 7-CH2, 9-CH2l 12-CH2,14-CH2, 16- 
CH2), 3.38 (1 H, dt, J = 4 and 10, 6 ’-CH), 4.49-4.59 (1 H, m, 3’-CH), 5.34-5.68 (2 H, m, CH2- 
NH-CO x 2). 13C NMR: 12.4 (18’-CH3), 13.8 (19’-CH3), 19.1 (21’-CH3), 21.5 (11’-CH2), 23.0 
(27’-CH3), 23.2 (26’-CH3), 24.2 (23’-CH2), 24.6 (15'-CH2), 25.8,26.3 (6 -CH2, IO-CH2, H-CH2),
28.0, 28.4,28.6, 28.8,28.9 (2-CH2) 15-CH2,2 ’-CH2,16’-CH2, 25’-CH, 0-C(CH3)3 x 4, 
overlapping), 34.7 (8 ’-CH), 36.1 (20’-CH), 36.5 (22’-CH2), 36.6 (10’-C), 38.1 (1-CH2, 1 6 -CH2),
37.4 (1’-CH2), 38.0 (24’-CH2), 39.8 (12’-CH2), 40.1 (7’-CH2), 42.0 (4’-CH2), 42.9 (13’-C), 43.9,
44.0.46.8.47.0 (3-CH2,10-CH2,7-CH2,9-CH2,12-CH2,14-CH2 overlapping), 52.0 (5’-CH),
54.0 (9’-CH), 56.5 (14’-CH, 17’-CH), 69.6 (6 '-CH), 74.1 (3’-CH), 79.7, 79.9 (0-C-(CH3)3 x 4),
155.6,156.3 (N-C0-0-C(CH3)3 x 4, NH-CO-O-CH, overlapping). FAB-MS mlz 1091 (MH+), 






1,12-diamino-4,9-diazadodecane 5” -(9” ’-fluorenylmethoxycarbonyl)-aminopentanoic 
ester 76
5-(9-Fluorenylmethoxycarbonyl)-aminopentanoic acid 6 8  (101 mg, 0.30 mmol) and DCC (62 
mg, 0.30 mmol) were stirred in anhydrous CH2CI2 (5 ml) and DMAP (7 mg, 0.06 mmol) was 
added at 25 °C. The solution was stirred for 1 min then secondary alcohol 54 (281 mg, 0.30 
mmol) was added and the solution stirred for 18 h then evaporated to dryness in vacuo. The 
residue was purified over silica gel (EtOAc-hexane 3:7 to 6:4 v/v) to afford the title compound 
as a white solid (312 mg, 83 %). Rf 0.66 (EtOAc-hexane 7:3 v/v). 1H NMR (CDCI3): 0.63 (3 H, 
s, I 8 - C H 3 ) ,  0.86,0.86 (6 H, 2 xd, overlapping 2 Hz, J = 6, 26’-CH3 and 27’-CH3), 0.83-0.92 (6 
H, m, 19-CH3,21’-CH3), 0.93-2.45 (71 H, m, 2-CH2, 6 -CH2, 7-CH2, H-CH2,1 ’-CH2,2 ’-CH2, 4’- 
CH2, 5’-CH2,7 ’-CH2,8 ’-CH, 9'-CH, 11’-CH2,12’-CH2,14’-CH, 15’-CH2,16’-CH2,17’-CH, 20’- 
CH, 22’-CH2, 23’-CH2,24’-CH2,25’-CH, 2’’-CH2,3 ”-CH2,4 ”-CH2,0-C(CH3)3 x 3), 3.10-3.31 (14 
H, m, I-CH2, 3 -CH2, 5-CH2, 8 -CH2, IO-CH2, 1 2 -CH2, 5”-CH2), 4.22 (1 H, t, J = 6 , 9” ’-CH), 4.38 
(2 H, d, J = 6 , 10” ’-CH2), 4.42-4.55 (1 H, m, 3’-CH), 4.63-4.75 (1 H, m, 6 -CH), 5.29-5.68 (2 H, 
m, CH2-NH-CO x 2), 7.31 (2 H, t, J = 7 ,2’”-CH, 7” ’-CH), 7.40 (2 H, t, J = 7 ,3” ’-CH, 6 ’”-CH), 
7.61 (2  H, d, J = 7, r-CH, 8”’-CH), 7.76 (2  H, d, J = 7 ,4”'-CH, 5”’-CH). NMR: 12 .1  (18’- 
CH3), 13.3 (19’-CH3), 18.7 (21’-CH3), 21.3 (11’-CH2), 22.4 (3’’-CH2), 22.7 (27’-CH3), 22.9 (26’- 
CH3), 24.0 (23’-CH2), 24.2 (15’-CH2), 25.0,25.7, (6 -CH2,10-CH2,11-CH2,4 ”-CH2), 28.1, 28.2,
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28.5, 28.9, 29.6 (2-CH2, 11-CH2, 2’-CH2i 16’-CH2, 25’-CH, 0-C(CH3)3 x 3, overlapping), 34.0,
34.1 (2”-CH2, 8 ’-CH), 35.8 (20’-CH), 36.2 (22’-CH2), 36.6 (10’-C), 37.4 (1'-CH2), 37.7, 37.9 (1- 
CH2,12-CH2, 24’-CH2, overlapping), 39.5,39.7 (7’-CH2,12’-CH2), 40.7 (4’-CH2,5 ”-CH2, 
overlapping), 42.6 (13’-C), 44.2,46.8,47.4 (3-CH2, 5-CH2, 8 -CH2,10-CH2, overlapping), 48.5 
(9” ’-CH), 49.1 (5’-CH2), 53.5 (9-CH), 56.1,56.2 (14'-CH, 17-CH), 6 6 .6  (10” ’-CH2), 72.3 (6 ’- 
CH), 73.4 (3’-CH), 79.6 (0-C(CH3)3 x 3), 119.8 (2” ’-CH, 7m-CH), 125.0 (3’”-CH, 6 m-CH), 126.9 
(1” ’-CH, 8 ’”-CH), 127.5 (4m-CH, 5” ’-CH), 141.1 (4”’a-C, 5ma-C), 143.8 (1”’a-C, 8 ” ’a-C), 156.3, 
156.6 (N-C0-0-C(CH3)3 x 3, N-C0-0-CH2 overlapping) 172.9 (CH-0-C0-CH2). FAB-MS m/z 









aminopentanoic acid ester 77
5-(9-Fluorenylmethoxycarbonyl)-aminopentanoic acid 6 8  (51 mg, 0.15 mmol) and DCC (19 mg, 
0.15 mmol) were stirred in anhydrous CH2CI2 (5 ml) and DMAP (3 mg, 0.02 mmol) was added 
at 25 °C. The solution was stirred for 1 min then secondary alcohol 75 (109 mg, 0.10 mmol) 
was added and the solution stirred for 26 h then evaporated to dryness in vacuo. The residue 
was purified over silica gel (EtOAc-hexane 2:8 to 4:6 v/v) to afford the title compound as a 
white solid (104 mg, 74 %). Rf 0.70 (EtOAc-hexane 7:3 v/v). 1H NMR (CDCb): 0.63 (3 H, s,
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18’-CH3), 0.86, 0.86 (6  H, 2 x d, overlapping 2 Hz, J = 6 , 26’-CH3 and 27’-CH3), 0.88-0.92 (6  H, 
m, 21’-CH3 and 19’-CH3), 0.94-2.45 (82 H, m, 2-CH2,6-CH2,10-CH2,11-CH2,15-CH2,1 ’-CH2, 
2’-CH2, 4’-CH2i 5’-CH2i 7'-CH2i 8 ’-CH, 9-CH, 11’-CH2, 12’-CH2i 14’-CH, 15’-CH2i 16’-CH2, 17’- 
CH, 20’-CH, 22’-CH2, 23’-CH2i 24’-CH2i 25’-CH, 2”-CH2i 3”-CH2i 4"-CH2i 0-C(CH3)3 x 4), 3.00- 
3.35 (18 H, m, 1-CH2, 3-CH2, 5-CH2,7-CH2, 9-CH2,12-CH2,14-CH2,16-CH2, 5”-CH2), 4.22 (1 
H, t, J = 6 , 9” ’-CH), 4.38 (2 H, d, J = 6 , 10m-CH2), 4.44-4.55 (1 H, m, 3’-CH), 4.63-4.73 (1 H, m, 
6 '-CH), 5.30-5.66 (2 H, m, CH2-NH-CO x 2), 7.31 (2 H, t, J = 7, 2m-CH, 7”’-CH), 7.40 (2 H, t, J 
= 7, 3” ’-CH, 6 ” ’-CH), 7.59 (2 H, d, J = 7 ,1” ’-CH, 8 ” ’-CH), 7.76 (2 H, d, J = 7 ,4m-CH, 5” '-CH). 
13C NMR: 12.4 (18’-CH3), 13.6 (19’-CH3), 19.1 (21’-CH3), 21.5 (11’-CH2), 22.2 (3”-CH2), 23.0 
(27'-CH3), 23.2 (26’-CH3), 24.3 (23’-CH2), 24.5 (15’-CH2), 25.9, 26.0, 26.6 (6 -CH2,10-CH2, 11- 
CH2,4 ”-CH2,), 27.9, 28.4, 28.8, 28.9, 29.2 (2-CH2,15-CH2, 2’-CH2,16’-CH2, 25’-CH, 0-C(CH3)3 
x 4, overlapping), 34.4 (2”-CH2) 34.7 (8 ’-CH), 36.1 (20’-CH), 36.5 (22’-CH2), 36.9 (10’-C), 37.3 
(1’-CH2), 37.8,37.9 (1-CH2,16-CH2), 38.0 (24’-CH2), 39.9 (12’-CH2), 40.0 (7’-CH2), 40.5 (5”- 
CH2), 41.0 (4’-CH2), 42.9 (13’-C), 44.2,44.5,45.1,46.8,47.3 (3-CH2, 5-CH2,7-CH2,9-CH2, 12- 
CH2,14-CH2 overlapping), 48.8 (9mCH), 49.2 (5’-CH2), 53.8 (9’-CH), 56.4, 56.5 (14’-CH, 17’- 
CH), 66.2 (10”’-CH2), 72.7 (6 ’-CH), 74.0 (3-CH), 79.7, 79.9, 80.0 (0-C-(CH3)3 x 4), 120.1 (2m- 
CH, 7” ’-CH), 125.2 (3m-CH, 6 m-CH), 127.2 (1m-CH, 8 m-CH), 127.8 (4’"-CH, 5m-CH), 141.4 
(4ma-C, 5a’-C), 144.1 (1ma-C, 8 ” ’a-C), 155.6,156.2,156.7 (N-C0-0-C(CH3)3 x 4, N-CO-O- 






Attempted synthesis of W-IB’a-hydroxy-S’a-cholesteryl-S’-oxycarbonyl)-!,16-diamino- 
4,8,13-triazahexadecane 5”-(Oregon Green 488-amido)-pentanoic acid ester 82
To a stirred solution of steroid 77 (6  mg, 4 pmol) in DMF (1 ml) was added KF (1 mg, 17 pmol) 
and TEA (1 ml, 7.7mmol) followed by Oregon Green 488 NSE (2 mg, 4 pmol). The solution 
was stirred at 25 °C under nitrogen for 10 h then evaporated to dryness in vacuo to give an 
orange oil. This oil was stirred in anhydrous CH2CI2 (9 ml) and TFA (1 ml) at 25 °C for 3 h, then 
the solvent was evaporated in vacuo to afford a green oil which was purified by semi­
preparative RP-HPLC (Supelcosil ABZ+Plus, 5 jam, 25 cm x 10 mm, X = 488 nm, MeCN-0.01 
% aq. TFA 9:1 v/v) to afford a green solid (11 mg, %). fo 4.5 min (Supelcosil ABZ+Plus, 5 pm, 
25 cm x 10 mm, X = 488 nm, MeCN-0.01 % aq. TFA 9:1 v/v). Absorption >.max (H2O): 489 nm. 







To a stirred solution of tri-Boc protected polyamine 5 (100 mg, 0.19 mmol) in CH2CI2 was 
added TEA (1 ml, 7.7 mmol) and dansyl chloride 80 (54 mg, 0.19 mmol). The solution was 
stirred at 25 °C for 5 h then evaporated to dryness in vacuo. The residue was purified over 
silica gel (CFbCh-MeOH-conc. aq. NH3 100:10:1 v/v/v) to afford the title compound as a green 
foam (8 8  mg, 63 %). Rf 0.82 (CH2CI2-MeOH-conc. aq. NH3 100:10:1 v/v/v). 1H NMR (CDCb): 
1.30-1.68 (35 H, m, 2-CH2) 6 -CH2, 7-CH2,11-CH2,0-C(CH3) 3 x 3), 2.88 (6  H, s, (CH3)2N), 2.97- 
3.26 (1 2  H, m, 1-CH2.3 -CH2.5 -CH2.8 -CH2, IO-CH2,12-CH2), 5.26-5.37 (1 H, m, CH2-NH-CO- 
O), 6.38-6.48 (1 H, m, NH-SO2), 7.17 (1 H, d, J = 7 ,6 ’-CH), 7.49 (1 H, t, J = 7, 3’-CH), 7.56 (1 
H, t, J = 7, 7’-CH), 8.21 (1 H, d, J = 7 ,4'-CH), 8.37 (1 H, d, J = 7, 8 -CH), 8.50 (1 H, d, J = 7, 2’- 
CH). 13c NMR: 25.8, 26.0 (6 -CH2,7-CH2), 28.3, 28.5 (2-CH2) 0-C(CH3)3 x 3, overlapping),
37.3 (I-CH2), 39.8 (1 2 -CH2), 43.7, 44.2 (3-CH2,10-CH2), 45.4 ((CH3)2N), 46.8 (5-CH2) 8 -CH2, 
overlapping), 79.4,79.8, (0-C(CH3)3 x 3, overlapping), 115.0 (6 ’-CH), 119.2 (8 ’-CH), 123.0 (3'- 
CH), 128.0 (4-CH), 128.7 (7-CH), 129.4,129.6 (1’-C, 4a’-C), 129.7 (2-CH), 135.5 (8 a’-C),
151.5 (5’-C), 155.7,156.1 (N-C0-0-C(CH3)3 x 3). FAB-MS m/z 736 (MH+), C37H61N5O8S 
requires 735; FAB-HRMS calculated 736.4319 (MH+), found 736.4321.
173
W-DansyM ,12-diamino-4,9-diazadodecane 87
Tri-Boc protected polyamine 8 6  (78 mg) in anhydrous CH2CI2 (18 ml) and TFA (2 ml) was 
stirred at 25 °C for 3 h, then the solvent was evaporated in vacuo. The residue was washed 
with diethyl ether (3x10 ml) then recrystallised from EtOAc to afford the title compound as a 
buff solid (18 mg, 21 %). fo 7.0 min (Supelcosil ABZ+Plus, 5 nm, 25 cm x 10 mm, X = 254 nm, 
MeCN-0.01 % aq. TFA 6:4 v/v). FAB-MS m/z 436 (MH+), C22H37N5O2S requires 435; FAB- 









oxycarbonyl)-1,16-diamino-4,8,13-triazahexadecane 5”-(dansylamido)-pentanoic acid 
ester 88
To a stirred solution of steroid 77 (7 mg, 5 nmol) in DMF (1 ml) was added KF (1 mg, 17 nmol) 
and TEA (1 ml, 7.7 mmol) followed by dansyl chloride (1 mg, 5 nmol). The solution was stirred 
at 25 °C under nitrogen for 3 h then diethyl ether (5 ml) and water (3 ml) was added. The 
organic layer was evaporated to dryness in vacuo to afford the title compound as a green wax. 
fit 0.93 (EtOAc). FAB-MS m/z 1422 (MH+), C78H131N7O14S requires 1421; FAB-HRMS 
calculated 1422.9553 (MH+), found 1422.9454.
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/V1-(3,a-hydroxy-5,p-cholan-24,-carbonyl)- 1,16-diamino-4,8,13-triazahexadecane 
hemisuccinate 4-(2-aminoethyl)-amino-iV-octadecyl-1,8-naphthalimide conjugate 
tetratrifluoroacetate salt 93
Tetra-Boc protected polyamine 97 (15 mg, 11 pmol) in anhydrous CH2CI2 (9 ml) and TFA (1 
ml) was stirred at 25 °C for 3 h. The solution was evaporated to dryness in vacuo and the 
residue purified by semi-preparative RP-HPLC (Supelcosil ABZ+Plus, 5 pm, 25 cm x 10 mm, X 
= 430 nm, MeCN-0.01 % aq. TFA 9:1 v/v) to afford the title compound as a yellow solid (11 mg, 
71 %). fo 5.2 min (Supelcosil ABZ+Plus, 5 pm, 25 cm x 10 mm, X = 430 nm, MeCN-0.01 % 
aq. TFA 9:1 v/v). Absorption Xmax (H2O): 453 nm. Fluorescence Xmx (Ex): 460 nm, Xmax (Em): 
531 nm. FAB-MS m/z 1011 (MH+), C59H94N8O6 requires 1010.
AP-P’a-hydroxy-S’p-cholan^’-carbonylJ-l.ie-diamino-^S.IS-triazahexadecane 
hemisuccinate 4-(2-aminoethyl)-amino-N-octadecyl-1,8-naphthalimide conjugate 
tetratrifluoroacetate salt 94
Tetra-Boc protected polyamine 98 (12 mg, 7 pmol) in anhydrous CH2CI2 (9 ml) and TFA (1 ml) 
was stirred at 25 °C for 3 h. The solution was evaporated to dryness in vacuo and the residue 
purified by semi-preparative RP-HPLC (Supelcosil ABZ+Plus, 5 pm, 25 cm x 10 mm, X = 430 
nm, MeCN-0.01 % aq. TFA 9:1 v/v) to afford the title compound as a yellow solid (8  mg, 64 %). 
fR 5.4 min (Supelcosil ABZ+Plus, 5 pm, 25 cm x 10 mm, X = 430 nm, MeCN-0.01 % aq. TFA 
9:1 v/v). Absorption ^ max (H2O): 439 nm. Fluorescence ^max (Ex): 450 nm, ^max (Em): 530 nm. 
FAB-MS m/z 1208 (MH+), C73H122N8O6 requires 1207.
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A/-(3’a-hydroxy-5’p-cholan-24’-carbonyl)-1-aminopropane hemisuccinate 95
Secondary alcohol 67 (400 mg, 0.96 mmol) and succinic anhydride (288 mg, 2.9 mmol) were 
stirred in hot pyridine (5 ml) at 110 °C for 20 h. Water (2 ml) was added, then the mixture was 
extracted with EtOAc (10 ml). The organic layer was washed with water (3x5  ml), dried 
(MgS0 4 ), and then evaporated in vacuo. The residue was recrystallised from EtOAc to afford 
the title compound as white crystals (416 mg, 84 %). 1H NMR (CDCb): 0.64 (3 H, s, 18’-CH3), 
0.89-0.95 (9 H, m, 3-CH3,21’-CH3,19’-CH3 overlapping), 0.96-2.30 (30 H, m, 2-CH2,1 ’-CH2, 2’- 
CH2,4 ’-CH2, 5’-CH, 6 ’-CH2i 7’-CH2, 8 ’-CH, 9’-CH, 11’-CH2,12’-CH2,14-CH, 15’-CH2, 16’-CH2j 
17’-CH, 20’-CH, 22’-CH2, 23’-CH2), 2.56-2.68 (4 H, m, HOOC-CH2-CH2), 3.21 (2 H, q, J = 6 ,1- 
CH2), 4.67-4.79 (1 H, m, 3’-CH), 5.74-5.84 (1 H, m, NH-CO). 13C NMR: 11.4 (N-CH2-CH2-CH3),
12 .1  (18’-CH3), 18.4 (21-CH3), 20.9 (1 1 ’-CH2), 2 2 .8  (N-CH2-CH2-CH3), 23.4 (19’-CH3), 24.2 
(15’-CH2), 26.3, 26.6 (7’-CH2 and HOOC-CH2-CH2), 27.0 (6 ’-CH2), 28.2 (16’-CH2), 29.1, 29.5 
(2’-CH2 and CH2-CH2-COO), 31.9 (22’-CH2), 32.3 (4’-CH2), 33.7 (23’-CH2), 34.6 (10’-C), 35.0 
(1’-CH2), 35.5 (20’-CH), 35.8 (8 ’-CH2), 40.1 (12’-CH2), 40.4 (9’-CH), 41.3 (N-CH2), 41.9 (5’-CH),
42.7 (13’-C), 56.0 (17-CH), 56.4 (14-CH), 74.8 (3’-CH), 171.6,173.9 (CO-NH, 0-CO-CH2),
176.3 (CO-OH).
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N^A/B.WWS-fretra-fe/t-butyloxycarbonyiJ-AP-P’a-hydroxy-S’p -c h o la n ^ ’-carbony!)-
1,16-diamino-4,8,13-triazahexadecane hemisuccinate 96
Secondary alcohol 50 (101 mg, 0.1 mmol) and succinic anhydride (50 mg, 0.5 mmol) were 
stirred in hot pyridine (5 ml) at 110 °C for 16 h. The reaction mixture was then concentrated in 
vacuo. The residue was purified over silica gel (CH2CI2-MeOH 20:1 v/v) to afford the title 
compound as a white foam (93 mg, 84 %). f t  0.25 (CH2CI2-MeOH 20:1 v/v). 1H NMR (CDCb): 
0.64 (3 H, s, 18’-CH3), 0.89-0.95 (6  H, m, 21’-CH3 and 19’-CH3 overlapping), 0.96-2.14 (74 H, 
m, 2 -CH2, 6 -CH2) 10-CH2i 11-CH2, 15-CH2i 1’-CH2, 2’-CH2i 4’-CH2, 5’-CH2, 6 ’-CH2, 7’-CH2, 8 ’- 
CH, 9’-CH, 11'-CH2,12’-CH2,14’-CH, 15’-CH2i 16’-CH2,17'-CH, 20’-CH, 22’-CH2, 23'-CH2i O- 
C(CH3)3 x 4), 2.55-2.68 (4 H, m, HOOC-CH2-CH2), 3.00-3.36 (16 H, m, 1-CH2, 3-CH2,5-CH2, 7- 
CH2, 9-CH2j 12-CH2,14-CH2,16-CH2), 4.69-4.80 (1 H, m, 3’-CH), 5.28-5.42 (1 H, m, CH2-NH- 
CO-O), 6.76-6.93 (1 H, m, CH2-NH-CO-CH2). NMR: 12.5 (18’-CH3), 18.8 (21’-CH3), 21.3 
(11’-CH2), 23.7 (19’-CH3), 24.6 (15’-CH2), 25.4,26.5 (10-CH2,11-CH2), 26.7, 27.0 (7’-CH2 and 
HOOC-CH2-CH2), 27.4 (6 ’-CH2), 28.1,28.1 (2-CH2,6-CH2,15-CH2), 28.6 (16’-CH2), 28.8,28.9 
(0-C(CH3)3 x 4), 29.5,29.9 (2’-CH2 and CH2-CH2-COO), 32.2 (22’-CH2), 32.6 (4-CH2), 34.1 
(23’-CH2), 35.0 (10’-C), 35.4 (1’-CH2), 35.9 (20’-CH), 36.2 (8 ’-CH), 37.8,37.8 (1-CH2,16-CH2),
40.5 (12’-CH2), 40.8 (9’-CH), 42.3 (5’-CH), 43.1 (13’-C), 45.1,45.1 (3-CH2, 5-CH2,7-CH2, 14- 
CH2), 56.4 (17’-CH), 56.8 (14’-CH), 75.1 (3’-CH), 79.8 (0-C(CH3)3 x 4), 172.0,173.0 (CO-NH, 
0-CO-CH2), 176.3 (CO-OH acid). FAB-MS m/z 1119 (MH+), 1117 (M-H+)-, C6iHio7N5Oi3 








EDC (8 mg, 36 pmol) and acid 96 (20 mg, 18 pmol) were dissolved in anhydrous CH2CI2 (5 ml) 
and HOBt (1 mg, 7 pmol, 41 % cat) was added with stirring at 25 °C under nitrogen. Amine 91 
(6 mg, 19 jamol) was added and the solution stirred for 16 h. The solution was evaporated to 
dryness in vacuo and the residue purified over silica gel (ChbCb-MeOH 20:1 v/v) to afford the 
title compound as a yellow foam (21 mg, 75%). Rt 0.62 (ChbCb-MeOH 10:1 v/v). /r 19.5 min 
(Supelcosil ABZ+Plus, 5 pm, 25 cm x 10 mm, X = 430 nm, MeCN-0.01 % aq. TFA 9:1 v/v). 




1,16-diamino-4,8,13-triazahexadecane hemisuccinate 4-(2-aminoethyl)-amino-/V- 
octadecyl-1,8-naphthalimide conjugate 98
EDC (6 mg, 32 (imol) and acid 96 (18 mg, 16 nmol) were dissolved in anhydrous CH2CI2 (5 ml) 
and HOBt (1 mg, 7 jamol, 46 % cat) was added with stirring at 25 °C under nitrogen. Amine 92 
(8 mg, 16 ^mol) was added and the solution stirred for 10 h. The solution was evaporated to 
dryness in vacuo and the residue purified over silica gel (ChbCb-MeOH 20:1 v/v) to afford the 
title compound as a yellow foam (20 mg, 63%). Rf 0.80 (ChhCh-MeOH 10:1 v/v). fo 21.8 min 
(Supelcosil ABZ+Plus, 5 (im, 25 cm x 10 mm, X = 430 nm, MeCN-0.01 % aq. TFA 9:1 v/v). 
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Abstract: The rational design and practical preparation o f unsymmetrical polyamine 
carbamates and amides, based on steroid templates o f  cholesterol and the bile acid 
lithocholic acid as the lipid moiety, provides fluorescent molecular probes that 
condense DNA. These novel lipopolyamine conjugates mimic the positive charge 
distribution found in the triamine spermidine and the tetra-amine spermine alkaloids.
These probes are useful in monitoring gene delivery for non-viral gene therapy.
1. Introduction and Background
Gene delivery for gene therapy o f a variety o f human and also for animal diseases 
e.g. cystic fibrosis [1], hepatitis [2], haemophilia [3], cancer [4-6], and more speculatively 
mitochondrial gene therapy for respiratory chain defects, i.e. defects that involve the final 
common pathway o f oxidative metabolism [7], can be performed with either a viral [8-10] 
or a non-viral vector [11-14]. Lipopolyamines (cationic lipids) recently developed for non- 
viral gene therapy show significantly lower toxicity than viral vectors, although they are 
currently less efficient transfection vectors than viruses [11-14]. The poor efficiency o f 
D N A  delivery to the nucleus, especially using non-viral vectors, is a major limitation o f the 
gene therapy approach. A  poor understanding o f the molecular mechanisms o f action in 
non-viral gene delivery [11,15], and a lack o f correlation between in vivo and in vitro 
biological activity [16-18] are unresolved issues and constitute the main current challenges. 
Whilst true gene therapy, i.e. the expression in cells o f genetic material that has therapeutic 
activity, holds promise for the treatment o f the significant human diseases listed above, the 
non-viral gene delivery vehicle, or vector, carrying the genetic material into the cell, must 
be optimised to increase the efficiency o f gene delivery to eukaryotic cells. Uptake o f 
condensed D N A  by target cells proceeds via endocytosis, but poor nuclear localisation is 
another major barrier to efficient gene expression (measured using reporter genes e.g. p- 
galactosidase expression). Thus, a greater knowledge o f the molecular mechanisms o f 
transfection w ill provide a basis for rational non-viral vector design [11-15, 19-24]. The 
possibility o f also enhancing the efficiency o f non-viral gene delivery to the nucleus by 
incorporating specific nuclear targeting (localisation) sequences in vectors is another area 
o f interest [23, 24]. Therefore, our aims in this research programme include the design and 
synthesis o f useful molecular probes, initially as model compounds and then for the study 





Polyamines are polycationic at physiological pH and play key roles in biological 
systems. In chromatin, polyamines such as the triamine spermidine 1 and tetra-amine 
spermine 2 (Fig. 1) help to package DN A into nuclei through neutralisation o f the poly­
anionic phosphate backbone charges, bringing about D N A  condensation and assisting in 
the control o f D N A  solution conformations. Lipopolyamines condense D N A  more 
efficiently than simple polyamines [25] - this is a key first step in non-viral gene delivery. 
Employing a high molecular weight cationic polymer for non-viral gene delivery to 
transfect target cells, is often associated with unacceptably high toxicity [26]. Small 
molecule lipopolyamines are therefore o f considerable interest due to their advantages o f 
low toxicity, low immunogenicity, controllable syntheses, and defined molecular structure 
for pharmaceutical characterisation. We are studying the synthesis o f steroidal polyamine 
conjugates, secondary alcohol functionalised cholesteryl carbamate 3 and lithocholic acid 
amide 4 (Fig. 1). Lipopolyamines reported in this research area (Fig. 2) include inter alia: 
Transfectam 5 [27] and RPR-120535 6  [28] have branched or linear spermine moieties 
linked to two Ci 8 -lipid chains, whereas Genzyme’s Lipid GL #67 7 possesses a cholesteryl 
lipid moiety [17]. Vitamin D 2  (ergocalciferol) polyamine conjugate 8  is a steroid with an 
open B-ring, designed to probe the structure-activity effects on transfection o f modifying 
the geometry within the hydrophobic steroid m otif [29]. Buckminster Fullerene tetra- 
ammonium ion conjugate 9 is typical o f a new class o f cationic lipid incorporating a C6 0  
hydrophobic core, where the amine moiety was conjugated to fullerene by a cycloaddition 
reaction [30]. Gemini surfactant GS4 10 is a tetra-lysine based cationic lipid, carrying a 
maximum o f 6  positive charges and conjugated with two C i2 -lipid chains [31, 32]. Novel 
spermine-based cationic gemini surfactants symmetrically acylated with two Ci 8 -lipid and 
two tri-lysine chains, with up to 8  positive charges, have also recently been reported [33].
Non-viral transfection efficiency cannot rationally be improved without a greater 
knowledge o f the detail o f intracellular events. In order to address the rational design o f 
small molecule vectors, the molecular mechanisms o f these poorly understood steps must 
be delineated. Fluorescent microscopy is useful for the study o f intracellular events. We 
are therefore synthesising the functionalised steroid polyamine conjugates cholesteryl 
carbamate 3 and lithocholic acid amide 4 (Fig. 1) as D N A  condensing agents which we 
have designed in order that a variety o f fluorophores can be introduced allowing the rapid 
synthesis o f a required library o f steroidal lipopolyamine fluorescent probes [34-38]. The 
polyamine conjugates are designed to mimic the charge distribution found in the naturally 
occurring triamine spermidine 1 , and are prepared by regio-controlled conjugation o f a 
suitably protected derivative 11 o f the symmetrical polyamine spermine 2 (Fig. 3) [39, 40].
Figure 2
2. Results and Discussion
2.1 Design and Synthesis o f Functionalised Polyamine-Steroid Conjugates
The synthesis o f the small molecule ligands 3 and 4 is described in outline. 
Spermine 2 was unsymmetrically tri-tert-Boc protected in a one-pot reaction (Fig. 3) [39, 
40]. Ethyl trifluoroacetate reacts rapidly and cleanly with primary amines, allowing poly- 
Boc protection o f all the remaining amine functional groups. Trifluoroacetamides are 
easily cleaved, in the presence o f Boc groups, at pH 11 and treatment with conc. aqueous 
N H 3 gave one free primary amine functional group in 50% overall yield. Acylation with 
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For fluorescent microscopy to study the intracellular phenomena o f non-viral gene 
delivery, Byk et al. reported a fluorescent derivative o f a polyamine conjugated to two Cis- 
lipid chains and they have synthesised fluorescent plasmid D N A  using rhodamine-type 
fluorophores [28,41]. Polyethylenimine (PEI) is a cationic aziridine polymer with known 
transfection activity [42]. Mikos and co-workers used Oregon Green labelled PEI in 
multicolour fluorescence studies and provided initial evidence that internalised DNA-PEI 
complex can be tracked to the nucleus [43]. We have set ourselves the goal o f lighting-up 
the inside o f the cell with wavelength-specific small molecule fluorescent probes and 
monitoring the processes in, and elucidating the barriers to efficient gene delivery.
For the introduction of a fluorescent label to cholesteryl, we decided to hydroborate
12 was reacted with borane-dimethyl sulfide (BH3 .dms) for 4 h in anhydrous CH2CI2 . The 
organoborane was oxidised for 30 min with basic (NaHCOs) H2O2 . The use o f BH3 .dms 
complex provides mild conditions for the selective reaction o f an alkene in the presence o f 
carbamate functional groups, despite the poor reactivity o f the cholesteryl alkene due to a 
significant steric constraint. The methyl substituents on the top face (p-face) o f cholesteryl 
direct the .syw-addition o f borane to the a-face in the major product. The desired 6 a- 
hydroxy steroid 13, with a frans-fused AB ring junction, is obtained on oxidative work-up 
and after chromatography in 70% yield. In addition, a small fraction o f the BBb.dms adds 
to the p-face affording the czs-fused AB, 6 P-OH stereoisomer 14 (5%) which is more polar 
and these products were separated by column chromatography over silica gel. Given that 
hydroboration is a sy/i-addition, in the less-polar major product H-6 ax displays two 7ax-ax 
and one Jax.eq coupling at 5 3.35 ppm, dt (J=  5 and 11 Hz) (Fig. 4), R f 0.5, EtOAc-hexane 
1:1 v/v, 13C NMR: 6  52.3 (C-5), 68.4 (C-6 ), 73.9 (C-3) ppm, HR FAB-MS found 
933.7321 (M+ + 1), C53H97N4O9 requires 933.7256, was the desired rraws-fused AB 
system. On further elution, a minor product was obtained, Rf 0.1, EtOAc-hexane 1:1 v/v, 
HR FAB-MS found 933.7274 (M+ + 1), this was assigned to the P-hydroxy isomer from a 
non-stereospecific reaction [45], The cis-fused AB ring junction, in the minor product 14, 
mimics the shape found in the naturally occurring steroid bile acids (Fig.5), e.g. lithocholic 
acid, polyamine amides o f which, e.g. 4 we have shown to condense duplex DNA [46, 47],
the cholesterol A5-alkene functional group [44]. Tri-Boc protected cholesteryl carbamate
B oc
i. BH3 .dms, CH2C12, 4 h
ii. H20 2/N aH C 03, 30 min
Major product, H-6 has two Jax.ax and one 


















Similarly, we prepared spermidine mimic target molecule 4 from TFA deprotection 
o f the three Boc protecting groups in 15, itself obtained by acylation o f amine 11 with 
lithocholic acid (DCC, HOBt, CH2CI2). In order to mimic the positive charge distribution 
o f naturally occurring spermine 2  in the target molecules, we have investigated a reductive 
alkylation approach using N ] ,N2 ,N*-tri-Boc spermine 11. N-Cbz protected 6 -aminohexan- 
l-ol was prepared using benzyl chloroformate. The alcohol was oxidised under Swem 
conditions (anhydrous DMSO-oxalyl chloride) to the corresponding aldehyde followed by 
reductive animation with N l,N2JV3-tri-Boc spermine 11 [39, 40]. The resulting secondary 
amine was Boc protected to form tetra-Boc-mono-Cbz pentamine with methylene spacing 
3.4.3 . 6  16. The Z group, orthogonal to Boc, was then cleaved by palladium catalysed 
hydrogenolysis or by transfer hydrogenation using cyclohexene as a H2-donor. These steps 
achieved an unsymmetrical extension o f V ^ jA ^ -tr i-B o c  spermine 1 1  with assured 
regiochemistry in the product 17 after acylation with cholesteryl chloroformate. The 
resulting tetra-Boc protected 3.4.3.6-cholesteryl carbamate 17 was hydroborated using the 
procedure outlined above and the major product was isolated, purified, and identified as 
secondary alcohol 18 FAB-MS found 1154 (M + Na+), C64H 117N 5O 11 requires 1131.
Fluorescent labels were then introduced to these lipopolyamine conjugates to 
generate our designed fluorescent target molecules. Fmoc, as either a fluorescent tag or as 
a primary amine protecting group, was first introduced by esterification (DCC, DM AP) 
with the short alkyl chain 5-Fmoc-aminopentanoic acid (SAPA), chosen as an appropriate 
and pragmatic spacer. The secondary alcohols o f cholestane B-ring 13 affording ester 19, 
and o f lithocholic acid A-ring 15 affording 20 were reacted in this manner (Fig. 6 ). Further 
manipulation o f these esters 19 and 2 0  by regioselective deprotection o f one primary amine 
functional group by fluoride facilitated Fmoc removal with TBAF [48], and then reaction 
with fluorescein isothiocyanate afforded, after TFA removal o f the Boc protecting groups, 
thiourea target molecules 21 and 22 respectively. It is significant that the secondary alkyl 
cholesteryl carbamate functional group remains intact during this poly-Boc deprotection. 
Final purification o f these water soluble poly-trifluoroacetic acid salts afforded the desired 
fluorescent steroidal lipopolyamine conjugates which can react with DNA.
Me
Fmoc-8 APA-OH





























2.2 Monitoring Lipopolyamine Interactions with DNA
Spectroscopic assays allow us to monitor D N A  condensation, the first stage in 
lipopolyamine mediated gene delivery, using our designed probes 3, 4, 21, and 22 (Fig. 7). 
These D N A  assays include both ethidium bromide fluorescence quenching [49] and light 
scattering (X = 320 nm) [50] as, at this stage, the D N A  is compacted into toroidal particles 
whose formation can be monitored by light scattering [50]. Using these techniques, we 
have shown that our synthetic steroidal lipopolyamines e.g. 4 and cholesteryl carbamate 23 
from Boc-deprotection o f 12 [40], an V-acylated regioisomer o f GL #67 7 [17], condense 
DNA more efficiently than the natural polyamines spermidine 1 and spermine 2. The 
synthetic lithocholic acid amide o f spermine 2 , converted into an ester and then a thiourea 
with fluorescein isothiocyanate, spermidine equivalent 2 2 , condensed both calf thymus and 
synthetic D N A  with the same efficiency as spermidine 1 in the ethidium bromide assay.
3. Conclusions and Future Studies
Using our designed steroidal lipopolyamine probes (Fig. 7), we are studying DNA- 
lipopolyamine complexes with respect to their formation by D N A  condensation. The 
design and synthesis o f fluorescent lipopolyamines allows us to study the intracellular 
events during transfection. Comparable DNA-binding efficiency to that o f the unlabelled 
lipopolyamines and robust fluorescent spectral properties across the varying cellular pH 
range are desirable properties in these ligands. We have achieved a controlled chain 
extension o f suitably protected polyamines using reductive alkylation [39] to mimic 
spermine 2 rather than spermidine 1 in the target molecules. A  practical method for the 
efficient hydroboration o f cholesteryl carbamates has allowed us to prepare our designed 
trans-AB steroidal lipopolyamines, together with the corresponding cis-AB ring junction 
as the minor product o f the hydroboration reaction or from naturally occurring bile acids. 
We are able to introduce fluorophores o f choice by our Fmoc-chemistry. In this way, we 
have synthesised the beginnings o f a library o f fluorescent lipopolyamine probes based on 
steroid moieties as the lipophilic unit. The design in our versatile synthetic route to Fmoc 
protected aminoesters o f cholesteryl carbamate 19 and lithocholic acid polyamine amide 
2 0  allows a range o f selected fluorophores to be readily incorporated e.g. fluorescein 
isothiocyanate which is a widely used fluorescent probe in confocal microscopy (cf 3 and 
21, and 4 and 22). The availability o f a wide range o f fluorophores is important in order 
that a library o f fluorescent derivatives may be accessed via this Fmoc deprotection route. 
A-Hydroxysuccinimide activated reagents to introduce these fluorophores include Oregon 
Green 488 24 (Fig. 7), a difluorinated fluorescein analogue which offers improved spectral 
properties over the physiological pH range involved in transfection processes and Alexa 
Fluor 350 25. Together with fluorescein, fluorophores 24 and 25 are negatively charged. 
Lissamine Rhodamine B 26 and other rhodamine-type fluorophores incorporate positive 
charges; Fmoc 27 and BO DIPY-FL 28 fluorophores are lipophilic. Steroid lipopolyamine 
conjugates o f these fluorophores w ill have different efficiencies in the modes o f conjugate 
binding to DNA. As well as our studies on lipopolyamine-mediated D N A  condensation, 
we are optimising these probes to use them in monitoring the steps o f gene delivery within 
cells. At present, a poor understanding o f the mechanisms o f action o f non-viral vectors 
remains an important unresolved issue. W ith a greater knowledge o f these mechanisms 
[51, 52], new non-viral vectors with improved transfection efficiency can be rationally 
designed. In conclusion, these results help us to design more efficient molecular probes for 
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Hydroboration of Cholesterol Carbamates: Novel Fluorescent Lipopolyamines 
ADRIAN P. NEAL and IAN S. BLAGBROUGH
Department o f  Pharmacy and Pharmacology, University o f  Bath, Bath BA2 7A Y
Lipopolyamines mimic naturally occurring 
polyamines in the condensation of DNA and have 
recently been developed as potential DNA delivery 
vectors for use in non-viral gene therapy. 
Currently, the mechanisms of lipopolyamine 
mediated transfection are poorly understood. This 
inefficiency cannot be resolved without a greater 
knowledge, and efforts to study intracellular 
events during non-viral transfection are underway. 
These efforts are focused around the use of 
fluorescent microscopy Byk et al (1998), Helbling- 
Leclerc et al (1999) and Godbey et al (1999). 
RPR-121653 is a fluorescent polyamine 
conjugated to two C l8  lipid chains, Byk et al 
(1998). Polyamine carbamates of cholesterol are 
currently the lead compounds in this area of non- 
viral transfection. Therefore, we have designed 
the first fluorescent steroidal polyamine (1).
68.4 (122.3) (C-6 ); 73.9 (74.1) (C-3) and FAB-MS 
found 956 (M+ + Na+), C53H96N40 9  requires 933).
i. BH3.dms, CH2CI2 
4 h, 20 °C, N2
ii. H20  then H202/NaHC03 
30 min, 0 °C
* Fluor ophore
Figure 1. Target fluorescent polyamine- 
cholesterol carbamate (1)
The key step in the functionalisation of cholesterol 
is hydroboration followed by oxidative workup. 
The use of borane-dimethyl sulfide complex 
provides mild conditions for the selective 
treatment of an alkene versus carbamate functional 
groups, despite poor reactivity of the alkene of 
cholesterol due to a heavy steric constraint Tavares 
et al (1993). The 5 7 /1-addition across the double 
bond of cholesterol furnishes the steroid with a 
6 a-hydroxy group and a trans-fused A-B ring 
junction (2). This step has been achieved in 70 % 
yield, observed key I3C NMR values (starting 
material in brackets) include: 52.3 (140.0) (C-5);
Figure 2. Introduction of 6 a-hydroxyl onto a 
polyamine-cholesterol carbamate (2 )
The functional group modification of the steroid 
will allow derivatisation of a lipopolyamine with a 
fluorophore of choice, via a short chain ester or 
ether. The synthesis concludes with poly-Boc 
deprotection in TFA-CH2C12 and purification by 
RP-HPLC.
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Department o f Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K.
The rational design of efficient non-viral gene delivery vectors is currently restricted by a poor 
understanding of the molecular detail of intracellular events. As fluorescent m icroscopy is 
potentially useful for the study of lipopolyamine-mediated transfection, the design of fluorescent 
probes is required. W e are studying steroidal polyamine conjugates, cholesteryl carbamates 
and lithocholic acid amides as efficient DNA condensing agents, that have been designed in 
order that a variety o f fluorophores may be introduced allowing rapid synthesis of a library of 
fluorescent lipopolyamines (with both c/'s- and frans-A-B steroids). The synthesis o f these novel 
fluorescent probes is described here.
Tri-Boc-protected spermine was acylated with the two chosen steroids in order to afford the 3- 
cholesteryl carbamate and the lithocholic acid amide of spermine. The introduction of the 
fluorescent label on cholesteryl carbamate requires hydroboration of the cholesterol A5 alkene 
functional group. syn-Hydroboration (BH3.dms, oxidised with basic H20 2) yielded the 6a- 
hydroxy steroid, a trans-A-B  ring junction, displaying H6ax (p) with two Jax-ax and one Jax-eq 
at 8 = 3.35 ppm, (dt, J  = 4.5 and 10.9 Hz). Further elution afforded the m inor isomer (~5 %), 6(3- 
hydroxy, a c/s-A-B ring junction. This 6a-hydroxy and the 3a-hydroxy of the protected 
lithocholic acid polyamine amide have been esterified with Fmoc-protected 5-aminovaleric acid 
(DCC/DMAP). Facile removal of the Fmoc-protecting group with TBAF allowed introduction of 
the fluorophore fluorescein isothiocyanate through the formation of a thiourea. Poly-Boc 
deprotection (TFA/CH2CI2) and purification (RP-HPLC ODS 60:40 0.1% aq. TFA-MeCN, X = 495 
nm) afforded the target polyamine conjugates 1 and 2 as orange powders.






Fluorescein-labelled spermine-lithocholic acid amide 2
H 0‘
Spectroscopic assays exist for monitoring DNA condensation using such designed probes. These 
include a fluorescence quenching ethidium bromide assay and a light scattering (X = 320 nm) 
assay. Using these techniques, we have shown that our synthetic lipopolyamines condense DNA 
more efficiently than the natural polyamines spermidine and spermine. A synthetic model 
lithocholic acid amide of spermine (a spermidine equivalent) derivatised with fluorescein 
isothiocyanate condensed both calf thymus and synthetic DNA with the same efficiency as 
spermidine in the ethidium bromide assay. These results help us to design more efficient 
fluorescent probes for DNA-binding in this area of non-viral gene delivery using alkyl spermine 
moieties. W e acknowledge financial support from the EPSRC (studentship to A.P.N.).
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Design and synthesis of fluorescent cholesterol and lithocholic acid polyamine 
conjugates
Adrian P. Neal and Ian S. Blagbrough
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K.
Lipopolyamines are lead compounds for efficient DNA delivery vectors in non-viral 
gene therapy. 3-Cholesteryl polyamine carbamates and lithocholic acid polyamine 
amides condense DNA, therefore we have designed fluorescent polyamine probes 
incorporating these steroid moieties. The synthesis of these novel fluorescent 
lipopolyamines, with both trans- and c/s-AB steroid polyamines, is described.
Tri-Boc-protected spermine was acylated with the two chosen steroids in order to 
afford the 3-cholesteryl carbamate and the lithocholic acid amide of spermine. The 
introduction of the fluorescent label on cholesteryl carbamate requires hydroboration 
of the cholesterol A5 alkene functional group. syn-Hydroboration (BH3.dms, oxidised 
with basic H20 2) yielded the 6 a-hydroxy steroid, a trans-A-B ring junction, displaying 
H6 ax (p) with two Jax-ax and one Jax-eq at 8  = 3.35 ppm, (dt, J  = 4.5 and 10.9 Hz). 
Further elution afforded the minor isomer (-5  %), 6 p-hydroxy, a cis-A-B ring junction. 
This 6 a-hydroxy and the 3a-hydroxy of the protected lithocholic acid polyamine 
amide have been esterified with Fmoc-protected 5-aminovaleric acid (DCC/DMAP). 
Facile removal of the Fmoc-protecting group with TBAF allowed introduction of the 
fluorophore fluorescein isothiocyanate through the formation of a thiourea. Poly-Boc 
deprotection (TFA/CH2CI2) and purification (RP-HPLC ODS 60:40 0.1% aq. TFA- 
MeCN, X = 495 nm) afforded the target polyamine conjugates as orange powders.
We acknowledge financial support from the EPSRC (studentship to A.P.N.).
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Fluorescent steroidal lipopolyamine conjugates for monitoring gene delivery
Adrian P. Neal and Ian S. Blagbrough
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K.
In non-viral gene therapy, the mechanisms of the intracellular steps are currently 
poorly understood. Transfection efficiency cannot be improved without a greater 
knowledge of the molecular detail of intracellular events. As fluorescent microscopy is 
potentially useful for the study of lipopolyamine-mediated transfection, the design of 
fluorescent probes is required. We are studying steroidal polyamine conjugates, 
cholesteryl carbamates and lithocholic acid amides, as efficient DNA condensing 
agents that have been designed in order that a variety of fluorophores may be 
introduced allowing rapid synthesis of a library of fluorescent lipopolyamines.
Spectroscopic assays exist for monitoring DNA condensation using such designed 
probes. These include a fluorescence quenching ethidium bromide assay and a light 
scattering (X = 320 nm) assay. Using these techniques, we have shown that our 
synthetic lipopolyamines condense DNA more efficiently than the natural polyamines 
spermidine and spermine. A synthetic model lithocholic acid amide of spermine (a 
spermidine equivalent) derivatised with fluorescein isothiocyanate condensed both 
calf thymus and synthetic DNA with the same efficiency as spermidine in the ethidium 
bromide assay. These results help us to design more efficient fluorescent probes for 
DNA-binding in this area of non-viral gene delivery using alkyl spermine moieties.
We acknowledge financial support from the EPSRC (studentship to A.P.N.).
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Design and synthesis of fluorescent cholesterol and lithocholic acid polyamine 
conjugates
Adrian P. Neal and Ian S. Blagbrough
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K.
Lipopolyamines are lead vectors designed to achieve efficient DNA delivery in non- 
viral gene therapy. 3-Cholesteryl polyamine carbamates and lithocholic acid 
polyamine amides condense DNA, therefore we have designed fluorescent 
polyamine probes incorporating these steroid moieties. We report the synthesis of 











Fluorescein labelled lithocholic acid spermidine equivalent
Tri-Boc-protected spermine was acylated with the two chosen steroids in order to 
afford the 3-cholesteryl carbamate and the lithocholic acid amide of spermine. The 
introduction of the fluorescent label on cholesteryl carbamate requires hydroboration 
of the cholesterol A5-alkene functional group. syn-Hydroboration (BH3.dms, oxidised 
with basic H20 2) yielded the 6a-hydroxy steroid, a frans-A-B ring junction, displaying 
H6ax (P) with two Jax-ax and one Jax-eq at 5 = 3.35 ppm, (dt, J = 4.5 and 10.9 Hz). 
Further elution afforded the minor isomer (~5 %), 6p-hydroxy, a c/s-A-B ring junction. 
This 6a-hydroxy and the 3a-hydroxy of the protected lithocholic acid polyamine 
amide have been esterified with Fmoc-protected 5-aminovaleric acid (DCC/DMAP). 
Facile removal of the Fmoc-protecting group with TBAF allowed introduction of the 
fluorophore fluorescein isothiocyanate through the formation of a thiourea. Poly-Boc 
deprotection (TFA/CH2CI2) and purification (RP-HPLC ODS 60:40 0.1% aq. TFA- 
MeCN, X = 495 nm) afforded the target polyamine conjugates. We acknowledge 
financial support from the EPSRC (studentship to A.P.N.).
Design and Synthesis of Fluorescent Cholesterol and 
Lithocholic Acid Polyamine Conjugates
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Department o f  Pharmacy and Pharmacology, University o f  Bath, Bath BA2 7AY, U.K.
Lipopolyamines are lead compounds for efficient 
DNA delivery vectors in non-viral gene therapy 
(Blagbrough et al 1997). 3-Cholesteryl polyamine 
carbamates (Geall et al 2000) and lithocholic acid 
polyamine amides (Geall et al 1998) condense 
DNA, therefore we have designed fluorescent 
polyamine probes incorporating these steroid 
moieties. The synthesis of these novel fluorescent 









Tri-Boc-protected spermine was acylated with the 
two chosen steroids in order to afford the 3- 
cholesteryl carbamate and the lithocholic acid 
amide of spermine. The introduction of the 
fluorescent label on cholesteryl carbamate requires 
hydroboration of the cholesterol A5-alkene 
functional group (Neal & Blagbrough 2000). syn- 
Hydroboration (BH3.Me2S, oxidised with basic 
H20 2) (Tavares et al 1993) yielded the 6a-hydroxy 
steroid, a trans-AB ring junction, displaying H6ax 
(p) with two Jax-ax and one /ax-eq at 5 = 3.35 ppm, 
(dt, J  = 4.5 and 10.9 Hz). Further elution afforded 
the minor isomer (~5 %), 6P-hydroxy, a cA-AB ring 
junction (Jung & Johnson 2001). This 6a-hydroxy 
and the 3a-hydroxy of the protected lithocholic acid 
polyamine amide have been esterified with Fmoc- 
protected 5-aminovaleric acid (DCC/DMAP). 
Facile removal of the Fmoc-protecting group with 
TBAF (Ueki & Amemiya 1987) allowed the 
introduction of fluorescein as a fluorophore and 
conjugation through a thiourea functional group. 
Poly-Boc deprotection (TFA/CH2C12) and 
purification (RP-HPLC ODS 60:40 0.1% aq. TFA- 
MeCN, A = 495 nm) afforded the target polyamine 
conjugates as orange powders.
We thank the EPSRC for a studentship to A.P.N.
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Figure 1. Target fluorescent steroidal 
llipopolyamines
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Fluorescent Steroidal Lipopolyamine Conjugates For Monitoring Gene Delivery
ADRIAN P. NEAL and IAN S. BLAGBROUGH
Department o f Pharmacy and Pharmacology, University o f Bath, Bath BA2 7AY, U.K.
In non-viral gene therapy, the mechanisms of the 
intracellular steps are currently poorly understood. 
Transfection efficiency cannot be improved without 
a greater knowledge of the molecular detail of 
intracellular events (Godbey et al 1999a and 1999b). 
As fluorescent microscopy is potentially useful for 
the study of lipopolyamine-mediated transfection, 
the design of fluorescent probes is required. We are 
studying steroidal polyamine conjugates, cholesteryl 
carbamates and lithocholic acid amides, as efficient 
DNA condensing agents that have been designed in 
order that a variety of fluorophores may be 
introduced allowing rapid synthesis of a library of 
fluorescent lipopolyamines (Neal and Blagbrough 
2000).
Spectroscopic assays exist for monitoring DNA 
condensation using such designed probes. These 
include a fluorescence quenching ethidium bromide 
assay and a light scattering (A, = 320 nm) assay. 
Using these techniques, we have shown that our 
synthetic lipopolyamines condense DNA more 
efficiently than the natural polyamines spermidine 
and spermine. A synthetic model lithocholic acid 
amide of spermine (a spermidine equivalent) 
derivatised with fluorescein isothiocyanate 
condensed both calf thymus and synthetic DNA with 
the same efficiency as spermidine in the ethidium 
bromide assay. These results help us to design more 
efficient fluorescent probes for DNA-binding in this 
area of non-viral gene delivery using alkyl spermine 
moieties.
Cholesteryl carbamates 1 and 2 and lithocholic acid 
amides 3 and 4 are spermine equivalents which 
efficiently condense DNA. Compound 5 is a 
fluorescent BODIPY derivative of 1, accessible 
through hydration of the unsaturated cholesteryl 
carbamate.
HO 4
Figure 1. Target fluorescent steroidal lipopolyamine 
conjugates.
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Fluorescent Steroidal Lipopolyamine Conjugates for Monitoring Non-Viral Gene Delivery
Adrian P. Neal and Ian S. Blagbrough
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K.
Lipopolyamines are lead vectors designed to achieve efficient DNA delivery in non-viral gene therapy, 
but the intracellular detail of the processes involved is poorly understood. 3-Cholesteryl polyamine 
carbamates and lithocholic acid polyamine amides condense polynucleic acids for transfection. In 
order to provide a rational basis for the design of new efficient vectors, we have designed fluorescent 
lipopolyamine probes incorporating trans- and cis-AB steroid moieties. W e report the synthesis of 
these novel analytical tools.
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protected sperm ine am ide
Fluorescein labelled lithocholic acid sperm id ine equ iva lent
A^.A^.A^-Tri-Boc-protected spermine was acylated with the two chosen steroids in order to afford the 3- 
cholesteryl carbamate and the lithocholic acid amide. The introduction of a fluorescent label to this 3- 
cholesteryl carbamate requires hydration of the cholesterol A5-alkene functional group, syn-Hydroboration 
(BH3.Me2S, oxidised with basic H20 2) yielded the 6a-hydroxy steroid, a trans-A-B ring junction, displaying 
H6ax (p) with two Jax-ax and one Jax-eq at 5 = 3.35 ppm, (dt, J  = 4.5 and 10.9 Hz). Further elution 
afforded the diastereoisomer ( -5  %), 6p-hydroxy, a cis-A-B ring junction. This 6a-hydroxy and the 3a- 
hydroxy of the protected lithocholic acid polyamine amide have been esterified with Fmoc-protected 5- 
aminovaleric acid (DCC/DMAP). Facile removal of the Fmoc-protecting group (KF/TEA) allowed 
introduction of fluorophores. Thus, sulfonylation with dansyl (sulfonyl) chloride afforded the lithocholic acid 
conjugate which will allow monitoring of pH sensitive fluorescence and cellular events during transfection. 
Fluorescein was introduced as a thiourea to afford cholesteryl and lithocholic acid spermine conjugates. 
This design and synthesis of a range of fluorescent conjugates allows multicolour confocal imaging of 
cellular environments and intracellular processes involved in transfection. Poly-Boc deprotection 
(TFA/CH2CI2 1:9 v/v) and purification (RP-HPLC ODS 60:40 0.1% aq. TFA-MeCN, X = 495 nm for 
fluorescein) afforded the target lipopolyamine conjugates. W e acknowledge financial support from the 
EPSRC (studentship to A.P.N.).
